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PREFACE
The N a t io n a l  I n s t i t u t e  f o r  O c c u p a t io n a l S a f e t y  and H e a lth  (NIOSH) h a s  
e v a lu a te d  th e  in fo r m a t io n  a v a i l a b l e  on  c o b a l t  and c o n c lu d e s  t h a t  a  p o t e n t i a l l y  
s e r io u s  h a za rd  c o u ld  e x i s t  In  th e  US w o r k fo r c e  from  e x p o su r e  to  u n c o n t r o l le d  
and e x c e s s i v e  am ounts o f  c o b a l t .  For c o b a l t  m e ta l  fume and d u s t ,  t o x i c  
e f f e c t s  h a v e  b een  o b se r v e d  In  th e  lu n g s  o f  w o rk ers  and e x p e r im e n ta l  a n im a ls  
ex p o sed  a t  o r  b e lo w  th e  c u r r e n t  F e d e r a l  l i m i t .  I n fo r m a t io n  on  many o f  th e  
c o b a l t  compounds i n  co m m ercia l u s e  I s  s o  l i m i t e d  t h a t  p e r m is s ib le  ex p o su r e  
l i m i t s  ca n n o t b e  d e r iv e d  a t  t h i s  t im e .
NIOSH w i l l  p e r i o d i c a l l y  r e v ie w  th e  a v a i l a b l e  d a ta  c o n c e r n in g  c o b a l t  and 
w i l l  make s u c c e s s i v e  r e p o r t s  and r e v i s e d  recom m en d ation s a s  new r e s e a r c h  and 
e p id e m io lo g ic  s t u d ie s  a r e  c o m p le te d . I f  a  p r e v io u s ly  u n s u s p e c te d  h a za rd  
becom es known, c o b a l t  w i l l  b e  c o n s id e r e d  a s  a  s u b j e c t  f o r  recom m ending new  
s ta n d a r d s .
C o n tr ib u t io n s  t o  t h i s  docum ent on  c o b a l t  by  NIOSH s t a f f  a r e  g r a t e f u l l y  
ack n ow led ged  a s  a r e  th e  comments o f  o th e r  F e d e r a l  a g e n c ie s  o r  d e p a r tm e n ts ,  
r e v ie w  c o n s u l t a n t s ,  and r e v ie w e r s  s e l e c t e d  by  th e  A m erican  M e d ica l  
A s s o c i a t i o n ,  th e  S o c i e t y  f o r  O c c u p a tio n a l and E n v iro n m en ta l H e a lth ,  and th e  
S o c ie t y  o f  T o x ic o lo g y ,  and R o b ert B. O 'C onnor, M .D ., NIOSH c o n s u lt a n t  i n  
o c c u p a t io n a l  m e d ic in e .  M ost o f  th e s e  r e v ie w e r s  p r o v id e d  comments on an  
e a r l i e r  d r a f t  c r i t e r i a  docum ent on  c o b a l t .
The v ie w s  and c o n c lu s io n s  e x p r e s s e d  i n  t h i s  docum ent a r e  th o s e  o f  NIOSH. 
They a r e  n o t  n e c e s s a r i l y  th o s e  o f  th e  c o n s u l t a n t s ,  th e  r e v ie w e r s  s e l e c t e d  by  
p r o f e s s i o n a l  s o c i e t i e s ,  o r  o th e r  F e d e r a l  a g e n c ie s .  The r e v ie w  c o n s u l t a n t s  and 
th e  F e d e r a l  A g e n c ie s  t h a t  r e c e iv e d  and commented on an  e a / I ^ e r  y e r s io n  o f  t h i s  
docum ent a r e  l i s t e d  on  p a g es  i v  and v .
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I .  SUMMARY AND CONCLUSIONS
More th an  a  m i l l i o n  w o rk ers i n  th e  U n ite d  S t a t e s  a r e  p o t e n t i a l l y  ex p o sed  
to  c o b a l t  compounds in  th e  c o u r s e  o f  t h e i r  em ploym ent. By f a r ,  m ost a r e  
ex p o sed  t o  c o b a l t  m e ta l  o r  c o b a l t  o x id e s .  Many a r e  p o t e n t i a l l y  ex p o sed  to  
o i l - b a s e d  p a in t  d r i e r s  c o n ta in in g  c o b a l t ,  b u t t h e i r  e x p o su r e  i s  l i m i t e d  
b e c a u s e  t h e s e  d r i e r s  c o n s t i t u t e  o n ly  a  s m a ll  p e r c e n ta g e  o f  th e  i n g r e d ie n t s  i n  
p a in t .  P r o d u c t io n  o f  a l l o y s  and h ard  m e ta l  a c c o u n ts  f o r  a b o u t 70% o f  c o b a l t  
u s e ,  b u t num erous o th e r  i n d u s t r i e s  p ro d u ce  o r  u s e  l e s s e r  am ounts o f  c o b a l t .  
The d e g r e e  o f  w orker e x p o su r e  i n  t h e s e  i n d u s t r i e s  d ep en d s on many f a c t o r s ,  
in c lu d in g  th e  amount o f  c o b a l t  u sed  i n  th e  p r o c e s s ,  th e  number o f  e n g in e e r in g  
c o n t r o ls  a v a i l a b l e ,  and th e  amount o f  c o b a l t - c o n t a in in g  m a t e r ia l s  h a n d led  
m a n u a lly . S in c e  w o rk ers a r e  r a r e ly  ex p o sed  t o  o n ly  a s i n g l e  s u b s ta n c e  i n  th e  
o c c u p a t io n a l  en v ir o n m e n t, e x p o su r e  to  c o b a l t  can  b e  l im i t e d  by th e  
a v a i l a b i l i t y  o f  e n g in e e r in g  c o n t r o ls  d e s ig n e d  to  r e d u c e  e m is s io n  o f  o th e r  
r e s p ir a b le  and p o t e n t i a l l y  h a rm fu l m e ta l  fum es and d u s t s .
The O c c u p a tio n a l S a f e t y  and H e a lth  A d m in is t r a t io n  (OSHA) s ta n d a r d  f o r  
c o b a l t  i s  0 .1  m il l ig r a m  o f  c o b a l t  i n  a  c u b ic  m eter  o f  a i r  (m g/cu  m ). OSHA h as  
in t e r p r e t e d  t h i s  s ta n d a rd  t o  a p p ly  t o  a l l  c o b a l t  com pounds. Of th e  w o r k p la c e s  
in s p e c t e d  by OSHA f o r  c o b a l t  e x p o s u r e , n e a r ly  20% w ere n o t  i n  c o m p lia n ce  w ith  
t h i s  s ta n d a r d . S i t e  v i s i t s  r e v e a le d  t h a t  p la n t s  u s in g  la r g e  q u a n t i t i e s  o f  
c o b a l t  h a v e  d i f f i c u l t i e s  m e e t in g  t h i s  s ta n d a r d  w ith o u t  e x t e n s iv e  e n g in e e r in g  
c o n t r o l s .
W orkers can  b e  ex p o sed  to  c o b a l t  i n  many w a y s . I n h a la t io n  i s  a  p o t e n t i a l  
r o u te  o f  e x p o su r e  o c c u r r in g  m ost commonly when m a t e r ia l  c o n t a in in g  c o b a l t  i s  
h e a te d ,  w here c o b a l t  pow ders a r e  h a n d led  m a n u a lly , o r  w h ere c o b a l t  m a t e r ia l s  
a r e  s u b j e c t e d  to  g r in d in g .  Derm al e x p o su r e  to  c o b a l t  can  o c c u r  i n  any  
o p e r a t io n  w here t h e s e  m a t e r ia l s  a r e  h a n d led  m a n u a lly , b u t i t  i s  a  s p e c i a l  
c o n s id e r a t io n  w here s o l u t io n s  c o n ta in in g  c o b a l t  a r e  p r e s e n t .  I n g e s t io n  o f  
c o b a l t  can  a l s o  o c c u r  and i s  b e s t  p r e v e n te d  by  good work p r a c t i c e s ,
s a n i t a t i o n ,  and p e r s o n a l  h y g ie n e .  The in fo r m a t io n  on th e  h e a l t h  e f f e c t s  o f
c o b a l t  i s  s u f f i c i e n t  to  c o n c lu d e  t h a t  e x p o su r e  to  i t  by any o f  t h e s e  th r e e
r o u te s  can  b e  a  h e a l t h  h a za rd  i n  th e  w o r k p la c e .
S u b s t a n t ia l  in fo r m a t io n  e x i s t s  sh ow in g  t h a t  w o rk ers who h a v e  in h a le d  
c o b a l t  can  d e v e lo p  lu n g  d i s e a s e .  Numerous c a s e  r e p o r t s  and m e d ic a l  and
in d u s tr y - w id e  s u r v e y s  i n  th e  cem ented  c a r b id e  in d u s tr y  h a v e  d em o n stra ted  th e  
p e r s i s t e n t  o c c u r r e n c e  o f  d i f f u s e  i n t e r s t i t i a l  f i b r o s i s  o f  th e  lu n g  i n  ex p o sed  
w o r k e r s . M ild  t o  f i b r o t i c  lu n g  ch a n g es  h a v e  b een  o b se r v e d  i n  w o rk ers ex p o sed  
t o  c o b a l t  a t  0 . 1 - 0 . 2  m g/cu  m, and a irw a y  o b s t r u c t io n  h a s b een  o b se r v e d  a t  0 .0 6  
m g/cu  m. A lth o u g h  w o rk ers r e c e iv e d  e x p o su r e s  t o  c o b a l t  m ixed  w ith  o th e r  
s u b s t a n c e s ,  a n im a ls  in h a l in g  c o b a l t  m e ta l  h a v e  s i m i l a r l y  d e v e lo p e d  l e s i o n s  
i n d i c a t i v e  o f  d e v e lo p in g  f i b r o s i s  a t  0 .1  m g/cu  m. The a d v e r s e  lu n g  e f f e c t s  
o b se r v e d  a t  o r  b e lo w  th e  F e d e r a l  p e r m is s ib le  e x p o su r e  l i m i t  ( 0 .1  m g /cu  m) p o se  
th e  s e r io u s  q u e s t io n  o f  w h eth er  t h a t  l i m i t  i s  a d e q u a te . T h is  i s  fu r t h e r  
a g g r a v a te d  by  r e p o r t s  o f  pulm onary h y p e r s e n s i t i v i t y  d e v e lo p in g  i n  w o rk ers
1
ex p o sed  t o  c o b a l t .  Such p e r s o n s ,  o n c e  s e n s i t i z e d ,  c o u ld  p r o b a b ly  n o t  t o l e r a t e  
i n h a l a t i o n  o f  ev e n  s m a l l  am ounts o f  c o b a l t .
I t  i s  w e l l  known t h a t  c o b a l t  i s  a  s k in  s e n s i t i z e r ,  and i s  commonly 
c o n s id e r e d  a s  a  p o s s i b l e  s o u r c e  o f  a l l e r g i c  d e r m a t i t i s .  In  th e  w o r k fo r c e ,  
p e r s o n s  who becom e s e n s i t i v e  t o  c o b a l t  a r e  u s u a l l y  t r a n s f e r r e d  t o  o th e r  j o b s ,  
a lth o u g h  t h e s e  c a s e s  a r e  r a r e l y  r e p o r te d  in  th e  s c i e n t i f i c  l i t e r a t u r e .  S in c e  
s o l u t i o n s  o f  c o b a l t  s a l t s  a r e  u se d  f o r  p a tc h  t e s t i n g  (w h ich  i t s e l f  can  c a u se  
s e n s i t i z a t i o n ) , i t  i s  r e a s o n a b le  t o  b e l i e v e  t h a t  t h e s e  in o r g a n ic  s a l t s  can  
a l s o  c a u s e  d e r m a t i t i s  and s e n s i t i z a t i o n  i n  th e  w o r k p la c e . H ow ever, some 
w o rk ers may a l s o  d e v e lo p  s k in  d i s e a s e s  from  th e  i r r i t a n t  e f f e c t s  o f  c o b a l t -  
c o n ta in in g  d u s t s .  T h ese  p rob lem s a r e  b e s t  c o n t r o l l e d  th ro u g h  p r e v e n t io n  o f  
d u s t  a c c u m u la tio n  by e n g in e e r in g  c o n t r o l s ,  prom pt c le a n u p  o f  s p i l l s ,  and 
c l o t h i n g  t h a t  p r e v e n t s  o r  l i m i t s  e x c e s s i v e  d erm al c o n t a c t  w ith  c o b a l t ,  e i t h e r  
a s  d u s t  o r  i n  s o l u t i o n .
I n fo r m a t io n  on th e  t o x i c  e f f e c t s  r e s u l t i n g  from  i n g e s t i o n  o f  c o b a l t  com es 
from  th e  n o n o c c u p a t io n a l e n v iro n m en t. F or ex a m p le , th e  e f f e c t s  o f  c o b a l t  on  
th e  h e a r t  h a v e  b een  s t u d ie d  b e c a u s e  o f  an o u tb r e a k  o f  a c u te  ca rd io m y o p a th y  in  
b e e r  d r in k e r s .  The amount o f  c o b a l t  consum ed by t h e s e  b e e r  d r in k e r s  was 
s u b s t a n t i a l l y  more th a n  t h a t  In h a le d  by  w o rk ers ex p o sed  a t  th e  c u r r e n t  F e d e r a l  
l i m i t .  The e f f e c t s  o f  c o b a l t  on th e  h e a r t  p r o b a b ly  a r e  l e s s  o f  a h a za rd  th an  
pulm onary f i b r o s i s ,  a lth o u g h  s t u d i e s  a r e  n eed ed  to  d e te r m in e  w h eth er  o r  n o t  
a d v e r s e  e f f e c t s  on th e  h e a r t  becom e d e m o n str a b le  f o l lo w in g  lo n g - te r m  e x p o su r e s  
(s u c h  a s  i n  a  s t a b l e  w o r k fo r c e ) . P o ly c y th e m ia  and su b se q u e n t  d ev e lo p m en t o f  
th y r o id  h y p e r p la s ia  h a v e  a l s o  o c c u r r e d  f o l lo w in g  i n g e s t i o n  o f  c o b a l t  s a l t s .  
H ow ever, p o l /c y th e m ia  d o e s  n o t  ap p ear  t o  b e  a  p a r t i c u l a r l y  t o x i c  r e s p o n s e ,  
e s p e c i a l l y  i n  w o rk ers ex p o sed  to  c o b a l t  a t  0 .1  m g/cu  m o r  l e s s .  E x p erim en ts  
i n  a n im a ls  s u g g e s t  t h a t  som e p e r s o n s  m ig h t d e v e lo p  ch a n g es i n  th e  th y r o id  ev en  
a t  t h e s e  lo w  c o n c e n t r a t io n s ,  e s p e c i a l l y  when in d i v i d u a l  s u s c e p t i b i l i t y  i s  
c o n s id e r e d .  T h is  e v id e n c e  i s  s u f f i c i e n t  t o  recommend p a lp a t io n  o f  th e  th y r o id  
a s  p a r t  o f  th e  m e d ic a l  s u r v e i l l a n c e  f o r  w o rk ers ex p o sed  to  c o b a l t .
S e v e r a l  o th e r  t o x i c  e f f e c t s  can  o c c u r  f o l lo w in g  e x p o su r e  t o  c o b a l t .  
D e g e n e r a t iv e  ch a n g es  in  o r g a n s ,  in c lu d in g  th e  l i v e r ,  k id n e y s ,  and p a n c r e a s ,  
ca n  be d em o n stra ted  i n  a n im a ls .  W h ile  few  s t u d i e s  o f  w o rk ers h a v e  exam ined  
t h e s e  e f f e c t s ,  th e y  do n o t  ap p ear  to  b e  s e v e r e  in  hum ans, ev en  a t  d o s e s  th a t  
p ro d u ce  o th e r  t o x i c  r e s p o n s e s .  I n fo r m a tio n  c o n c e r n in g  th e  a b i l i t y  o f  c o b a l t  
t o  a l t e r  b lo o d  c l o t  fo r m a tio n  i n d i c a t e s  t h a t  t h i s  e f f e c t  may o c c u r  a t  l e v e l s  
c h a r a c t e r i s t i c  o f  th e  w o r k p la c e . C o b a lt  a d m in is te r e d  o r a l l y  a t  1 mg d a i l y  f o r  
o n ly  3 d ays r e s u l t e d  in  a  p r o lo n g e d  tim e  f o r  b lo o d  c l o t  fo r m a tio n  i n  hum ans. 
T h ese  ch a n g es  a r e  n o t  e a s i l y  d is c o u n t e d ,  h a v in g  o c c u r r e d  a t  a low  d o s e ,  b u t  
th e y  n eed  f u r t h e r  d o c u m e n ta tio n .
A t l e a s t  q u a l i t a t i v e l y ,  s y s t e m ic  e f f e c t s ,  su ch  a s  th o s e  on th e  h e a r t ,  
b lo o d ,  and t h y r o id ,  do n o t  ap p ear t o  d i f f e r  g r e a t l y  b e tw een  c o b a l t  compounds 
t e s t e d  o r  r o u te s  o f  a d m in is t r a t io n  u s e d .  Some q u a n t i t a t iv e  d i f f e r e n c e s ,  
h o w ev er , may b e found  a s  more in fo r m a t io n  becom es a v a i l a b l e .  A c r i t i c a l  
q u e s t io n  i s  w h eth er  o r  n o t  a l l  c o b a l t  compounds sh o u ld  b e c o n s id e r e d  t o  be  
p o t e n t i a l l y  c a p a b le  o f  p ro d u c in g  pulm onary f i b r o s i s .  Of th e  many c o b a l t
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compounds in  com m ercia l u s e ,  o n ly  c o b a l t  m e ta l  and c o b a lto u s  o x id e  h a v e  b een  
t e s t e d  by i n h a l a t i o n .
B oth  s u b s ta n c e s  p rod u ced  f i b r o t i c  o r  p r e f i b r o t i c  l e s i o n s  and d em o n stra ted  
a  s u r p r i s in g l y  h ig h  d e g r e e  o f  s o l u b i l i t y  i n  lu n g  t i s s u e .  T h is  in f o r m a t io n ,  
c o u p le d  w ith  r e c e n t  s t u d ie s  i n d i c a t in g  t h a t  w o rk ers e x p o sed  t o  c o b a l t  s a l t s  
h a v e  d e v e lo p e d  a d v e r s e  e f f e c t s  i n  th e  lu n g s ,  m akes i t  p ru d e n t t o  c o n c lu d e  t h a t  
a l l  c o b a l t  compounds may b e c a p a b le  o f  p r o d u c in g  pulm onary f i b r o s i s .
In  r e v ie w in g  th e  in fo r m a t io n  a v a i l a b l e ,  NIOSH fou n d  t h a t  much r e s e a r c h  
rem a in s t o  b e  done b e fo r e  th e  t o x i c  e f f e c t s  o f  th e  many c o b a l t  compounds now 
i n  com m ercia l u s e  can  b e d ocu m en ted . One g o a l  o f  t h i s  p u b l i c a t i o n  i s  t o  b r in g  
th e  p r e s s in g  n eed  f o r  in fo r m a t io n  t h a t  w ould  p e r m it  a b e t t e r  a n a ly s i s  o f  
o c c u p a t io n a l  e x p o su r e  l i m i t s  f o r  c o b a l t  compounds t o  th e  a t t e n t i o n  o f  th e  
r e s e a r c h  and o c c u p a t io n a l  c o m m u n itie s . In  th e  in t e r im ,  ju d gm en ts m u st b e  made 
on how t o  c o n t r o l  w orker e x p o su r e  and e s t a b l i s h  e n v ir o n m e n ta l and m e d ic a l  
m o n ito r in g  p rogram s. A summary o f  t h e s e  recom m en d ation s i s  p r e s e n te d  b e lo w .
E n g in e e r in g  C o n tr o ls
W e ll-m a in ta in e d  c lo s e d  sy s te m s  sh o u ld  b e  u se d  w h en ever p o s s i b l e ,  and 
d i l i g e n t  a t t e n t i o n  p a id  t o  th e  p r e v e n t io n  o f  d u s t  a c c u m u la t io n . P r o p e r ly -  
d e s ig n e d  l o c a l  v e n t i l a t i o n  s h o u ld  b e  u t i l i z e d  f o r  s p e c i f i c  o p e r a t io n s  su ch  a s  
g r in d in g  o r  b u f f in g ;  p a r t i c u l a r  c a r e  i s  n e c e s s a r y  i n  d e s ig n in g  v e n t i l a t i o n  f o r  
h a n d lin g  o p e r a t io n s  w h ere c o b a l t - c o n t a in in g  pow ders may b e  fo rm ed . R e g u la r  
m o n ito r in g  sh o u ld  be c a r r ie d  o u t  f o r  a l l  v e n t i l a t i o n  s y s te m s  by tr a in e d  
p e r s o n n e l .
Work P r a c t i c e s
E m ployers sh o u ld  i n s t i t u t e  and e n su r e  th e  q u a l i t y  o f  program s t h a t  
em p h a size  good p e r s o n a l  h y g ie n e .  P h y s ic a l  h a z a r d s  in v o lv e d  i n  h a n d lin g  
c o b a l t - c o n t a in in g  m a t e r ia l s  sh o u ld  b e  i d e n t i f i e d  and m ea su res ta k en  to  
e l im in a t e  them . The co m b u stio n  p r o p e r t ie s  o f  in d i v i d u a l  c o b a l t  compounds 
s h o u ld  b e known by a l l  who work w ith  them . P ro p er  m eth ods o f  c le a n u p  and 
p la n t  m a in ten a n ce  sh o u ld  b e e s t a b l i s h e d .  S p e c ia l  p r e c a u t io n s  sh o u ld  b e  ta k en  
w h en ever a  ta n k  o r  v e s s e l  i s  e n te r e d .
Work C lo th in g  and P r o t e c t iv e  Equipm ent
The u s e  and p ro p er  c le a n in g  o f  a p p r o p r ia te  work c lo t h in g  i s  r e q u ir e d  t o  
p r e v e n t  s k in  e f f e c t s  and s e n s i t i z a t i o n .  P r o t e c t iv e  eq u ip m en t t h a t  i s  
a p p r o p r ia te  t o  t h e i r  p o t e n t i a l  e x p o su r e s  t o  c o b a l t  sh o u ld  b e  p r o v id e d  f o r  a l l  
w o r k e r s . I f  r e s p i r a t o r s  m ust b e  u sed  f o r  s p e c i f i c  s i t u a t i o n s ,  th e y  sh o u ld  b e  
o f  p ro p er  d e s ig n ,  and w e l l  f i t t e d  and m a in ta in e d .
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Worker E d u ca tio n  and M o n ito rin g
C o n tin u in g  e d u c a t io n  program s sh o u ld  b e  e s t a b l i s h e d  t h a t  em p h a size  to  
w o rk ers p ro p er  h a n d lin g  and c lea n u p  p r o c e d u r e s  f o r  c o b a l t  and i t s  com pounds. 
I n s t r u c t i o n a l  m a t e r ia l  sh o u ld  b e  a v a i l a b l e  t h a t  c o v e r s ,  i n  w r i t t e n  fo rm , good  
work p r a c t i c e s  and known h e a l t h  e f f e c t s ,  a s  w e l l  a s  o th e r  p h y s i c a l  and 
c h e m ic a l p r o p e r t ie s  o f  th e  s u b s ta n c e s  p r e s e n t .
I n d u s t r i a l  h y g ie n e  s u r v e y s  sh o u ld  b e  c a r r ie d  o u t  t o  d e te r m in e  l o c a t i o n s  
w here w o rk ers m ig h t b e ex p o sed  t o  c o b a l t .  T h ese  s u r v e y s ,  c a r r ie d  o u t  a t  3 -  
y e a r  i n t e r v a l s ,  sh o u ld  c o n s i s t  o f  p e r s o n a l  m o n ito r in g  p r o c e d u r e s  a d eq u a te  t o  
e n su r e  th a t  an u n d e r s ta n d in g  o f  w orker e x p o su r e  i s  o b ta in e d .  A l l  m o n ito r in g  
r e c o r d s  sh o u ld  b e m a in ta in e d  f o r  30 y e a r s  f o l lo w in g  te r m in a t io n  o f  em ploym ent.
M e d ica l S u r v e i l la n c e
B eca u se  o f  th e  e f f e c t s  o f  th e  v a r io u s  form s o f  c o b a l t  on th e  b o d y , m e d ic a l  
s u r v e i l l a n c e  program s sh o u ld  b e e s t a b l i s h e d  t h a t  a l lo w  th è  r e s p o n s ib le  
p h y s ic ia n  to  en su r e  t h a t  w o rk ers a r e  a d e q u a te ly  s u r v e y e d . P rim ary  em p h a sis  
sh o u ld  b e p la c e d  on th e  o c c u p a t io n a l  h i s t o r y  and th e  s u r v e i l l a n c e  o f  th e  lu n g s  
and s k in .  D epend ing on th e  s p e c i f i c  work b e in g  d o n e , th e  p h y s ic ia n  may w ish  
to  e v a lu a t e  o th e r  o rg a n s  su ch  a s  th e  b lo o d  and h e a r t .  M e d ic a l r e c o r d s  m ust 
a l s o  b e k e p t  f o r  30 y e a r s  f o l lo w in g  te r m in a t io n  o f  em ploym ent.
The f o l lo w in g  c h a p te r s  p r e s e n t  more d e t a i l e d  in fo r m a t io n  on th e  t o x i c  
e f f e c t s  o f  c o b a l t  and th e  e x t e n t  and d e g r e e  o f  w orker e x p o su r e  to  s u b s ta n c e s  
c o n ta in in g  c o b a l t .  M ethods f o r  sa m p lin g  and a n a ly s i s  o f  a ir b o r n e  c o b a l t ,  
in c lu d in g  a  d e t a i l e d  p r o c e d u r e , a r e  g iv e n .  E n g in e e r in g  c o n t r o ls  and work  
p r a c t i c e s  d e s ig n e d  t o  c o n t r o l  c o b a l t  e m is s io n s  i n t o  th e  w o r k p la ce  a i r  a r e  
p r o v id e d , a s  i s  a  program  recommended f o r  m e d ic a l  and e n v ir o n m e n ta l  
s u r v e i l l a n c e  and w orker t r a in i n g .
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I I .  HEALTH EFFECTS
C o b a lt  o c c u r s  n a t u r a l ly  and c o n s t i t u t e s  a b o u t 0.001%  o f  th e  e a r t h ' s  c r u s t  
[ 1 ] ,  I t  i s  an i n t e g r a l  p a r t  o f  th e  cy a n o co b a la m in  m o le c u le  (v ita m in  B12) , 
w h ich  i s  e s s e n t i a l  i n  th e  human d i e t  t o  p r e v e n t  th e  d ev e lo p m en t o f  p e r n ic io u s  
anem ia [ 2 , 3 ] .  The a v e r a g e  d a i l y  in t a k e  o f  c o b a l t  from  fo o d  f o r  a d u l t s  in  th e  
U n ite d  S t a t e s  h a s b een  e s t im a te d  t o  b e  a b o u t 300 jug> w ith  an a d d i t i o n a l  6 jug 
o b ta in e d  from  w a te r  and l e s s  th a n  0 .1  jug from  com m unity a i r  [ 4 ] .
Even th ou gh  c o b a l t  s a l t s  had b een  u se d  f o r  c e n t u r ie s  to  c o lo r  p o t t e r y  and 
j e w e lr y  [ 1 , 5 ] ,  th e  f i r s t  m ajor i n d u s t r i a l  a p p l i c a t io n  o f  c o b a l t  m e ta l  d id  n o t  
o cc u r  u n t i l  1927 [ 6 ] .  A t t h a t  t im e  i t  w as d is c o v e r e d  t h a t  tu n g s te n  c a r b id e ,  
o f t e n  in  co m b in a tio n  w ith  t i ta n iu m  c a r b id e  and o th e r  m e t a l s ,  c o u ld  b e h e a te d  
i n  th e  p r e s e n c e  o f  c o b a l t  u sed  a s  a  b in d e r .  T h is  p r o c e s s  r e s u l t e d  i n  a  new  
s u b s ta n c e  r e f e r r e d  t o  a s  cem ented  tu n g s te n  c a r b id e  o r  hard  m e ta l .
The c u r r e n t  OSHA s ta n d a r d  f o r  o c c u p a t io n a l  e x p o su r e  t o  c o b a l t  i s  b a sed  on  
th e  T h r esh o ld  L im it  V a lu e  (TLV) o f  th e  A m erican  C o n fer en ce  f o r  G overnm ental 
I n d u s t r i a l  H y g ie n is t s  (ACGIH) in  e f f e c t  i n  1968 [ 7 ] .  In  1 9 7 5 , th e  ACGIH 
C om m ittee on T h r esh o ld  L im it  V a lu e s  p ro p o sed  lo w e r in g  th e  TLV f o r  c o b a l t  m e ta l  
fume and d u s t  to  0 .0 1  mg c o b a l t / c u  m [ 8 ] .  T h is  p ro p o sed  v a lu e  was 
s u b s e q u e n t ly  amended t o  0 .0 5  mg c o b a l t / c u  m i n  1976 [ 9 ] ,  and i t  rem ained  a s  an  
in te n d e d  ch an ge i n  1980 [ 1 0 ] .
D a ta  p r o je c t e d  f o r  th e  f i r s t  q u a r te r  o f  1980 from  th e  N a t io n a l  
O c c u p a tio n a l H azard S u r v e y , co n d u c ted  by NI0SH i n  1 9 7 2 -7 4 , i n d i c a t e  w id e sp r e a d  
p o t e n t i a l  f o r  e x p o su r e  t o  c o b a l t .  About 8 6 7 ,0 0 0  w o rk ers w ere e s t im a te d  t o  be  
e x p o sed  t o  c o b a l t  o x i d e s ,  and 2 3 5 ,0 0 0  t o  c o b a l t  m e ta l .  A t l e a s t  3 0 0 ,0 0 0  w ere  
e s t im a te d  t o  b e  ex p o sed  to  w hat was i d e n t i f i e d  o n ly  a s  c o b a l t  d r i e r ,  and 
7 9 ,0 0 0  p o s s ib l y  ex p o sed  t o  on e d r i e r ,  c o b a l t  n a p h th e n a te . E xp osu re  e s t im a t e s  
f o r  v a r io u s  c o b a l t  s a l t s  a r e  much lo w e r ,  r a n g in g  from  1 ,7 0 0  t o  2 1 ,0 0 0  w o r k e r s ,  
b u t a r e  s t i l l  s u b s t a n t i a l .  (E x a c t  f i g u r e s  a r e  g iv e n  i n  T a b le  I X - 1 . )
Much o f  th e  in fo r m a t io n  on c o b a l t ' s  e f f e c t s  on humans i s  n o t  from  th e
o c c u p a t io n a l  s e t t i n g .  F or ex a m p le , a t  on e t im e  i t  w as common t o  p r e s c r ib e  
m ix tu r e s  o f  c o b a l t  and ir o n  t o  anem ic p a t i e n t s  i n  o r d e r  t o  s t im u la t e  red  b lo o d  
c e l l  p r o d u c t io n . T h is  p r a c t i c e  l e d  t o  th e  d is c o v e r y  t h a t  c o b a l t ,  in  a d d i t io n  
t o  p ro d u c in g  p o ly c y th e m ia , c o u ld  a d v e r s e ly  a f f e c t  th e  t h y r o id .  A n oth er  
exam ple i s  th e  c o n s id e r a b le  r e s e a r c h  co n d u c ted  on th e  h e a r t  e f f e c t s  o f  c o b a l t  
a f t e r  an o u tb rea k  o f  a c u te  ca rd io m y o p a th y  i n  b e e r  d r in k e r s  who had consum ed  
c o b a l t  a s  an a d d i t iv e  in  b e e r .
A lm ost a l l  in fo r m a t io n  on a d v e r s e  e f f e c t s  i n  w o rk ers ex p o sed  t o  c o b a l t  i s  
from  th e  h ard  m e ta l  in d u s t r y .  Pulm onary f i b r o s i s  was f i r s t  d e s c r ib e d  i n  hard  
m e ta l  w o rk ers i n  a  1940 r e p o r t  in  Germany [ 1 1 ] ,  w h ich  was so o n  fo l lo w e d  by
o t h e r s .  Such r e p o r t s  p e r s i s t  ev en  th ou gh  th e  c u r r e n t  F e d e r a l  s ta n d a r d  (2 9  CFR
Background
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1 9 1 0 .1 0 0 0 )  f o r  c o b a l t  o f  0 .1  m g/cu  m w as b a s e d , t o  a g r e a t  e x t e n t ,  on 
p r e v e n t io n  o f  h ard  m e ta l  d i s e a s e .
R e s p ir a to r y  E f f e c t s
E xp osu re to  a  s i n g l e  s u b s ta n c e  i n  th e  o c c u p a t io n a l  en v iro n m en t r a r e ly  
o c c u r s .  For c o b a l t ,  a lm o s t  a l l  r e p o r te d  c a s e s  o f  r e s p ir a t o r y  e f f e c t s  in  
w o rk ers co n cern ed  m ixed  e x p o s u r e s  In  th e  cem en ted  tu n g s te n  c a r b id e  I n d u s tr y .  
O th er s u b s ta n c e s  p r e s e n t  w ere tu n g s te n  c a r b id e ,  and so m etim es o th e r  m e ta l  
c a r b id e s  o r  m a t e r ia l  from  g r in d in g  w h e e ls .  W orkers who m a n u fa c tu re  a l l o y s  
c o n ta in in g  c o b a l t  a r e  p o t e n t i a l l y  e x p o sed  t o  many o th e r  m e ta ls  in c lu d in g  
n i c k e l ,  chrom ium , i r o n ,  van ad iu m , and m olybdenum . The e f f e c t s  o f  c o n co m ita n t  
ex p o su r e  t o  th e s e  m a t e r ia l s  i s  unknown.
(a )  Hard M eta l D is e a s e
Numerous c a s e  r e p o r t s  [ 1 2 - 2 2 ] ,  m e d ic a l  e x a m in a tio n s  [ 1 1 ,2 3 - 3 2 ] ,  and 
in d u s tr y - w id e  s t u d ie s  [3 3 -3 8 ]  d e m o n str a te  th e  p r e s e n c e  o f  hard  m e ta l d i s e a s e  
in  th e  o c c u p a t io n a l  en v iro n m en t (T a b le  I X - 2 ) . A lth o u g h  t h i s  i s  by no means a 
r e c e n t  d i s c o v e r y ,  pulm onary f i b r o s i s  rem a in s a  p rob lem  in  th e  cem ented  c a r b id e  
in d u s t r y .  A common p a t t e r n  o f  th e  i l l n e s s  i s  d e s c r ib e d  i n  th e s e  r e p o r t s .  
F i r s t ,  th e  w orker d e v e lo p s  a  co u g h , f o l lo w e d  by la b o r e d  b r e a th in g  on e x e r t i o n .  
The p e r so n  may l o s e  a  s u b s t a n t i a l  amount o f  w e ig h t  and d e v e lo p  a  p r o g r e s s iv e  
i n t e r s t i t i a l  pulm onary f i b r o s i s ;  in  th e  f i n a l  s t a g e s  le a d in g  t o  d e a th ,  co r  
p u lm o n a le  and c a r d io r e s p ir a t o r y  c o l l a p s e  a r e  u s u a l l y  e x p e r ie n c e d .  C h est  
r a d io g r a p h s  r e v e a l  in c r e a s e d  l i n e a r  s t r i a t i o n s  and d i f f u s e  n o d u la r  o p a c i t i e s  
i n  th e  m id d le  and lo w e r  z o n es  o f  th e  lu n g  [ 3 9 ] .  The d e g r e e  o f  a b n o r m a lity  
e v id e n t  i n  th e  r a d io g r a p h s  becom es g r e a t e r  a s  th e  s t a g e  o f  th e  d i s e a s e  becom es  
more s e v e r e .  In  some c a s e s ,  th e  d i s e a s e  h a s  b een  r e v e r s i b l e  o r  h a s n o t  
p r o g r e s s e d  [ 1 3 ,2 3 - 2 8 ]  i f  i t  was d e t e c t e d  a t  an e a r ly  s t a g e  and th e  w orker  
r e c e iv e d  no fu r t h e r  e x p o su r e  to  c o b a l t .
W h ile  c h e s t  r a d io g r a p h s  can  d e t e c t  f i b r o t i c  l e s i o n s ,  d ia g n o s t i c  t o o l s  
c a p a b le  o f  m ea su r in g  a d v e r s e  e f f e c t s  a t  an e a r l i e r  s t a g e  a r e  c l e a r l y  n e e d e d .  
S p ir o m e tr ic  e x a m in a tio n  t o  d e t e c t  r e s t r i c t i v e  v e n t i l a t o r y  im p airm en t i s  one  
p o s s i b i l i t y ,  b u t th e  r e s u l t s  do n o t  a g r e e  t o t a l l y  on th e  s e n s i t i v i t y  o f  t h i s  
t e s t .  P erh a p s much o f  th e  c o n f l i c t i n g  e v id e n c e  i s  th e  r e s u l t  o f  th e  l e s s  
s o p h i s t i c a t e d  eq u ip m ent a v a i l a b l e  to  th e  e a r l i e r  i n v e s t i g a t o r s .  M i l l e r  e t  a l  
[ 2 3 ] ,  i n  1 9 5 3 , o b se r v e d  th a t  th r e e  t o o l  g r in d e r s  had red u ced  v i t a l  c a p a c i t y ,  
b u t a l l  th r e e  a l s o  had r e t i c u l a t i o n s  c l e a r l y  e v id e n t  i n  c h e s t  r a d io g r a p h s .  
B a rb o r ik  [ 3 3 ] ,  i n  1 9 6 6 , o b se r v e d  d is t u r b a n c e s  o f  pulm onary v e n t i l a t i o n  i n  25 
o f  116 cem ented  c a r b id e  w r k e r s ,  b u t he a l s o  o b se r v e d  ch a n g es  i n  th e  c h e s t  
r a d io g r a p h s  o f  31 o f  193 (n o t  a l l  r e c e iv e d  s p ir o m e t r ic  e x a m in a t io n s ) . T uros  
e t  a l  [ 2 9 ] ,  i n  1 9 6 9 , a c t u a l l y  fou n d  a  g r e a t e r  number o f  abnorm al r a d io g r a p h s  
th a n  ch a n g es in  v i t a l  c a p a c i t y  i n  a  group o f  62 cem ented  c a r b id e  w o r k e r s . In  
c o n t r a s t ,  a  more r e c e n t  s tu d y  o f  22 t o o l  g r in d e r s  by L ic h t e n s t e in  e t  a l  [4 0 ]  
fou n d  no r a d io g r a p h ic  e v id e n c e  o f  f i b r o t i c  l e s i o n s  ev en  th ou gh  s e v e r a l  w ork ers  
had s l i g h t  r e d u c t io n s  in  fo r c e d  v i t a l  c a p a c i t y .
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A s e r i e s  o f  r e p o r t s  [4 1 -4 3 ]  d e s c r ib e d  th e  r e s u l t s  o f  lu n g  f u n c t io n  t e s t s  
in  155 S w ed ish  cem ented  c a r b id e  w o rk ers and 74 c o n t r o ls  m atched  f o r  s e x ,  a g e ,  
and sm oking h i s t o r y .  T e s t s  co n d u c ted  In c lu d e d  s p ir o m e tr y  and s i n g l e  b r e a th  
n it r o g e n  w a sh o u t . P e r s o n s  ex p o sed  a t  c o b a l t  c o n c e n t r a t io n s  o f  0 .0 0 5 - 0 .0 1  
m g/cu  m, p e r s o n s  d ry  p o l i s h i n g  s i n t e r e d  m a t e r ia l  (a v e r a g e  e x p o su r e  o f  0 .0 1  
m g/cu  m ), and p e r s o n s  w e t p o l i s h i n g  s i n t e r e d  m a t e r ia l  (a v e r a g e  e x p o su r e  o f  
0 .0 0 8  m g/cu  m) showed som e ch a n g es  i n  pulm onary f u n c t io n  d u r in g  th e  w ork in g  
w eek , b u t  r e c o v e r e d  o v e r  th e  w eek en d . I n s p e c t o r s  (a v e r a g e  e x p o su r e  o f  0 .0 0 2  
m g/cu  m) showed no c h a n g e s . P e r s o n s  who w ere h e a v i l y  e x p o sed  (a v e r a g e  c o b a l t  
c o n c e n t r a t io n  o f  0 .0 6  m g/cu  m) show ed ch a n g es  th ro u g h o u t th e  w eek , w h ich  d id  
n o t  r e g r e s s  o v e r  th e  w eekend o r  ev e n  o v e r  1-m onth  v a c a t io n s .  Sm okers w ere  
m ore a f f e c t e d  th a n  n o n sm o k ers. The a u th o r s  in t e r p r e t e d  th e  ch a n g es  in  
pulm onary f u n c t io n  t e s t s  a s  e v id e n c e  o f  a irw a y  o b s t r u c t io n .  T hey n o te d  t h a t  
th e y  c o u ld  n o t  e x c lu d e  th e  p o s s i b i l i t y  o f  c h r o n ic  r e d u c t io n  o f  lu n g  f u n c t io n  
i n  th e  m ost ex p o sed  g ro u p .
A lth o u g h  d i f f u s e  i n t e r s t i t i a l  lu n g  d i s e a s e  h a s  c l e a r l y  b een  d em o n stra ted  
a s  an o c c u p a t io n a l  d i s e a s e  r e la t e d  t o  e x p o su r e  in  th e  h ard  m e ta l  in d u s t r y ,  th e  
d u s t  c o n c e n t r a t io n s  t h a t  c a u se  an e f f e c t  and th e  r o l e  o f  c o b a l t  m ust b e  
c o n s id e r e d .  E xp osu re e s t im a t e s  w ere  g iv e n  i n  some c a s e s ,  b u t th e  d u r a t io n  o f  
e x p o su r e  was u n c le a r  f o r  p e r s o n s  who d e v e lo p e d  f i b r o s i s .  In  som e i n s t a n c e s ,  
f i b r o s i s  was r e p o r te d  a f t e r  o n ly  a  few  y e a r s  o f  e x p o su r e  [ 1 1 ,1 3 ,2 9 ] ;  i n  
o t h e r s ,  some p e r s o n s  had b een  ex p o sed  m ore th a n  20 y e a r s  [ 2 6 , 3 0 ,3 4 ] .  R ecen t  
i n v e s t i g a t i o n s  [3 0 ,4 0 ]  h a v e  shown l o c a l i z e d  c lo u d s  o f  d u s t  i n  th e  b r e a th in g  
z o n es  o f  g r in d in g  m ach in e o p e r a t o r s ,  a  f a c t o r  t h a t  may h a v e  b een  m is s e d  i n  
e a r l i e r  r e p o r t s .  A l l  o f  t h e s e  f a c t o r s  c o u ld  a c c o u n t  f o r  d is c r e p a n c ie s  i n  th e  
o b se r v e d  l e v e l s  o f  a ir b o r n e  c o b a l t  a t  w h ich  f i b r o s i s  h a s  o c c u r r e d .
N e v e r t h e l e s s ,  some c o r r e l a t i o n  b e tw e en  c o b a l t  e x p o su r e  and a d v e r s e  e f f e c t s  i n  
h ard  m e ta l  w o rk ers can b e m ade. B eca u se  m ixed  e x p o s u r e s  t o  c o b a l t  and o th e r  
s u b s ta n c e s  o c c u r r e d , th e  r o l e  o f  c o b a l t  in  p ro d u c in g  th e  e f f e c t s  can  b e  
e s t a b l i s h e d  o n ly  when s u p p o r t in g  e v id e n c e  i n  e x p e r im e n ta l  a n im a ls  becom es  
a v a i l a b l e .  Such in fo r m a t io n  e x i s t s  now o n ly  f o r  c o b a l t  m e ta l  [4 4 ] and
c o b a lto u s  o x id e  [ 4 5 ] .
E x p o su res  i n  th e  hard  m e ta l  in d u s t r y  w here th e  c o b a l t  c o n c e n t r a t io n  i n  th e  
a i r  a v er a g ed  s e v e r a l  m i l l ig r a m s  w ere c l e a r l y  i n t o l e r a b l e  t o  w o r k e r s . For  
ex a m p le , K a p lu n 's  s tu d y  [ 3 5 ] ,  r e p o r te d  i n  1 9 5 7 , d e s c r ib e d  pulm onary ch a n g es  in  
8 o f  247 w o r k e rs; e x p o su r e  l e v e l s  m easured  i n  th e  p la n t  w ere  0 .8 - 1 2  mg o f  
c o b a l t / c u  m o f  a i r .  The w o rk ers co m p la in ed  o f  n a u s e a , ab d om in al p a in s ,  l o s s  
o f  a p p e t i t e ,  co u g h , and a  d e t e r i o r a t i o n  o f  th e  s e n s e  o f  s m e l l .  Some a l s o  had  
d e c r e a s e d  h em o g lo b in  (Hb) l e v e l s  and red  b lo o d  c e l l  (RBC) c o u n t s ,  l i v e r  and 
s p le e n  e n la r g e m e n t , and d e r m a t i t i s .  A f t e r  d u s t  c o n t r o l  m ea su res w ere
im p lem en ted , th e  l e v e l s  o f  a ir b o r n e  c o b a l t  d e c r e a s e d  t o  0 . 4 - 3 . 3  m g/cu  m. 
L a te r ,  117 w o rk ers w ere ex a m in ed , and 35 (30%) had c h r o n ic  b r o n c h i t i s ,  33
(29%) had e a r ly  f i b r o t i c  ch a n g es  e v id e n t  i n  c h e s t  r a d io g r a p h s ,  and 52 (44%) 
had d e c r e a s e d  b lo o d  p r e s s u r e .  R ea so n s f o r  th e  in c r e a s e d  in c id e n c e  o f  
pulm onary ch a n g es a t  th e  lo w e r  e x p o su r e  l e v e l  w ere  n o t  g iv e n .  Any number o f  
f a c t o r s  c o u ld  h a v e  b een  in v o lv e d ,  in c lu d in g  th e  s lo w ly  p r o g r e s s iv e  n a tu r e  o f  
f i b r o s i s  i n  an a g in g  w o r k fo r c e .
7
B a rb o r ik  [3 3 ] d e s c r ib e d  an i n v e s t i g a t i o n  o f  193 hard  m e ta l  w o rk ers (104  
men and 89 women) who had b een  em ployed  fo r  1 -1 3  y e a r s .  D u st c o n c e n t r a t io n s  
i n  th e  p la n t  w ere 1 3 -1 0 0  m g/cu  m, and th e  d u s t  c o n ta in e d  5-25% m e t a l l i c
c o b a l t .  Of th e  193 w o r k e r s , 47% s u f f e r e d  from  cou gh ; num erous w o rk ers i n  th e
p r e p a r a to r y  a r e a  and th e  fo rm in g  a r e a  a l s o  co m p la in ed  o f  la b o r e d  b r e a t h in g ,  a 
b u rn in g  s e n s a t io n  in  th e  t h r o a t ,  and l o s s  o f  th e  s e n s e  o f  s m e l l .  In  31 
w o r k e r s , d i s t i n c t  ch a n g es w ere o b serv e d  i n  r a d io g r a p h ic  f i lm s  o f  th e  lu n g s ,  
and 25 o f  th e  116 w o rk ers exam ined  show ed m o d e r a te ly  s e v e r e  t o  s e v e r e
d is t u r b a n c e s  o f  pulm onary v e n t i l a t i o n .
S a lik h o d z h a y e v  and V en g ersk a y a  [3 6 ] r e p o r te d  t h a t  73 o f  178 h ard  m e ta l  
w o rk ers (41%) had c h r o n ic  r h i n i t i s  and r h in o p h a r y n g i t i s .  C o b a lt
c o n c e n t r a t io n s  in  th e  a i r  ran ged  from  0 .4  m g/cu  m w h ere th e  d i s t i l l e r s  w ere  
u n lo a d ed  to  2 .9  m g/cu  m a t  th e  s i f t i n g  s i t e .  In  a  su b se q u e n t  r e p o r t  [4 6 ] th a t
a p p ea rs  to  b e on th e  same w o r k e r s , 50% o f  th o s e  exam ined  r e p o r te d  t o x i c  s ig n s
or sym ptom s. The m ost fr e q u e n t  w orker c o m p la in ts  in c lu d e d  la b o r e d  b r e a t h in g ,  
c o u g h in g , p ounding o f  th e  h e a r t ,  h e a d a c h e , d i z z i n e s s ,  n a u s e a , l o s s  o f
a p p e t i t e ,  and o l e f a c t o r y  d i s o r d e r s .  M e d ic a l t e s t s  r e v e a le d  e v id e n c e  o f  
a l t e r e d  k id n e y  and l i v e r  f u n c t io n .
In  s e v e r a l  s t u d i e s ,  a ir b o r n e  d u s t  m easurem en ts w ere m ade, b u t th e
in fo r m a t io n  i s  in a d e q u a te  t o  p r o v id e  a m e a n in g fu l r e l a t i o n s h i p  b etw een  c o b a l t  
ex p o su re  and f i b r o s i s .  F or ex a m p le , M o sc h in sk i e t  a l  [3 4 ] exam ined  282 m ale  
and 23 fe m a le  w ork ers a t  fo u r  p l a n t s ,  56 o f  whom had r a d io g r a p h ic  e v id e n c e  o f  
f i b r o s i s ,  b u t found no r e l a t i o n s h i p  b e tw een  d u r a t io n  o f  e x p o su r e  and o n s e t  o f
sym ptom s. A s im i la r  d i f f i c u l t y  e x i s t s  in  a n a ly s i s  o f  th e  r e p o r t  o f  R eber and
B urck h ard t [ 1 3 ] .  N in e  w o rk ers showed s ig n s  o f  p n e u m o c o n io s is ,  b u t on e o f  two 
ex p o su r e  e s t im a t e s  v a r ie d  from  0 .0 6  t o  0 .3  mg c o b a l t / c u  m. T o lo t  e t  a l  [24 ]
and D o r s i t  e t  a l  [2 5 ] o b serv e d  3 c a s e s  o f  f i b r o s i s  and 26 c a s e s  o f  l e s s e r
pulm onary in v o lv e m e n t i n  w o rk ers em ployed  i n  a  p la n t  th a t  m a n u fa ctu red  a l l o y s  
o f  s in t e r e d  m e t a ls .  S in c e  d u s t  c o n c e n t r a t io n s  w ere 2 .3 - 1 0 .6  m g/cu  m and 
c o n ta in e d  0 .0 1 -0 .3 %  c o b a l t ,  t h i s  m ig h t d e m o n str a te  a f i b r o t i c  r e s p o n s e  a t  v e r y  
low  c o n c e n t r a t io n s  o f  c o b a l t .  H ow ever, th e  m ajor com ponents o f  th e  d u s t  w ere  
n o t  i d e n t i f i e d .  J ir k o v a  [ 3 0 ] ,  i n  1 9 7 1 , d e s c r ib e d  an e x a m in a tio n  o f  61 
g r in d e r s  em ployed in  th e  p r o d u c t io n  o f  s i n t e r e d  c a r b id e s .  C o n c e n tr a t io n s  o f  
a ir b o r n e  c o b a lt  n ea r  g r in d in g  m a ch in es w ith  c o o l in g  o r  d u s t - c o l l e c t i n g  
eq u ip m ent a v era g ed  0 .0 4 3  m g/cu  m (r a n g e ,  0 . 0 0 6 - 0 .0 9 ) .  N ear g r in d in g  m a ch in es  
w ith o u t  s a f e g u a r d s ,  th e  c o n c e n t r a t io n  was 1 .2  m g /c u m  (r a n g e ,  0 . 8 4 - 1 . 3 ) .  
U n fo r t u n a te ly ,  th e  r e p o r t  d id  n o t  s t a t e  w h eth er  a l l  6 w o rk ers w ith  f i b r o s i s  or  
th e  23 w ith  l e s s e r  s ig n s  w ere ex p o sed  a t  th e  h ig h e r  d u s t  l e v e l s  and w h eth er  
a l l  o f  th e  w ork ers u sed  b o th  ty p e s  o f  eq u ip m en t.
Few r e p o r t s  d e s c r ib e d  t o x i c  e f f e c t s  i n  hard  m e ta l  w o rk ers a t  r e l a t i v e l y  
low  and c o n s ta n t  c o n c e n t r a t io n s  o f  c o b a l t .  F a i r h a l l  e t  a l  [3 7 ] fou n d  l i t t l e  
e v id e n c e  o f  f i b r o s i s  i n  a group o f  1 ,8 0 2  w o r k e r s , some o f  whom w ere p ro b a b ly  
ex p o sed  to  c o b a l t  a t  m easured  l e v e l s  o f  0 . 0 5 - 0 .1 4  m g/cu  m. B eca u se  t h i s  
c r o s s - s e c t i o n a l  in d u s tr y  su r v e y  was r e p o r te d  o n ly  20 y e a r s  a f t e r  th e  p r o c e s s  
was f i r s t  d e v e lo p e d , many p e r s o n s  i n  th e  group  had p r o b a b ly  b een  ex p o sed  to  
c o b a l t  f o r  o n ly  a s h o r t  t im e . M i l l e r  e t  a l  [ 2 3 ] ,  a l s o  i n  an o ld e r  s tu d y ,  
d e s c r ib e d  th r e e  c a s e s  o f  f i b r o s i s  in  t o o l  g r in d e r s .  The c o n c e n t r a t io n s  o f  
c o b a l t  i n  th e  b r e a th in g  zon e o f  g r in d in g  m ach in e o p e r a to r s  w ere 0 . 1 - 0 .2
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mg/cu m; tungsten was not found in general air samples. These three workers 
had been exposed for 6-8.5 years, and had used silicon carbide and aluminum 
oxide wheels, although a diamond wheel was used for most grinding. In 1975, 
Lichtenstein et al [40] found some cases of early signs of restrictive 
ventilatory impairment, but no radiographic evidence of fibrosis, in 22 
grinding machine operators using diamond wheels and exposed to cemented 
carbide dust for 1-30 years. The mean TWA concentration of cobalt in the 
breathing zones of seven individuals was 0.18 mg/cu m (range, 0.03-0.43); four 
concentrations exceeded 0.1 mg/cu m. The latter two studies [23,40] support a 
tentative conclusion that hard metal workers can develop fibrosis or 
prefibrotic changes when exposure to cobalt is in the range of 0.1-0.2 
mg/cu m. The Swedish studies [41-43] suggest possible chronic lung 
obstruction at average concentrations of 0.06 mg/cu m.
(b) Other Respiratory Diseases in Hard Metal Workers
Several reports have also described evidence of bronchitis [11,13,29,34], 
emphysema [13,14,16,30], or asthma [13,14,24-26,47] in workers exposed to 
cobalt in the hard metal industry. Bronchitis was said to be more prevalent 
in workers exposed to what were described only as large dust particles;
pneumoconiosis was said to have occurred more often after exposure to dusts of 
smaller size [11].
The asthmatic responses seem to represent a true sensitization to cobalt. 
These persons developed a hacking [26] or wheezy [14,26] cough within 1 month 
[26] to 1.7 years [24,25] of initial exposure to cobalt. One person also had 
eczema [13]. Recovery occurred when the workers left the work environment 
[13,14,24-26,47]. One worker remained on his job as a tool grinder, and he 
developed nodules visible on chest radiographs 2.5 years later [26]. The 
others had no signs of fibrosis.
A recent study at a Swedish hard metal plant attributed four cases of 
allergic alveolitis to exposure to soluble cobalt dissolved in the coolant 
used for wet grinding [48]. One worker showed only signs and symptoms of
asthma, but the other three showed evidence of mild pulmonary fibrosis as
well. All four had contact eczema and were sensitive to cobalt. Even though 
they ceased all exposure to cobalt, the four persons have continued to show 
abnormalities on their chest radiographs.
(c) Other Reports of Respiratory Disease in Workers Exposed to Cobalt
Studies of the effects of cobalt exposure on workers not employed in the 
manufacture or use of hard metal are rare, but some indicate pulmonary disease 
in these workers. At a Finnish metal refinery, one or two new cases of
bronchial asthma had been diagnosed annually in a group of 230-240 cobalt 
workers [49]. A cross-sectional study demonstrated a highly significant 
correlation between exposure to cobalt sulfate and asthma. In contrast, 
nonasthmatic cobalt workers at the same plant had no evidence of any excess of 
chronic bronchitis. Kochetkova [50] described the death of a woman with a 
history of 7 years of exposure to metallic cobalt dust. The cause of death 
was cardiopulmonary insufficiency resulting from massive fibrosis. Levels of
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cobalt in the lung, liver, heart, ««id kidney tissue were described as markedly 
elevated. Her heart was enlarged, the liver and spleen were congested, and 
the cortical layer of the kidneys was swollen. In contrast, Cau et al [51] 
did not find radiographic evidence of fibrotic damage to the lungs of seven 
workers employed as sifters of cobalt powder. The workers had been exposed 
from 2 to 5 years, and they complained of cough, exertional dyspnea, 
nasopharyngeal irritation, and digestive disorders; two subjects had 
polycythemia. The authors concluded that exposure to finely divided cobalt 
metal dust did not induce pulmonary damage. In light of the toxic signs 
described by the workers and the short duration of exposure, this conclusion 
seems inappropriate.
An extensive study of workers exposed to cobalt was reported by Verhamme 
[52] in 1973. Medical examinations had been given to workers at a plant where 
cobalt oxides, powders, and salts were produced. Measurements of airborne 
cobalt were not reported, but the author believed that workers in the 
hydrometallurgic area had little or no dust exposure and that workers in the 
salts, oxides, and finished powders production areas were the most exposed 
groups. The finished powders had an average diameter of less than 1.4 jum, and 
oxides averaged 3 m  in diameter. Radiographic examination of 120 workers 
revealed no changes in 112 persons, accentuated pulmonary reticulations in 1
worker, fibrotic changes in 4 individuals known to have had tuberculosis, and
evidence of pneumoconiosis in 3 workers with extensive coal mining experience. 
Several workers employed 15-20 years in the production of cobalt oxides showed 
symptoms of chronic bronchitis that improved or disappeared with job transfer. 
The plant had assigned workers to areas on the basis of their medical 
histories.
(d) Evidence in Animals
Several investigative groups have administered cobalt intratracheally in 
animals and reported adverse effects on the lung. Harding [53] found marked 
edema and hemorrhages in the lungs of rats shortly after they were
administered large doses of cobalt metal. Guinea pigs given 10 or 25 mg of
cobalt metal developed acute pneumonitis [54]. The lungs of guinea pigs that 
survived a 50-mg injection of cobalt metal had perivascular diffuse cellular 
infiltration and many eosinophils within the alveoli [55]. Regional 
obliterative bronchiolitis, with peribronchiolar fibrosis and arteriolar 
spasm, was also present. After 12 months, there was fibrocellular 
infiltration and there were regions of adenomatosis where cobalt metal was 
deposited. Those that survived a 25-mg dose had similar but less intense 
evidence of damage to the lungs, and a 10-mg dose produced no long-term tissue 
damage. The effects in guinea pigs [55] were consistent with those described 
by Schiller [56], who observed that as little as 1 mg of cobalt produced 
intra-alveolar pulmonary edema and inflammation of the bronchioles of rats 
after 6 hours; no tissue damage was observed 3 months later. These studies 
clearly demonstrate adverse reactions of both a short- and long-term nature.
Although tungsten carbide was nontoxic when administered intratracheally 
to animals, different results occurred when this substance was mixed with 
cobalt. Delahant [54] noted that tungsten metal dust, tungsten carbide, and a
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91:9 mixture of tungsten carbide and cobalt administered in 150-mg doses 
produced no deaths in guinea pigs. Elaborating on this study, Schepers [57] 
reported that the lungs of guinea pigs administered the 91:9 mixture contained 
focal accumulation of massed particles In the alveolar spaces surrounded by 
fibrous tissue. This study [57] supports the previous one [55] suggesting a 
fibrogenic potential for cobalt, but it does not clarify whether the reaction 
is intensified by the presence of tungsten carbide.
Studies that have examined subchronic or chronic effects of inhalation of 
cobalt compounds are limited. In one such experiment, Kerfoot et al [44] 
exposed miniature swine to aerosols of cobalt metal. Two experimental groups, 
exposed to cobalt at 0.1 mg/cu m or 1 mg/cu m, and one control group of five 
animals were used. To investigate the suggestion of Bruckner [58] that 
pulmonary reactions to cobalt may be mediated through a hypersensitivity 
mechanism, Kerfoot et al first exposed the experimental animals 6 hours a day 
for 5 days. After a 10-day lapse, the animals were reexposed 6 hours daily, 5 
days a week for 3 months. All animals appeared normal until the 4th week of 
exposure, after which time the animals from both cobalt groups became
lethargic. Some animals appeared to be wheezing during exposure; this was 
confirmed by auscultation.
Postexposure pulmonary function tests showed a significant reduction in 
mean tidal volume, mean total compliance, and mean specific compliance in both 
cobalt-exposed groups [44]. The authors interpreted change in compliance as 
demonstrating functional lung impairment. This change was reversed in animals 
examined 2 months after the cobalt exposure ended.
Serial radiographs conducted on all animals showed no evidence of diffuse 
pulmonary disease [44]. The animals were examined grossly and by light
microscopy at necropsy, and the lungs, heart, liver, and kidneys did not show 
any persistent or significant abnormalities. There was no evidence of cobalt 
in any lung tissue examined. Electron microscopic examination of lung biopsy 
tissue taken at the end of exposure revealed masses of collagen, elastic 
tissue, and fibroblasts in some of the tissues. However, no quantitative 
analysis was presented, nor was there mention of the methodology used in 
selecting tissue sites for examinations. The greatest changes were observed 
in the high-concentration cobalt exposure group, with the fewest changes being 
observed in controls.
In a Soviet study, male albino rats received exposures to aerosols of 
metallic cobalt continuously (24 hours a day, 7 days a week) for 3 months
[59,60]. There apparently was a concurrent control group, but the reports did
not contain important details such as the number of animals exposed or tables 
of results presenting actual data. Chronic inhalation of cobalt at 0.5 
mg/cu m was said to be irritating to the lungs [59]. The animals exposed to 
cobalt at 0.05 and 0.005 mg/cu m were described as having changes similar to, 
but less pronounced than, the changes in animals exposed at 0.5 mg/cu m. The 
lowest concentration (0.001 mg/cu m) produced what was described only as a 
weak general toxic effect.
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Microscopic examination of lung tissue from animals exposed at the highest 
concentration of 0.5 mg/cu m revealed accumulations of macrophages in the 
alveoli [60]. Interalveolar septa were consolidated in several areas of the 
lung. The severity of these changes reportedly was related to the exposure 
concentration. The lungs of animals exposed at 0.001 mg/cu m were described 
as similar to those of controls. While information in this report is not 
completely satisfactory, effects such as consolidation of the alveolar septa 
are indicative of a prefibrotic condition.
Wehner et al [45] exposed 2-month-old Syrian golden hamsters to cobaltous
oxide aerosols at 10 mg/cu m for their lifespans. The animals were exposed 
for 7 hours daily for 5 days a week to aerosols with a median diameter of 0.45 
(an. Particulate material accumulated in alveolar macrophages and became 
denser as exposure continued. Emphysema became apparent. The extent of the 
changes became more severe as exposure time increased, and hyperplasia and 
hypertrophy of alveolar lining cells also appeared. Macrophages, frequently 
containing particulate matter, increased in number throughout the lung, and 
numerous focal accumulations of these cells could be found. Proliferative 
changes involving the epithelial components of bronchi and bronchioles became 
detectable early during exposure and increased in severity with exposure time. 
Laryngeal lesions occurred in five animals (10%) during the study. The
lifetime exposure of hamsters to cobaltous oxide clearly resulted in 
pneumoconiosis, but it did not significantly shorten their lives.
From the experimental studies in animals, the ability of some cobalt 
compounds to cause pulmonary fibrosis is evident. However, the information is 
insufficient to determine what effect, if any, exposure to other substances 
often present in cemented tungsten carbide may have on the development of hard 
metal disease. Thus, the possibility must be considered that adverse effects 
in workers exposed to cobalt at the 0.06-0.2 mg/cu m range were aggravated by 
exposure to mixtures. However, the degree of worker exposure to cobalt is 
clearly related to the number of signs and symptoms observed in workers.
Thus, decreasing exposure to cobalt should reduce the risk of adverse health 
effects. For cobalt metal, results in animals indicate that worker exposure 
should be limited as much as possible, and that in no case should the present 
Federal limit be exceeded. Similar information is not available for any other 
cobalt compound, including those in commercial use.
Effects on the Skin
The incidence of sensitivity to cobalt in the general population appears 
to be low; in a small group (41 persons), none showed a positive response 
[61], whereas 0.8% and 1.8% did in two larger studies [62,63]. In persons 
with dermatosis, the observed incidence of sensitivity to cobalt, although 
somewhat dependent on experimental design, has been about 5-10% [62,64-66]. 
Intradermal testing results were more easily correlated to occupation than the 
results from patch tests [67]. Some cobalt-sensitive persons react to 
extremely low concentrations; in one study, 14 of 60 responded to topical 
application of 0.16% cobaltous chloride [68]. In another group, several of 
the 18 cobalt-sensitive individuals tested responded to 0.000001% cobaltous
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chloride given intradermally [69]. Of 379 persons with hand dermatitis, 17 
who had not been cobalt-sensitive responded to cobaltous chloride when given a 
second patch test 6-21 months later [65]. These results suggest that the 
patch test itself induced sensitivity to cobalt in some cases. A single 
report [70] demonstrated that most persons who are sensitive to cobalt sulfate 
respond to cobaltic trisethylenediamine chloride, chloropentamine cobaltic 
chloride, and sodium cobaltinitrite as well. Thus, sensitization to cobalt, 
regardless of the compound involved, seems probable.
A number of studies [67,70-80] have considered sensitivity to nickel and 
chromium as well as to cobalt in persons with dermatitis or eczema. The 
populations studied ranged from 9 [74] to 5,416 persons [75]. The percentage 
showing a positive response to cobalt ranged from 1.6 [67] to 100 [76].
Cobalt-sensitive individuals showed an incidence of positive responses to 
nickel, or chromium, or both substances that ranged from 18.2% [77] to 100%
[74,76,78-80]. When all available data are combined, approximately 5% of the 
persons studied were cobalt-sensitive; 82% of these had combined metal 
sensitivities. All three metals are prevalent in the general environment, 
which suggests that individuals with cobalt sensitivity also have had contact 
with nickel and chromium. Their responses thus could represent independent 
sensitization reactions, so that cross-sensitivity is not necessarily implied.
Very few reports on skin diseases in workers who have contacted cobalt 
have been published. Skog [81] evaluated the reaction of 14 hard metal 
workers with eczema to patch tests with a 2% cobaltous chloride solution. 
Only three were sensitive to cobalt. In the other cases, eczema was believed 
to be due to the irritant effect of hard metal dust. In another study [29], 6 
of 68 hard metal workers had dermatitis or eczema at the time of a medical 
examination. Four persons, including one with no skin disorders, responded to 
topical applications of 2% cobaltous chloride. Two remained sensitive to 
cobalt when tested 3 years later even though they had transferred to work 
environments free of hard metal dust. Among 436 pottery workers, 12 responded 
to the topical application of a 5% solution of cobaltous nitrate [82]. In 
workers with dermatitis, only 1 of 18 (5.6%) who had this condition for a 
month or less was sensitive to cobalt, compared with 9 of 28 (32.1%) workers 
with dermatitis for more than a month. In a survey of 1,004 persons with 
eczema from occupational and nonoccupational causes, 41 of 246 (16.7%) 
building trades workers with cement eczema were sensitive to a 5% solution of 
cobaltous chloride [83]. Twenty-six of 293 (8.9%) other individuals with 
occupationally-related eczema were sensitive to cobalt, as opposed to 77 of 
296 (26%) with nonoccupational dermatoses. Considerably more information is
needed before a realistic estimate can be made of the extent to which cobalt- 
induced dermatosis affects the workforce. Nevertheless, sensitization to 
cobalt does occur, and persons once sensitized would have difficulty 
continuing to work with cobalt. It is probable that many of these persons are 
transferred to other jobs.
The mechanism of the allergic response to cobalt after dermal contact is 
unknown. Haxthausen [84] contended that about 90% of the cobalt is absorbed 
from the skin following intradermal administration before any allergic 
reaction becomes visible. Norgaard [85], however, reported that cobalt is not
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absorbed through intact skin when applied to the forearm as a 0.3% or 5% 
solution. This same study reported systemic absorption of cobalt in solutions 
applied to the depilated skin of rabbits and guinea pigs [85]. Another 
investigative group also observed systemic absorption when solutions of 
cobaltous chloride were placed on the clipped backs of guinea pigs [86]. From 
this Information, NIOSH concludes that the risk of systemic poisoning from 
dermal absorption of soluble salts of cobalt is minimal for skin contact under 
normal working conditions. Abraded skin should be adequately protected to 
prevent contamination with cobalt compounds so that systemic absorption will 
not occur.
No information is available to judge the effects of many cobalt compounds. 
Some organocobalt complexes are uncharged and relatively apolar, which would 
indicate that they probably can be absorbed dermally at least as effectively 
as the inorganic salts. At least some of these complexes may be stable 
compounds in body fluids, so that their toxic effects could differ from the 
simple salts.
Cardiac Effects
Some cobaltous salts have been implicated as a causative agent in certain 
forms of cardiac disease. Cobalt, in the form of cobaltous sulfate or 
cobaltous chloride, was used as a foam stabilizer in beer during the mid- 
1960's in various countries, including the United States. Between 1964 and 
1966, American breweries reportedly added 1-1.5 ppm of cobaltous chloride to 
20-25% of all beer sold in the United States [87]. At the same time, several 
epidemics of a peculiar form of cardiomyopathy occurred among heavy beer 
drinkers in Quebec, Belgium, Omaha, Minneapolis, and New York [87-92]. All 
patients were heavy beer drinkers. For example, the Quebec group consumed 
daily from 2 to more than 6 liters of beer containing 0.8 to more than 1.6 mg 
cobalt/liter [93-95]. The signs and symptoms of illness in the beer-drinking 
patients included gastrointestinal problems, labored breathing, abdominal 
pain, cyanosis, lowered blood pressure, heart enlargement, pericardial 
effusion, rapid heart rate, and electrocardiographic (ECG) abnormalities. In 
one group, azotemia or oliguria, or both, were frequently noted, especially in 
fatal cases [90]. Sullivan et al [96] found cobalt concentrations 10 times 
normal in heart tissue of several persons who had died from beer drinkers' 
cardiomyopathy. In 20 who survived, 11 had ECG abnormalities persisting for 
up to 24 months [97].
The extensive literature on beer drinkers' cardiomyopathy suggests that 
factors in addition to cobalt may have contributed to the effects seen. 
Several authors suggested that cobalt may have increased existing cardiac 
impairment induced by thiamine deficiency [90,93] or excessive ethanol 
consumption [87,90]. Nutritional deficiencies other than lack of thiamine 
also may have contributed to the cardiomyopathy. The diet of a group of 
Belgian beer drinking patients was nutritionally inadequate, especially in 
regard to protein [91]. In contrast, chronic beer drinkers who did not 
develop marked cardiac abnormalities had nutritionally adequate diets. They
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were brewery workers who had consumed a daily average of 16 glasses of beer 
containing 1.2 ppm cobalt.
The effects of cobalt on cardiac function have been examined in controlled 
experiments in humans. Garello et al [98] hypothesized that cobalt exerts a 
direct effect on the biochemical phenomena responsible for cardiac 
contraction. This hypothesis was based on the observation that a daily 
intramuscular (im) injection of 20 mg cobalt benzenesulfonate (equivalent to 
3.2 mg cobalt) for 5 consecutive days resulted in slight increases in heart 
rate, atrioventricular conduction time, and duration of systole. Similar ECG 
changes had been reported [99] after im injection of mixtures containing 20 mg 
cobaltous chloride and 10 mg cobaltous benzenesulfonate. These experiments, 
of short duration, in humans do not account for the severe effects observed in 
the beer drinkers.
Animal experiments, often conducted for longer periods, present a 
different picture. In 20 male guinea pigs fed cobaltous sulfate for 5 weeks 
at high levels (stated to be 20 mg cobalt/kg daily), heart weights and ratios 
of heart weight to body weight were increased, and pericardial effusion was 
observed in 9 (45%) animals; myocardial degenerative changes were present in 
15 (75%) [100]. Swigart [101] also found a significant increase in mean heart 
weights as well as right ventricular hypertrophy in rats administered 2.5 mg 
cobalt/kg (as cobaltous chloride) intraperitoneally (ip) for 63 days. 
Although microscopic changes were not reported in Swigart's experiment, Lin 
and Duffy [102] found cardiac lesions in rats following ip injection of 5 
mg/kg cobalt (as cobaltous nitrate) daily for up to 7 days. The lesions 
resembled those observed in cardiomyopathy due to alcoholism, thiamine 
deficiency, and chemical toxins, and similar observations in rats [103] and in 
rabbits [104] were made by other investigators.
Kucharin and Sinitsin [105], in 1976, reported on a condition 
characterized as allergic myocarditis in five workers employed in the cobalt 
shop of a foundry for 2-19 years. Cardiac enlargement was the principal 
clinical finding. All five persons had abnormalities in ECG patterns that 
improved or disappeared in 1-2 years. At the height of their illness, heart 
volume was increased 51-110%. Blood counts reported for one subject indicated 
elevated Hb and RBC levels. The authors considered the disease to be of 
occupational origin and attributable to cobalt. However, data to support this 
conclusion were not provided in the report.
Alexandersson and Atterhog [106] examined dry and wet grinders exposed to
cobalt at 0.01 mg/cu m and powder handlers exposed at 0.06 mg/cu m. No ECG
changes were observed in dry grinders or powder handlers, even though the 
powder handlers showed evidence of impaired pulmonary function. The ECG's of 
wet grinders were abnormal and showed a high incidence of ectopic (premature) 
heartbeats. However, the authors believed that the ECG changes were related 
to exposure to cutting oils rather than cobalt.
Only one study in animals has examined the effects on the heart of cobalt
exposure similar to that encountered in the workplace. In the study on 
miniature swine exposed to cobalt metal dust at 0.1 or 1 mg/cu m, Kerfoot and
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coworkers [44] observed abnormalities in ECG's taken at the end of the 3-month 
exposure period. These alterations were interpreted by the authors to 
indicate a decrease in the strength of ventricular contraction and 
repolarization abnormalities.
Sufficient evidence exists to suggest that both cobalt metal and cobalt 
salts can produce cardiac changes, but apparently only at high doses. It 
should be noted that the amount of cobalt ingested daily by persons who 
consumed 6 liters a day of beer was about 5-10 mg, much higher than the amount 
inhaled by a worker breathing 10-15 cu m of air in a day at the current 
Federal limit of 0.1 mg/cu m. The question of whether changes such as those 
seen in the miniature swine could result in significant problems over a long 
period of exposure in especially susceptible individuals, such as those with 
existing heart disease and, possibly, persons who consume alcohol on a regular 
basis, needs to be examined.
Effects on Blood
Cobalt-induced polycythemia is a well known effect. This property of 
cobalt has been exploited therapeutically in the treatment of refractory 
anemia [107-115]. The information collected for this review, however, 
revealed that other lesser known effects may occur at concentrations below 
those needed to produce polycythemia. The information available, although 
often incomplete, is presented below.
The polycythemic effects of cobalt have been observed not only in patients 
but also in controlled experiments in persons with normal blood counts and in 
animals. Volunteers receiving oral doses of cobaltous chloride ranging from 
100 to 1,200 mg daily for 1—12 weeks [107] or 120-150 mg daily for 1-3 weeks 
[116] experienced an increase in RBC and Hb levels. Numerous studies 
[117-125] in animals administered cobaltous chloride at high dosage levels for 
as long as 16 weeks either orally, or by subcutaneous (sc) or ip injection, 
also reported slight to substantial increases in RBC or Hb. One study in mice 
demonstrated an increase in RBC's subsequent to ip injection of cobaltous 
nitrate [126]. However, inhalation studies in animals exposed to cobalt metal 
[44,59] provide little evidence to support the contention that polycythemia 
would be expected in workers exposed to cobalt at low concentrations. Similar 
studies on cobalt salts have not been conducted. Since the effects of cobalt 
on the blood would be expected to depend on its ability to concentrate at 
certain critical sites, cobalt salts might demonstrate effects at levels 
differing from cobalt metal. However, the mechanisms responsible for the 
changes in blood that are induced by cobalt are not known.
While a polycythemic effect is clearly demonstrated in the reports 
described above, cobalt may also interfere with iron absorption from the 
gastrointestinal tract, indirectly affecting Hb formation. Rats administered 
0.3-3 mg of iron by stomach tube had a significant decrease in iron absorption 
with the addition of 3 mg cobalt as the chloride salt [127,128]; this finding 
was confirmed in a subsequent study [129].
16
Several surveys have examined the possibility that polycythemia might 
result from industrial exposure to cobalt. Fairhall and coworkers [37] found 
no evidence of polycythemia in a survey of 1,802 cemented carbide workers. 
Cobalt exposures ranged from 0.05 to 0.14 mg/cu m. Verhamme [52] also found 
no evidence of polycythemia in 83 workers at a plant producing cobalt oxides, 
powder, and salts. However, Barborik [130] and Kaplun [35] independently 
found evidence of polycythemia in hard metal workers. Kaplun reported that 
RBC's were increased in workers described as having many years of service; 
the levels of airborne cobalt were 0.4-3.3 mg/cu m. Barborik found a higher 
mean Hb level in 88 male and 70 female workers than in a control group of 149 
men and 70 women. RBC’s, measured in 41 men and 34 women, were also elevated. 
Sixteen workers had Hb levels at least 19% above those found in controls, and 
seven had RBC increases in excess of 12.5%. All but two workers remained at 
their jobs, and a subsequent survey failed to duplicate these results. In 
contrast to the well known polycythemic effect, Sozieva [131] found a reduced 
Hb level in 22.8% of a group of hard metal workers exposed to cobalt. 
Hypotension was also said to be present in most of the exposed workers. Dust 
levels ranged from less than 10.6 to 62.6 mg/cu m, but the cobalt content was 
not reported. Kaplun [35] also found decreased Hb levels and RBC's in 247 
hard metal workers exposed to cobalt at 0.8 to 12 mg/cu m. Although limited, 
this information suggests complex and possibly conflicting mechanisms of 
action of cobalt on blood components.
Even though experiments in animals suggest the possibility that cobalt 
could affect the white blood cell (WBC) count, this effect has apparently not 
been examined in workers. Miniature swine exposed to cobalt metal dust showed 
an increase in WBC's during the 3rd week of exposure [44]. Other 
investigators have examined the effect of cobaltous chloride [122,132-136] or 
cobaltous nitrate [126] on the WBC's of animals. Some reported a slight to 
significant increase [122,133-136], one reported a decrease [132], and one 
reported no significant change [126]. Since WBC's would be affected by 
infection, NIOSH concludes that this limited information is insufficient to 
demonstrate a causal relationship with exposure to cobalt.
Effects on blood components other than the cells may occur at exposure 
levels not producing polycythemia. A number of animal studies demonstrated 
certain nonspecific changes in blood protein levels. Significant increases in 
total protein and globulin levels were found in rabbits receiving im 
injections of cobaltous chloride [135]. Similar changes in serum globulin 
levels, but not in total protein, were found in a second study [137]. 
Cobaltous chloride administered to-dogs by sc injection and to rabbits by ip 
injection resulted in significant increases in alpha-globulin levels even 
though RBC and Hb levels were unaffected [138]. Similar results were obtained 
when rabbits were exposed to aerosols of cobalt metal. Miniature swine 
exposed to cobalt metal dust at 0.1 or 1 mg/cu m had slight increases in 
alpha-globulin levels [44]. In humans, the mean erythropoietin level was 58% 
above that of controls in 21 persons employed in the hydrometallurgical 
production of cobalt even though no changes in RBC, hematocrit, or Hb levels 
were found [139]. Concentrations of airborne cobalt ranged from 0.43 to 1.6 
mg/cu m. Increased serum globulin levels cannot be related readily to any 
specific disease state, but the increases in erythropoietin, a substance that
17
migrates electrophoretically with the alpha-globulins, may be highly relevant 
to the polycythemic effects of cobalt. Erythropoietin is involved in the 
regulation of erythrocyte production.
A second effect that could be relevant to persons exposed to cobalt in the 
occupational environment is the apparent ability of cobalt to prolong the time 
needed for blood clot formation. Ternovi and Mosketi [140] reported 
significant changes in blood clotting time (35% increase), thromboplastic 
activity (28% decrease), and clot retraction time (20% increase) in 15 persons 
administered cobalt orally as a solution of cobaltous chloride at 1 mg a day 
for 3 days. These findings seem to be supported by results of animal studies 
[133,136,141-143] and from patients administered cobaltous chloride for
treatment of anemia. In the patients, infants receiving 120-200 mg cobaltous 
chloride for up to 100 days had increased leukocyte and thrombocyte counts
[112], but these findings were not confirmed in those that received cobalt for
1-3 weeks [116].
The information available suggests to NIOSH that the effects of cobalt on 
the blood are multiple and poorly understood. Polycythemia is clearly one 
manifestation of exposure to cobalt metal or cobalt salts, and increases in 
erythropoietin could be a factor in producing this effect. The airborne 
concentrations of cobalt at which this polycythemic effect would be 
significant are poorly documented, but they appear to be well above the
Federal standard for cobalt metal. Information is not adequate to judge
whether this airborne concentration, 0.1 mg/cu m, would be adequate to prevent 
polycythemia from other cobalt compounds. Because RBC's have been found to 
decrease in exposed workers only at very high airborne concentrations of 
cobalt, this effect is judged insignificant if exposure is through inhalation. 
The role of cobalt in retarding blood clot formation is not well documented, 
but preliminary evidence suggests that it could be highly significant.
Effects on the Thyroid
The goitrogenic effects of cobaltous chloride were first noted in 1954 in 
individuals being treated for sickle cell anemia [144]. More detailed
descriptions later reported that two children given approximately 3 mg/kg 
daily of cobalt preparation developed visible goiters [145,146]. One child 
also had signs of hypothyroidism. A third patient who developed a goiter also 
had a significant reduction in radioiodine uptake. Placebo tablets were
substituted for the cobalt preparation, and thyroid function returned to 
normal by 12 weeks. Numerous additional reports that followed now show that
2-10 mg cobalt (as chloride)/kg given orally each day for 2-4 months will 
induce goiter formation in a small percentage of persons [147-154]. In all 
cases, the thyroid hyperplasi^ has been reduced or reversed after cobalt 
administration was stopped.
Controlled clinical studies have also examined the effects of cobalt on 
the thyroid gland. In one study, 12 adults with normal thyroids were given 50 
mg of cobaltous chloride orally three times a day for 2 weeks [155]. 
Radioactive iodine uptake was reduced in all but one person after the 1st
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week; by 2 weeks all uptake levels were near zero. The effect was reversible 
after cobalt administration ceased. In a separate study, the majority of 
individuals given cobaltous chloride either orally or by iv infusion also had 
decreased iodine uptake in the thyroid [156]. In fact, cobaltous chloride has 
been tested as a treatment for hyperthyroidism. Pimentel-Malaussena et al 
[157] observed that four of eight patients receiving 150-600 mg a day for up 
to 117 days responded with clinical improvement as manifested by reductions in 
tachycardia, metabolic rate, and uptake of radioactive iodine. Three of four, 
however, had thyroids of increased size, and the authors concluded that the 
action of cobalt was unpredictable.
The results of studies in guinea pi$s [158] and rats [159,160] support the 
evidence in humans that cobaltous chloride can affect thyroid function and 
cause microscopically observable changes. In addition, a moderate reduction 
of iodine uptake was demonstrated in rats that received 20 mg/kg of cobaltous 
oxide or cobaltic oxide sc daily for 45 days [161]. These studies, like those 
in humans, were all conducted at high doses and by routes of administration 
not typically found in the workplace.
The most conclusive evidence that cobalt can affect the thyroid at low 
doses is the study of Popov et al [60]. In this experiment, rats exposed 
continuously to aerosols of cobalt metal were killed for examination after 1.5 
or 3 months of exposure or after 3 months of recovery. The thyroid glands of 
animals exposed at the highest concentration, 0.5 mg/cu m, showed microscopic 
evidence of follicles containing foci of epithelial hyperplasia. Changes in 
thyroid function were noted in animals exposed at 0.05 mg/cu m but not at 
0.005 and 0.001 mg/cu m. This continuous exposure at 0.05 mg/cu m would 
correspond to an 8-hour exposure of about 0.2 mg/cu m.
Cobalt metal, cobalt oxides, and cobalt salts have caused alterations of 
the thyroid glands of humans or animals. These effects represent both 
functional and morphologic alteration of the gland. The only experiment using 
low doses was conducted by Popov and coworkers [60], and it suggests that 
slight changes in thyroid function would be expected in workers exposed at 0.2 
mg/cu m. This value is near the permissible exposure limit for cobalt metal 
fume and dust, and long-term effects at low levels have not been studied in 
humans for any cobalt compounds. This information suggests that alterations 
of thyroid function should be considered as a possible effect of workplace 
exposure to cobalt.
Carcinogenicity and Mutagenicity
Fibrosis, and not carcinogenicity, has received most of the attention of 
the occupational health community concerned with cobalt. The many reports 
available concerning fibrosis would not be adequate to demonstrate any 
carcinogenic effect, because none are epidemiologic studies concerned with 
incidence rates. The three case reports describing the development of benign 
or malignant tumors in hard metal workers [17,32,38] and two epidemiologic 
studies describing an increased risk of lung cancer in cobalt recovery areas 
of nickel refineries [162,163] are not useful in demonstrating a possible
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carcinogenic effect of cobalt. Arsenic was also present in the air of some 
plants examined in the epidemiologic studies. Mixed exposures to substances 
known to be or suspected of carcinogenicity were involved in all cases. The 
case reports cannot distinguish between the role of occupational exposure and 
other factors, including normal incidence. Thus, information from human 
studies does not provide any answers about the possible carcinogenic potential 
of cobalt.
The two studies conducted in animals by routes of administration most 
applicable to workplace exposure did not demonstrate a carcinogenic effect for 
cobalt [45,164]. The incidence of tumor development was low and did not 
differ significantly from controls in male Syrian golden hamsters exposed for 
their life spans to aerosols of cobaltous oxide at 10 mg/cu m, 7 hours daily, 
5 days a week [45]. Many of these animals did develop fibrotic changes.
Hamsters injected intratracheally once a week for 30 weeks with 4 mg of
cobaltous cobaltic oxide (Co304) failed to develop a statistically significant 
excess of tumors compared with control animals [164]. It should be noted, 
however, that the two tumors that developed in the 50 animals exposed to 
cobalt were alveolar in origin while the four tumors in controls were at sites 
unrelated to exposure. These studies provide little evidence to suggest that 
cobalt oxides are carcinogens, but no similar studies have been conducted in 
animals other than hamsters.
The results of studies of the carcinogenic potential of cobaltous chloride 
are conflicting. Gunn et al [165] reported that no tumors were observed for 
10-16 months in Wistar rats given four simultaneous injections of cobaltous 
chloride (0.18 mg cobalt/site) into a vital organ (liver or kidney), a gland
(salivary or ventral prostate), and two mesenchymal mesodermal structures
(chest, interscapular area, thigh, or femur). Similarly, Shelley [166] 
reported that no tumors were observed in 10 ICR mice given cobaltous chloride 
(3.5 mg cobalt) in the dorsal earlobe, although the 2- to 5-month observation 
period was relatively short. On the other hand, Shabaan et al [167] found 
subcutaneous fibrosarcomas in 14 of 27 rats surviving 8-12 months following 10 
injections of cobaltous chloride at 40 mg/kg into the central abdominal wall. 
Two tumors were at the injection site, and the remainder were at various 
distances from the abdominal region. Metastases were not found in any tumor- 
bearing animal. This study provides evidence that cobaltous chloride could be 
a carcinogen, and it argues for the need to perform chronic testing of cobalt 
salts in animals by routes of exposure more applicable to the workplace.
Several investigators have examined the carcinogenic potential of cobalt 
given parenterally. In one study, neither metallic cobalt nor cobalt sulfide 
induced tumors in rats when these substances were injected into the poles of 
the right kidney [168]. Heath and associates [169-174], in a series of papers 
from 1954 to 1972, examined the effects of cobalt metal powder or alloys 
injected into rats. Many animals developed injection site sarcomas 3-12 
months after im administration of the powder in fowl serum. Sarcomas were 
also induced in cardiac muscle following the administration of cobalt metal 
powder by intrathoracic injection [175,176]. Gilman [177] and Gilman and 
Ruckerbauer [178] were also able to induce injection site sarcomas in rats 
following im injection of cobaltous oxide or cobaltous sulfide, but they did
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not observe tumors in mice similarly injected with cobaltous oxide. In 
experiments with cobaltous naphthenate, five rabbits injected im developed 
rhabdomyomas at the injection site after 2-6 months [179]; similarly, one of 
three injected iv developed an osteochondroma at the site. A rabbit given 
cobaltous naphthenate by intrahepatic injection and another animal receiving 
the compound intrapleurally also showed tumor formation. In a similar study 
in mice, injection site tumors developed after what was apparently an im 
injection of cobaltous naphthenate [180].
Mutagenicity tests in Allium cepa cells [181], Vinca faba roots [182], 
bacteriophage T4 [183], and yeast [184,185] have indicated that cobalt 
interferes with mitosis and can cause cell death in sufficient concentrations. 
Four cobalt compounds (CoC12, Co(OH)3, CoS04, and 2CoC03.3Co(0H)2) were weakly 
positive in rec assays, but cobalt chloride and cobalt hydroxide were negative 
in spot mutation induction tests with two strains of J2 coli and five strains 
Salmonella [186]. Cobalt nitrate had no effect on the chromosomes of human 
leukocytes [187], but cobalt chloride has decreased the fidelity of DNA 
synthesis [188]. Cobalt salts have also enhanced transformation of hamster 
embryo cells exposed to simian adenovirus SAT [189]. These studies are 
insufficient to serve as any indicator of possible carcinogenicity.
Information on cobalt is inadequate to conclude that cobalt is a 
carcinogen. The information is also Inadequate to conclude that cobalt is 
noncarcinogenic. In fact, limited data [167,175,176] provide suggestive 
evidence that at least some cobalt compounds may prove carcinogenic when 
subjected to long-term testing by currently accepted protocols. Until such 
testing is performed, no definitive guidelines can be given. Tumor induction 
at the injection site, however, would argue for the need to adequately clean 
any wound contaminated with cobalt.
Effects on Reproduction
Whether exposure to a substance in the workplace can result in adverse 
effects on reproductive capacity or harm to the developing fetus is of grave 
concern to workers and to all persons responsible for the health of workers. 
The information available on cobalt is conflicting and insufficient to draw 
definite conclusions on the effects of cobalt on reproduction. Although this 
information dees not substantiate any effects, it is presented below.
Studies in humans [190-192] and animals [193,194] demonstrate that cobalt 
can cross the placenta. This effect does not appear related to the 
essentiality of vitamin B12 [193]. Whether or not cobalt compounds possess 
any teratogenic activity is not established. Only 1 of 41 hamster embryos 
exposed to cobaltous acetate through the iv injection of 5 mg/kg in the dam on 
the 8th day of gestation was resorbed [195]. No gross abnormalities were 
evident. This experiment, however, would only have detected teratogenic 
effects under very limited conditions because of the single exposure and the 
lack of any microscopic examination. The most frequent malformations observed 
in chick embryos exposed to cobaltous chloride through injection of 0.4 or 0.5 
®g per egg were in the skeletal system and eyes [196]. No embryo exposed
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through injection of 0.1-0.3 mg was malformed. The mortality of the embryos 
was high, 75.7% in those injected with cobaltous chloride and 54.3% in control 
embryos. This experiment is of questionable relevance because of the 
nonmammalian test system used.
The literature describing the effects of cobalt on testicular function is 
characterized by disagreement among investigators. Hoey [197] reported marked 
but reversible changes (including suppression of spermatogenesis, abnormal 
sperm, deformation of the epididymal tubules, and necrosis of the duct system) 
in rats administered cobaltous chloride by sc injection. Kamboj and Kar [198] 
injected cobaltous nitrate sc in mice or intratesticularly in rats, and they 
found no microscopic damage to the testes or effects on spermatozoa. Niebroj 
[199] injected cobaltous chloride ip, and considered the effects on the testes 
of these mice to be generally positive.
Other Effects
There are numerous studies of additional toxic effects attributed to 
cobalt. Some, such as the acute lethality studies in animals, have little 
impact on the occupational environment since such exposure conditions are 
rarely, if ever, encountered. Some effects, such as increased levels of
plasma lipids, have been observed in humans, but only rarely in anemic
patients receiving cobalt [145,150,200]. Some, such as experimental induction 
of epilepsy by implantation of cobalt in the brain of animals, appear 
irrelevant. Other effects, such as kidney and liver changes, may be relevant; 
but information on occupational exposure is quite limited.
(a) Kidney Effects and Hyperglycemia
Workers exposed for no more than 3 years to cobalt at 0.6-3.2 mg/cu m in a 
Soviet plant manufacturing tungsten bars and hard metal alloys showed evidence 
of disturbed kidney function and hyperglycemia [46]. About half of the 178
workers complained of some symptom, including labored breathing, coughing,
pounding of the heart, headache, dizziness, nausea, loss of appetite, and 
olefactory disorders. Blood glucose, measured in 37 subjects, was elevated in 
8 (22%). Glucose tolerance tests produced prolonged elevations of blood
glucose in 8 of 14 (57%) individuals. Blood chloride levels were increased in 
press operators but decreased in reducers; both groups showed a reduced 
chloride concentration in the urine. In a separate study, a worker apparently 
acutely poisoned by exposure to cobalt acetate suffered from albuminuria 
[201]. A similar effect was observed in guinea pigs administered large doses 
of cobaltous chloride for 6-7 days [202], Both the cortex and the glomeruli 
were damaged, and pronounced changes occurred in nearly all tubules of the 
kidney. This study [202] and another using cobalt oxides [161] were 
consistent with the limited information provided by Popov et al [60]. In this 
study [60], rats exposed to cobalt dust continuously at 0.5 mg/cu m for 3 
months reportedly had slight degenerative changes in the convoluted tubules. 
Except for the statement that this effect was not seen at 0.001 mg/cu m, no 
additional information was provided.
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Cobaltous chloride therapy for anemia has reportedly led to hyperglycemic 
reactions in patients [203]. This response is more clearly demonstrated in 
experiments with animals. Parenterally administered cobalt salts and 
trisethylenediamine cobaltic chloride have produced time- and dose-related 
rises in blood glucose levels (hyperglycemia). This effect was noted in rats 
[204-207], guinea pigs [208], rabbits [209], and dogs [210], The typical 
increase in blood glucose level usually peaked after 1-2 hours and lasted up 
to 10 hours depending on the dose. The hyperglycemia induced by cobalt 
appeared to be independent of its effects in alpha cells of the pancreas (see 
section (c)), but the mechanism of action is not yet understood.
NI0SH considers the information available sufficient to conclude that 
cobalt metal and salts, and probably cobalt oxides and a number of 
organocobalt complexes, can damage the kidneys. These effects are thought to 
occur only at levels that also produce other toxic effects.
(b) Liver Effects
Hard metal workers exposed to cobalt at 0.6-3.2 mg/cu m had slight to 
moderate changes in liver function tests in 19 of 34 (56%) individuals
examined [46]. Other workers, exposed at 0.8-12 mg/cu m, had enlarged livers 
[35], and a woman who died from massive fibrosis had liver congestion [50]. 
These reports would indicate that cobalt can affect the liver, either directly 
or indirectly. However, the lack of similar information at lower doses 
suggests that the liver is not the critical organ for cobalt toxicity.
Exposure to cobalt has produced liver damage in laboratory animals. Popov 
et al [60] noted that the hepatocytes of liver tissue of rats exposed 
continuously to cobalt dust at 0.5 mg/cu m had necrotic changes. This effect 
was reported to be dose-dependent, with no effect at 0.001 mg/cu m. At higher 
doses (10-18 mg/kg of cobaltous chloride in a single iv injection), rabbits 
examined for up to 7 days developed a transient but marked glycogen depletion, 
necrotic changes in a few liver cells, and moderate to marked fatty 
degeneration [209]. In a study on rabbits given sodium cobaltic nitrate or 
cobaltic oxide im at relatively high doses for up to 219 days, areas of focal 
necrosis and liver cell degeneration were observed [211]. This information, 
in experimental animals, supports the contention derived from human data that 
cobalt can adversely affect the liver but only at high doses.
(c) Pancreatic Effects
Parenteral administration of cobalt salts in high doses has induced 
degenerative changes in pancreatic tissue of experimental animals. The guinea 
pig pancreas appears to be very sensitive to the effects of cobalt, resulting 
in it often being used in research [212-223]. The characteristic effect noted 
after administration of cobalt salts at 10-80 mg/kg was alpha cell 
degranulation and necrosis. Beta cells were usually not affected. Changes 
reached a peak 24-48 hours after a single dose. Animals that survived 
regenerated pancreatic tissue. This phenomenon may not be occupationally 
relevant because of the high doses used. In addition, no human data are
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available that indicate a potential problem with pancreatic function after 
cobalt exposure.
(d) Additional Studies
Cobalt solutions, unless they are strongly acidic or basic, probably do 
not pose a serious risk of damage to the eye from splashes or spills. 
Subconjunctival administration of 1 ml of a 0.1-0.2% cobaltous sulfate 
solution to three rabbits produced no irritation of the mucosa [224]. 
However, the greatest risk of damage to the eyes from cobalt is probably a 
physical effect caused by flying chips of cobalt or hard metal.
Kaplun [35] studied olfactory acuity in 37 workers employed in the 
manufacture of hard-metal alloys. Twenty-eight subjects worked with tungsten 
carbide and cobalt and tungsten, and the rest worked with tungsten carbide 
alone. The author concluded that 25 of 28 persons working with tungsten 
carbide and cobalt had impaired senses of smell when compared with individuals 
working with tungsten carbide alone. However, details of the experimental 
design were not provided.
Distribution and Retention
Since it is a constituent of vitamin B12, cobalt should be present in 
small amounts in the normal human body. In 1962, Yamagata et al [225] used 
neutron activation analysis (NAA) to calculate the whole body content of 
cobalt (1.1 mg in humans). Approximately 44% was stored in muscle, 32% in
bone, and the remainder in soft tissue. In workers who died of pulmonary
fibrosis, however, the few studies available present contradictory evidence of 
cobalt accumulation in the lung; most found little or no cobalt 
[12,15,19,22,26], but others found large amounts [16,50,226]. Two groups of 
investigators examined the urine of workers exposed to cobalt compounds, and 
found a substantial elevation in the amount of urinary cobalt [226,227].
Accidental inhalation of radioactive cobalt as the metal or the oxides has 
provided some data on the kinetics of cobalt elimination after entry into the 
lungs. Several reports [228-231] have shown that lung clearance occurs in at 
least three stages, a rapid component having a half-life of 0.5-2 days, an
intermediate component of 3-42 days, and a long-term component of 60-120 days. 
The International Commission on Radiological Protection, in a 1959 report,
estimated the biologic half-life of inhaled cobalt-60 to be 9.5 days [232], 
but investigators have since reported data indicating that some inhaled cobalt 
can be retained in the body for many years [233,234].
Controlled experiments on the distribution of cobalt in humans have 
considered only cobaltous chloride. When administered orally, most was 
eliminated in the feces [156]. Absorption through the gastrointestinal tract 
appeared to be reduced if cobalt was given after a meal, in an albumin 
complex, or as a carrier-free solution [235]. Cobaltous chloride, given iv, 
was rapidly cleared from the blood [236], but a substantial amount (5-16%) was 
retained in the body for a year or longer [236,237].
24
The results of animal studies confirm and supplement the reports in 
humans. Numerous studies in animals also demonstrate that most cobaltous 
chloride administered orally is eliminated in the feces [238-241]. When 
cobaltous chloride was administered repeatedly in the drinking water of rats 
[242] or mice [243] (an exposure more typical of general human consumption), 
cobalt accumulated to increasingly higher tissue levels until a steady state 
was reached after 30 days. Cobaltous oxide was poorly absorbed in hamsters; 
when administered by gavage, less than 0.5% accumulated in body tissues [244]. 
Cyanocobalamin, in contrast, showed a much greater absorption and retention 
than cobaltous chloride [245]. Several investigators [242,243] have noted the 
tendency of cobalt to accumulate in the liver following administration of 
cobaltous chloride, and two [238,242] also described its long-term 
accumulation in bone. Considering these sites of deposition, it is not at all 
surprising that a fraction of the administered dose is retained for a long 
time.
Retention of cobalt oxides after inhalation has been examined in animals. 
Wehner and Craig [244] reported that hamsters eliminated 90% of the total dose 
of cobaltous oxide, inhaled at 15.6 mg/cu m 7 hours a day for 2 days, within 
the subsequent 3 days (day 5 of experiment); however, the remainder was 
retained tenaciously in the body of the animal. Barnes et al [246] 
administered respirable-sized particles of cobalt oxides by inhalation to 
dogs. In 10 days, only 10% of the cobaltous oxide was retained, compared with 
60% of the cobaltous cobaltic oxide. Cobaltous cobaltic oxide showed 
accumulation in the lymph nodes of the lung, a typical reaction of tissue- 
insoluble substances, while substantially more cobaltous oxide was found in 
the tissues and blood.
The information on distribution and retention of cobalt is typical of 
substances showing moderate to substantial tissue solubility. Information on 
the chloride salt is particularly revealing. It appears that enough of the 
salts can be absorbed through the gastrointestinal tract to warrant good 
sanitation and personal hygiene by workers so that they can avoid absorbing 
significant amounts of cobalt through ingestion. The long-term accumulation 
of cobalt in the liver may also be relevant.
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I I I .  EXTENT AND MEASUREMENT OF EXPOSURE
Uses of Cobalt
Cobalt (atomic number 27, atomic weight 58.93) Is a transition element 
located between iron and nickel in group VIII of the periodic table. The 
metallic form is silver gray to bluish white and is magnetic. There are three 
oxides of cobalt: cobaltous oxide, CoO; cobaltic oxide, Co203; and cobaltous
cobaltic oxide, Co304. Ionic cobalt can exist in either a divalent or a 
trivalent form. The cobaltous ion can form numerous inorganic and organic 
salts [247], and cobalt can form complexes with amines, nitrites, and cyanides 
[248]. Divalent cobalt can have a coordination number of either 4 or 6, 
whereas trivalent cobalt has a coordination number of 6 [2]. The physical and 
chemical properties of some cobalt compounds are given in Table IX-3, and 
substances containing cobalt that are listed in the Toxic Substances Control 
Act Chemical Substance Inventory [249] are listed in Tables IX-4 to IX-6.
Cobalt is a byproduct or coproduct of the refining of other mined metals 
such as copper and nickel. Some of the commercially mined ores are 
carrollite, CuCo2S4; smaltite, CoAs2; cobaltite, CoAsS; siegenite, (Co, 
Ni)3S4; and sphaerocobaltite, CoC03 [1,5]. The amount of cobalt mined is 
relatively small in comparison with copper or nickel, and the cobalt supply 
depends to a large extent on the demand for the latter two metals.
According to the Bureau of Mines (RA Markle, written communication,
September 1978), there has been no domestic mine production of cobalt for 
several years, and there is only one refinery that processes cobalt in the 
United States. Most of the cobalt imported, nearly 77%, comes from Zaire and 
Zambia. Imports were up 6%, to 17.5 million pounds, in 1977. Cobalt 
consumption in the United States for 1977 was about 16.6 million pounds, up
0.6% from 1976. Much of that increase was due to demand in the aircraft
industry.
About 70% of the cobalt used in the United States goes into the alloy and 
hard metal industries, mostly to produce magnetic and super-hard alloys [250]. 
The aluminum-nickel-iron-cobalt alloys are widely used in permanent magnets 
[39]. Vanadium-iron-cobalt alloys are used for ductile permanent telephone 
diaphragms. Vitallium, an alloy of cobalt, chromium, nickel, and molybdenum, 
has been used for prostheses in bone replacement surgery [39,250]. Cobalt is 
used extensively in the tungsten carbide or hard metal industry as a binder of 
ingredients in these heat- and wear-resistant metals [39,250-252].
Cobalt-bearing high-speed steel and cemented carbides have excellent cutting 
properties. Major uses include various chemical, cutting tool, and hard
facing applications. Cobalt alloyed with chromium and nickel is used in 
heat-resistant gas turbine blades and jet engine parts. Hard metal is found 
in high-speed cutting tools, armaments, masonry drills and cutters, high-speed 
dental drills, and tire studs.
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Cobalt compounds have important uses as catalysts [39,250,253-255]. 
Cobalt naphthenate, octanoate, oleate, resinate, tallate, and linoleate are 
used as drying agents for oil-based paints, varnishes, and printing inks. The 
cobalt compounds act as oxidizing catalysts for the polymerization of
unsaturated glycerides. Cobalt is an important catalyst in oxidation and in 
desulfurization, a process used in refining crude oils. Cobalt acetate is 
used in the manufacture of dimethyl terephthalate and terephthalic acid. 
Cobalt catalysts are also used in the production of several primary alcohols 
and aldehydes.
Cobalt salts have a variety of uses [39,250,255]. Cobalt sulfate and
chloride are used in electroplating. Cobalt carbonate, chloride, and sulfate 
are incorporated as additives in animal feeds. Cobalt chloride is a dessicant 
indicator, the hydrated form being pink and the anhydrous form blue. This 
property also leads to its somewhat unusual use as “invisible" ink. Cobalt 
pigments are very important in the ceramic and pottery industry. A wide 
variety of pigments in differing shades and colors contain cobalt, often as 
mixtures with other metal salts. Black cobalt oxide paint is of particular 
value because of its heat and wear resistance. A mixture of cobalt oxide and 
cobalt aluminate forms a blue color. Cobalt blue is sometimes added to glass 
to detint the yellowish color that occurs if iron is present. Small amounts 
of cobalt salts are also used as boiler water scavengers, in magnetic tapes, 
and in steel-belted tires.
Table III-l lists some occupations in which there is potential exposure to 
cobalt compounds [256]. The amount of exposure to cobalt that workers 
actually receive in these occupations probably varies widely. Large amounts 
of cobalt are used in some industries, such as cobalt salts manufacturing, the
cemented carbide industry, and the manufacture of cobalt-containing alloys.
Many users of these products handle extremely small quantities of cobalt. 
Others perform cutting, grinding, or welding operations on products, and the 
potential for worker exposure to cobalt is significant. Exposure of painters 
to cobalt driers is probably minimal; exposure of spray painters to cobalt 
pigments is not.
Environmental Data
Cobalt is present in low concentrations in ambient air. Dams et al [257] 
found mean concentrations of 2.6 ng/cu m (1 mg ■ 10 exp +6 ng) in an urban 
area (East Chicago, Indiana) and 0.95 ng/cu m in a rural area (Niles, 
Michigan). Rancitelli et al [258] reported cobalt concentrations in North and 
South America ranging from 0.07 ng/cu m (Thule, Greenland) to 3.6 ng/cu m 
(Santiago, Chile). Hewitt [259] found a concentration of 5 ng/cu m in urban 
air in England. Also, Janssens et al [260] reported that air samples 
collected in Belgium, apparently near a cobalt-manufacturing plant, showed 
levels of 0.4-7.3 ng/cu m (mean, 2.8). All of these levels in ambient air are 
far below the Federal standard of 0.1 mg/cu m for cobalt metal fume and dust.
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TABLE I I I - l
OCCUPATIONS WITH POTENTIAL EXPOSURE TO COBALT
Acetic acid makers Gasoline blenders
Alloy makers Glass colorers
Alnico magnet makers Glaze workers
Ammonia mask makers High-speed tool steel workers
Barometer makers Hygrometer makers
Bright platers Ink makers
Catalyst workers Iron-cobalt platers
Cement makers Lamp filament makers
Cemented carbide workers Magnet steel workers
Ceramic workers Metal smelters
Cermet makers Nickel byproduct workers
Cobalt soapmakers Paint drier makers
Cosmetic makers Painters
Dye workers Porcelain workers
Drug makers Protective-coating makers
Electroplaters Refractory brick makers
Enamelers Rubber makers
Ethyl acrylate makers Silicate paint makers
Fertilizer workers Stone preserver makers
Frit workers Weatherproof cement makers
Gas mask makers Welders
Adapted from reference [256]
Much of the data on occupational exposure to cobalt have come from the 
tungsten carbide industry. McDermott [261], in 1971, found the average 
concentration of cobalt in 40 general air samples of seven tungsten carbide 
facilities to be below 0.1 mg/cu m (range, 0.005-0.15). About 70% of the 133
breathing zone samples were also less than 0.1 mg/cu m. Based on the data
provided, however, mean concentrations in breathing zones of press operators 
and machine tool operators averaged 0.16 and 0.21 mg/cu m, respectively.
A tungsten carbide facility reported that during 1977-78 the concentration 
of cobalt in worker breathing zones averaged 0.048 mg/cu m in the powder area,
0.033 mg/cu m in the pressing area, 0.019 mg/cu m in grinding, and 0.025 for 
general maintenance [255]. The highest concentration measured was 0.17 
mg/cu m and the lowest was 0.004 mg/cu m.
A study of eight cemented carbide plants in Sweden revealed that exposure
to cobalt varies considerably with job classification [262]. Groups handling 
powder were most exposed, while press operators, shapers, dry grinders, wet 
grinders, face grinders, and inspection personnel received decreasing levels 
of exposure to cobalt (in that order). Some workers handling powder probably 
received short-term exposures in excess of 0.1 mg cobalt/cu m.
28
At an operation where tungsten carbide tools containing 6.0-8.5% cobalt 
were sharpened by wet grinding, general air samples were well below 0.1 
mg/cu m [40]. Two-thirds of the breathing zone samples, however, were above
0.1 mg/cu m of cobalt (range, 0.04-0.93 mg/cu m). Full-shift TWA exposures 
were measured on a number of the grinders. Two-thirds of those values were 
above 0.1 mg/cu m with a range of 0.03-0.56 mg/cu m and a mean of 0.24 
mg/cu m.
A US nickel refinery provided cobalt dust exposure data collected in June 
1978 (B Roy, written communication, September 1978). Average concentrations 
of cobalt were generally low, ranging from less than 0.002 to 0.099 mg/cu m, 
except for two tower cleanup workers whose exposures averaged 0.156 mg/cu m. 
Within the occupational groups, the concentration ranges were sometimes quite 
variable; for example, the exposure of one cobalt operator was 0.313 mg/cu m, 
and for a supervisor it was 0.148 mg/cu m, even though averages for all 13 
workers in these groups were substantially lower.
In a plant manufacturing cobalt salts, concentrations of cobalt were 
measured at work stations where the salts were handled manually [255]. 
Workers in dusty areas were required to wear respirators. Cobalt 
concentrations where fine powders were dried were low, ranging from 1 to 2 
/ig/cu m. Where the dried cakes were broken into fine powders, cobalt 
concentrations varied, ranging from not detectable to 0.2 mg/cu m. On the 
average, the drum-loading operations were the dustiest, but the cobalt 
concentrations, 0.04-0.5 mg/cu m, varied widely. Other operations in the 
plant were contained and well ventilated so that the concentration of cobalt 
in those areas would be expected to be low.
An environmental survey conducted in May 1978 at a US jet aircraft engine 
assembly plant provided exposure data for three occupational groups (Table 
III-2) [255]. Workers processed metal alloy parts containing 1-15% cobalt and 
varying percentages of nickel and chromium. For each location, personal and 
area samples were collected.
A US manufacturer of cobalt-containing alloys provided data on 
concentrations of airborne cobalt near the furnaces (most were in the melt 
shops) and other operations [255]. These data covered 1970 to 1974. 
Exposures to cobalt on the average were substantially less than 0.1 mg/cu m, 
but they were quite variable, even for the same areas. For example, exposure 
to cobalt in the breathing zones of workers in the melt shops were 0.001-1.43 
mg/cu m. In the powder products area, six samples ranged from 0.09 to 9.7 
mg/cu m. General area samples tended to show a lower cobalt concentration 
than breathing zone samples.
Almost no published data on exposure to cobalt in welding and thermal 
cutting operations were found. Hewitt [259] measured cobalt and other 
metallic contaminants in a number of welding operations in well ventilated 
areas. Airborne cobalt concentrations were all 0.1-0.4 jug/cu m. Cobalt- 
containing welding rods can contain other metals such as nickel or chromium 
that can also be hazardous if they become airborne.
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TABLE I I I - 2
ENVIRONMENTAL DATA FOR COBALT ALLOY OPERATIONS
Occupation, Area Alloy Composition 
(% cobalt)
Cobalt Concentration 
(mg/cu m)
Parts Polisher 1 (maximum) <0.001
t f II <0.001
f t 15 0.008
Polishing Area — <0.001
Bench Operator 1 (maximum) 0 . 0 0 1
I I 12-15 0 . 0 0 1
Bench Area — <0.001
Cutter-Grinder 5-8 0.006
I f 7.75-8.25 0.005
I I 7.75-8.25 0 . 0 0 1
Cutting-Grinding Area 0.003-0.006
Although small amounts of cobalt driers are commonly added to paints and 
varnishes, suggesting that worker exposure Is minimal, almost no Information 
was found to confirm this suggestion. In a survey of a boat manufacturer, 
none of 13 lamination workers was exposed to detectable amounts of cobalt 
[263]. Cobalt naphthenate was present in small amounts in the resin used for 
lamination.
From July 1972 to January 1978, OSHA collected and measured samples in 79 
different workplaces for cobalt dust concentrations; 15 had concentrations 
exceeding the Federal limit of 0.1 mg/cu m (29 CFR 1910.1000). The majority 
of inspections were conducted in various metal manufacturing industries, with 
the remainder in inorganic chemical manufacturing and glass container, 
abrasive products, ceramics, and other industries [264].
Eight plant site visits were conducted to collect information for this 
report [255]. The number of production workers ranged from less than 50 to 
25,000. The three largest plants (at least 800 production workers) all had 
formal plans for sampling and inhouse capabilities for analysis. Two other 
plants sampled for cobalt on an irregular basis, and one other sampled for 
nuisance dust only. The two plants with less than 50 production workers had 
no program for air monitoring. These plants had relied on corporate 
headquarters, insurance carriers, and contractors for air monitoring where 
in-house capability was unavailable.
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Sam pling M ethods
Air sampling for particulate cobalt can be performed by methods 
recommended for metals in general [258,265,266] (see the Appendix). 
Collecting media include cellulose ester membrane filters, polycarbonate 
membrane filters [267], cellulose fiber filters [259,260], and polystyrene 
filters [257]. Cellulose ester membrane filters are widely used and 
recommended [268,269]. They have high sampling efficiency, relatively low 
background contamination from cobalt and other trace metals, ease of ashing, 
and convenience for personal monitoring [40,269,270]. Glass fiber filters, 
which are widely available, are less suitable for metals because of high and 
variable background contamination [257] and incompatibility with many routine 
analytical procedures.
Particle sizing can be performed by using an optical or electron 
microscope or by light-scattering techniques. Cascade impactors or cyclone 
separators can be used to separate particles according to size as they are 
collected [271]. Impaction devices have been used to determine the size 
distribution of cobalt-containing aerosols [259,270,272]. Since the Federal 
standard for cobalt requires measurement of total cobalt and not the 
respirable component, these devices should not be used for compliance 
purposes. However, they could have use in conducting basic research on the 
effects of exposure to cobalt.
Electrostatic precipitators were once widely used to sample air for cobalt 
and other metal aerosols [261], but they have been replaced, for the most 
part, by some of the more convenient sampling methods discussed above. 
Electrostatic precipitators have the advantage of being free of filter 
clogging and problems with flowrate or humidity. They are also effective in 
collecting particles of all sizes. One disadvantage of electrostatic 
precipitators is that actual worker exposure may not be estimated as closely 
as is possible with personal sampling.
Analytical Methods
Many methods have been developed for the analysis of cobalt samples 
collected from air. Among these, colorimetric procedures can be satisfactory 
provided that other metals do not interfere with the results. Color reagents 
that have been used include nitroso R salt (sodium nitroso-2-naphthol-3,6- 
disulfonate) and sodium thiocyanate [273-275]. Although these methods are 
tedious and require skill, they can give satisfactory results.
Emission spectrometric methods have been used frequently to analyze 
airborne particulate material. Because of its sensitivity, the emission 
spectrograph has been used to measure pollutants in the community atmosphere 
[276], but this technique is also useful to determine concentrations of 
airborne cobalt in the workplace. One investigator, using a specialized 
electrode for air sampling, was able to perform direct analysis of samples 
using the emission spectrograph [277]. Equipment cost and limited
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availability are important factors to consider in recommending the use of the 
emission spectrograph in routine analysis of samples.
A widespread method used for determination of airborne cobalt levels is 
analysis by atomic absorption spectrophotometry (AAS) [266,267,278,279]. The 
advantage of the atomic absorption method is that it can be made both highly 
specific and sensitive for the detection of cobalt. The NIOSH P&CAM method 
173 recommends AAS for detection of cobalt [268]. This method is sufficiently 
sensitive to detect cobalt in the concentration ranges normally found in the 
air of plants manufacturing or using cobalt products if sampling is carried 
out at a flowrate of 1.5 liters per minute for up to 8 hours using a 37-mm
cellulose ester filter with a pore size of 0.8 Atm. The method will not
distinguish between individual cobalt compounds. In a collaborative test of 
P&CAM 173, the mean cobalt concentration detected by 17 laboratories was 11.9% 
below a reference value, suggesting some loss of sample. The coefficient of
variation was 45.5% for all of the laboratories, but only 2-10% for single 
laboratories on replicate samples [266]. With the use of graphite electrodes, 
flameless AAS methods have extended detection limits for cobalt to ambient air 
levels [267].
Atomic absorption spectrophotometry has been used extensively to analyze 
biologic samples for cobalt [280-282]. Because of the extremely low
concentrations of many metals (including cobalt) normally in such samples, 
innovative methods to enhance sensitivity have been developed. An example is 
the formation of an organometallic complex, such as with a dithiocarbamate, 
which is readily extracted into an organic solvent, eg, methyl isobutyl ketone 
[283,284]. This procedure increases sensitivity, not only because it 
concentrates the cobalt in the sample, but also because of enhanced 
sensitivity of the AAS obtained from the use of an organic solvent. Using ion 
exchange separation and electrothermal atomic absorption, Alexandersson and 
Lidums [282] found reasonably good correlation between blood and urine 
concentrations of cobalt in workers and airborne levels in cemented carbide 
plants.
Neutron activation analysis (NAA) can analyze a single small sample for a 
number of trace metals. Dams et al [257], using NAA, reported a detection 
limit for cobalt of 2 ng. The minimum concentration of cobalt reported to be 
detectable in a 24-hour sample of urban air was 25 pg/cu m (1 mg = 10 exp +9 
pg) in the presence of 32 other trace elements that were similarly determined. 
Although this method is sensitive and does not destroy the sample, the 
requirements for elaborate equipment, the safety precautions necessary for use 
of an irradiating beam or radioactive sources, and the relatively small 
thermal neutron cross section of cobalt make NAA less practical than AAS for 
routine use.
Another technique for analysis of airborne cobalt use is the x-ray 
fluorescence method [258,266,272]. The fluorescence method resembles the 
neutron activation procedure in specificity, sensitivity, and ability to 
analyze a single sample for a number of elements. It is nondestructive and 
requires a minimum of sample handling. Results can be obtained quite rapidly 
for cobalt as well as for a number of other metals [266,272], and the x-ray
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fluorescence method can be an acceptable alternative to M S  when analyzing 
cobalt.
In summary, the collection of air samples on membrane filters and the 
analysis of those samples by AAS, as described in the NIOSH P&CAM 173, are the 
methods of choice for monitoring of workers' exposure to cobalt (see the 
Appendix). Other methods, at least as sensitive and precise, are also 
acceptable.
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IV. CONTROL OF EXPOSURE
Over a million workers have some potential for exposure to at least one 
cobalt-containing compound in the course of their employment. Many receive 
little exposure because they work with very small amounts of cobalt on an 
intermittent basis. Others, however, work with large amounts of cobalt 
regularly. These workers can become exposed through inhalation, dermal 
contact, or ingestion. In some operations, exposure to cobalt is limited 
because of the use of extensive engineering controls. Other operations, 
however, require manual handling of materials containing cobalt. Local 
exhaust ventilation [261,285] and good work practices can minimize exposure to 
cobalt in such circumstances. In all cases, ingestion of cobalt is easily 
prevented by the use of good personal hygiene in combination with the 
maintenance of a clean worksite. Workers who maintain or repair equipment, 
enter confined spaces such as tanks or vessels, or are involved in emergencies 
or other nonroutine situations have an especially high risk of exposure to 
cobalt. These workers should be trained to recognize hazards, and in some 
circumstances they may require special protective equipment or clothing to 
decrease exposure.
Information on typical industrial practices for the control of cobalt came 
from several site visits to plants manufacturing or using cobalt-containing 
products. These plants included a refinery, an alloy producer, cemented 
tungsten carbide producers, and cobalt salt manufacturers. Other sites 
visited included a welding-rod maker and an aircraft engine manufacturing 
facility. There is some published information on control of cobalt [261,285], 
but much of the following information came from plant visits [255].
Engineering Controls
Well-maintained closed systems and the prevention of dust generation, when 
compatible with the operation involved, are the most effective methods of 
limiting worker exposure. When a closed system is used, it must prevent or 
minimize the release of materials. When closed systems are not practical, 
worker exposure can often be reduced by process equipment modification, the 
use of control rooms, or local exhaust ventilation.
Properly designed and maintained ventilation systems, including local 
exhaust systems, can prevent the accumulation of airborne cobalt-containing 
dusts and fumes. Local exhaust systems were in frequent use in the plants 
visited. Examples include the use of glove boxes for welding, exhaust hoods 
provided to individuals using hand-held buffers and grinders, local exhaust on 
the other grinding machines and on press machines, and dust-collecting hoses 
for packaging operations [255]. In addition, a ventilation system is 
desirable as a standby, should a closed system fail. Where exhaust 
ventilation is required, adequate makeup air, conditioned as necessary for 
worker comfort, must be provided.
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Ventilation requirements for grinding, buffing, and polishing operations 
were described in a NIOSH research report [286]. Dry grinding equipment was 
classified as pedestal type, abrasive cutoff tools, surface-type disc 
grinders, portable grinders and cutoff machines, and other grinding machines 
according to ventilation system design requirements. Polishing (coated 
abrasive) equipment was classified as wheel and drum type, disc type, belt 
polishers, and complex machines. Buffing (loose abrasive) equipment was 
classified as pedestal type, portable, or multiple buffer machines. For 
grinding and abrasive polishing, most of the equipment-generated particulate 
material was thought to be from the workplace. This would be so even for hard 
metal if a diamond wheel is used. Much more dust was contributed by the 
abrasive and the abrasive support materials in buffing. The report, in noting 
that the TLV for cobalt is very much less than for nuisance dust, considered 
that adequate control of cobalt is not likely to be possible with standard 
ventilation systems. Totally enclosed ventilation systems and respiratory 
protection for personnel within the enclosure were recommended. However, many 
alloys containing only a small percentage of cobalt are used, and restrictions 
could be less severe in such cases. Engineering controls for most buffing and 
grinding machines are built to conform to the configuration of the equipment 
and the materials being handled. Specific guidelines, therefore, are 
difficult to propose. Figure X-l shows a diagram of typical local exhaust 
ventilation for hand held grinders [287]. Workers doing grinding or buffing 
should be adequately trained to recognize the proper configuration of
ventilation equipment for each shape being handled.
Several potentially dusty situations exist in the manufacture or use of 
cobalt salts, especially if powders rather than crystals are formed. While 
filter presses are not considered especially dust-producing, they are readily 
enclosed by local exhaust ventilation as shown in Figure X-2 [288]. Powders
formed through filtration, however, present a significant dust problem both in 
their packaging and in subsequent repackaging and use. The material removed
from the filter press is dried, and this dry cake can cause substantial 
amounts of airborne dust as it is being placed in the pulverizer. One
possible type of local exhaust ventilation that would greatly reduce worker 
exposure is shown in Figure X-3 [288]. Solutions, powders, and crystals of 
cobalt compounds and fine powders of cobalt metal or mixtures of tungsten 
carbide and cobalt should be packaged while using local exhaust ventilation. 
Two typical arrangements are shown in Figure X-4 [288]; many other
configurations are also possible. When material is transferred to or from a 
container to obtain the nominal weight of the package or to use the product, 
material is often scooped from one container to another. This can be 
exceedingly dusty, especially with fine powders. Hoods that prevent the 
powder from dispersing into the work area and do not interfere with the
weighing procedure are difficult, but not impossible, to design. Design
requirements, however, are quite dependent on the size and shape of the
container.
In most of the plants visited, engineering controls in use were generally 
not specific to cobalt alone, but rather to the entire process [255]. For 
example, emissions from furnaces preparing specialty steels must be controlled
for all the metals in the melt. Cobalt may not be the limiting factor in
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control of exposure in such situations. Ball mills used in the cemented 
carbide industry use solvents, such as acetone, and these emissions must be 
controlled. Several plants used cobalt in foundry operations where silica and 
other substances used in the molds dictated many of the control measures used. 
In milling, hot and cold rolling, and other operations, noise was often a 
factor in the use of control booths and of other means of control that often 
helped to lower exposure to cobalt. In buffing, exposure to the abrasive 
support material must be controlled as must oil mists generated in wet 
grinding. In manufacture of salts, extensive use of strong acids led to
requirements for emission control and cleanup procedures that also limited 
exposure to cobalt. These overall requirements must be considered in
designing engineering controls for cobalt.
To ensure effective operation of ventilation systems, trained personnel 
should conduct a regular monitoring program. Routine inspection should 
include face velocity measurements of the collecting hood, examination of the 
air mover and collection or dispersion system, and measurements of atmospheric 
concentrations of cobalt in the work environment. Where appropriate, the use 
of continuous airflow indicators, such as water or oil manometers properly 
mounted at strategic locations and marked to indicate acceptable air flow, 
should be considered. Any changes in the work operation, process, or
equipment that may affect the ventilation system must be evaluated promptly to
ensure that control measures adequately protect workers. All exhaust
emissions from ventilation systems should be passed through a system designed 
to minimize the release or recirculation of raw materials, cobalt, and wastes 
into the occupational and community environments.
Work Practices
Ultimately, any program of worker protection must consider the prevention 
of pulmonary fibrosis, which has been clearly demonstrated to result from 
excessive exposure to cobalt metal and oxides. Dermatitis and an occasional 
case of extreme pulmonary hypersensitivity to cobalt, however, are much more 
frequently encountered problems in the day-to-day operation of health care for 
cobalt workers. These problems cannot be neglected in establishing an 
effective program for worker protection.
Employers should institute programs that emphasize good personal hygiene 
to prevent skin and respiratory irritation caused by cobalt-containing dusts. 
After working with cobalt products, workers should thoroughly wash their hands 
and face before drinking, eating, or smoking. If skin contact with cobalt 
solutions occurs, the worker should wash the affected skin promptly. The 
employer should provide showers if workers have substantial contact with 
cobalt. These workers should be encouraged to wash or shower after each 
workshift. Employers should prohibit smoking or carrying of tobacco products 
in work areas because of possible cobalt contamination. For the same reason, 
employers should prohibit eating, food handling, or food storage within the 
work area.
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To maintain a safe workplace, employers must identify the many physical 
hazards involved in handling cobalt and take measures to eliminate them. In 
particular, several potentially hazardous situations were observed in plant 
site visits [255]. These included sharp edges on some rolled alloys and 
rolled-alloy scraps, the need to lift heavy containers of cobalt, and press 
operators who placed their fingers under moving machinery to remove parts. 
Rolled alloy workers can avoid finger cuts by wearing gloves. Trained workers 
who follow proper lifting techniques could avoid back injuries when they lift 
dense material such as cobalt metal. Protective clothing must not increase 
the potential for injury of workers who handle cobalt when working with 
machinery with moving parts.
In storage, cleanup of spills, and emergencies involving fires, employers 
must be aware of the properties of individual cobalt compounds to ensure 
proper planning. Finely divided cobalt will ignite, but its fire and 
explosion hazard is very weak [289]. Certain cobalt compounds used in 
paints, including cobalt linoresinate, cobalt tallate, and cobalt 2-ethyl 
hexanoate, are often mixed with kerosene or mineral spirits as solvents. 
These materials present a moderate fire hazard when exposed to heat or flame 
[255]. Cobaltous acetylacetonate and cobaltous nitrate are incompatible with 
easily oxidized material. Cobaltous nitrate can react to cause ignition, 
violent combustion, or explosion. Cobaltous acetylacetonate flashes at its 
sublimation point. Other substances can emit highly toxic or acrid fumes when 
heated to decomposition; these substances include cobaltous nitrate, cobalt 
benzoate, and cobaltous phosphate.
General plant maintenance must be conducted regularly to prevent cobalt- 
containing dusts from accumulating in work areas. Cleaning should be 
performed with vacuum pickup or wet mopping to minimize the amount of dust 
dispersed into the air. A decontamination room should be available for 
cleaning equipment that is to receive major overhaul or maintenance. Spills 
of cobalt-containing material should be promptly cleaned up to minimize 
inhalation or dermal contact. Liquid material spills can be copiously flushed 
with water and channeled to a treatment system or holding tank for reclamation 
or proper disposal. Spills of dry material can be removed by vacuuming or wet 
mopping. Some spills can be removed by hosing, first with a mist of water to 
dampen the spilled material and then with a more forceful stream that flushes 
it into a holding tank or other facility for handling contaminated water. 
Work surfaces or contaminated clothing should never be cleaned by dry sweeping 
or blowing with pressurized hoses. Recovery systems used to reclaim waste 
metals should comply with Federal, state, and local regulations. All waste 
material generated in the handling of cobalt-containing substances should be 
disposed of in compliance with Federal, state, and local regulations.
Maintenance and repair workers face special problems regarding their 
potential exposure. The very circumstances that require the maintenance or 
repair work and dictate the work conditions will often preclude use of some 
control procedures. Consequently, very careful supervisory control must be 
exercised over such activities. These workers must wear appropriate 
protective equipment and clothing, and they must be trained to recognize and 
control the hazards they face.
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Special precautions are necessary when workers must enter tanks or 
vessels, such as reaction vessels containing cobalt catalysts or vessels used 
to prepare cobalt salts [290]. Before any worker enters a vessel, all sources 
for transferring cobalt and other materials into or out ot the vessel must be 
blanked to prevent their entry. The vessel interior must then be washed with 
water and purged with air. After purging the vessel's interior, trained 
personnel should test the vessel's atmosphere with suitable instruments to 
ensure that no hazards from fire, explosion, oxygen deficiency, or dust 
inhalation exist. No one should enter a tank or vessel without first being 
equipped with an appropriate respirator and a secured lifeline or harness. 
Mechanical ventilation should be provided continuously when workers are inside 
the tank. At least one other worker similarly equipped with respiratory 
protection, lifeline, and harness should watch at all times from outside the 
vessel. Workers inside the tank must be able to communicate with those 
persons outside. Other workers must be available to assist in an emergency. 
Flame- or spark-generating operations, such as welding or cutting, should be 
performed only when an authorized representative of the employer has signed a 
permit based on a finding that all necessary safety precautions have been 
taken.
Work Clothing and Protective Equipment
Cobalt causes skin sensitization, and some substances, such as cemented 
carbides, are abrasive to the skin as well [81]. The use of coveralls or 
similar work clothes can minimize the possibility of skin irritation, 
especially if the clothing is changed daily or more promptly in the event of 
gross contamination from a spill or leak. Workers in flame- or 
spark-generating operations should, in addition, wear work clothes made of 
fire-retardant materials. Gloves and protective sleeves should be used in
manual transfer operations, together with a face shield (if respiratory
protection is not needed) to keep soiled fingers from touching the face. 
Employers should provide change rooms and dual lockers so workers can remove 
soiled coveralls during breaks. Work clothing should be worn for only a 
single day work period, then collected directly into a designated and labeled
container, and laundered by a management-selected laundry service. This is
encouraged to prevent the spread of contamination into the homes of workers.
Eye irritation has apparently not been a problem for workers handling 
cobalt products; however, in operations that do scatter fine particles in the 
air, such as grinding, eye protection must be used that complies with 29 CFR
1910.133. Workers who are especially sensitive to cobalt or who handle 
solutions of cobalt in such a manner that cobalt can splash on the skin or 
into the eyes must wear protective suits, or face shields with goggles as 
appropriate, to prevent appreciable skin and eye contact. Emergency 
eyewashing facilities, where needed, must be readily available to affected 
workers. Workers experiencing skin irritation should see a physician 
promptly.
Respirators are not a substitute for proper engineering controls. 
Respirators may be needed, however, for nonroutine maintenance work, entry
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into confined spaces, pending installation of adequate controls, and in 
emergencies where the concentration of cobalt could be unknown or excessive. 
In these situations, employers must provide workers with respirators, and 
establish a respiratory protective program meeting the requirements of 29 CFR
1910.134. These programs should emphasize the importance of having clean, 
well-maintained, well-fitted respirators for use in unusual circumstances and 
emergencies. Workers must be aware of the need to guard against contamination 
of the interior of the facepiece. Table IV-1 is a respirator selection guide 
for cobalt developed under the joint NIOSH/OSHA Standards Completion Program 
[291]. It is based on the Federal standard for cobalt.
Effective Planning
No program to minimize worker exposure to cobalt can be effective unless 
adequate attention has been given to problems before they arise. When a new 
facility is to be constructed, persons knowledgeable in occupational safety 
and health and industrial hygiene engineering should review plans both in the 
design phase and during construction. They should ensure that working areas 
and engineering controls are designed so that spills and airborne cobalt will 
be minimized when the plant is in operation.
For plants already in operation, management should review material- 
handling operations, maintenance and repair procedures, and process operations 
periodically. This review should identify areas and job locations where 
workers might be exposed to cobalt or cobalt-containing waste products, either 
through inhalation or direct contact with the skin or eyes. If work practices 
or engineering controls in any area are no longer adequate, management should 
modify them promptly.
Contingency planning for emergencies, inadvertent release of materials, 
and breakdown of facilities is vital. These plans should be developed for 
each department as well as plantwide. They should outline where appropriate 
equipment and trained personnel are located, and should be written, well 
understood by workers, and updated as required. Each plant should also be 
prepared to assess the impact or hazards of a specific spill or release of 
material should it reach a waterway or create a cloud. Supervisors should 
have information available, including lists of appropriate names and telephone 
numbers, for reporting emergencies. In addition to internal reporting 
procedures, plant management should clearly understand what situations require 
recordkeeping or external reporting to OSHA, the Environmental Protection 
Agency (EPA), and any appropriate state agencies.
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TABLE IV -1
RESPIRATOR SELECTION GUIDE FOR COBALT
Concentration 
(mg/cu m, as cobalt)
Respirator Type Approved under 
Provisions of 30 CFR 11*
Less than or equal to 0.5
Less than or equal to 1.0
Less than or equal to 5
Less than or equal to 20
Escape
(1) Dust and mist respirator, except 
single-use respirators
(1) Dust and mist respirator, except 
single-use and quarter-mask 
respirators
(2) Fume or high-efficiency particulate 
respirator
(1) High-efficiency particulate respir­
ator with a full facepiece
(2) Supplied-air respirator with full 
facepiece, helmet, or hood
(3) Self-contained breathing apparatus 
with full facepiece
(1) Powered air-purifying respirator 
with a high-efficency
filter and a full facepiece**
(2) Type C supplied-air respirator with 
a full facepiece operated in pres- 
sure-demand or other positive 
pressure or continuous-flow mode
(1) High-efficiency particulate respir­
ator with full facepiece
(2) Self-contained breathing apparatus
♦Respirators specified for use in higher concentrations of cobalt may be 
used in atmospheres of lower concentrations.
**A high-efficiency filter is defined as one having a penetration of <0.03% 
when tested against a 0.3-jum dioctyl phthalate (DOP) or equivalent aerosol.
Worker Education and Monitoring
A fundamental part of any program designed to provide a more healthful 
workplace involves education and monitoring of workers. Workers who
understand the reasons for rules concerning hygiene and work practices are
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more likely to help keep their work area clean. For cobalt, medical and 
environmental monitoring are especially important since the potential effects 
of exposure are poorly understood. Employers must follow the results of 
medical examinations and correlate them with exposure measurements to ensure 
that workers are adequately protected. Workers should understand the 
importance of the medical and environmental monitoring to ensure that they 
will cooperate and report any possible adverse reaction to cobalt promptly.
(a) Training Programs
Workers must know how to handle cobalt safely. Instructions concerning 
proper handling methods, cleanup procedures, personal protective equipment, 
and emergency procedures should be part of a continuing education program 
presented in training sessions and in written form. The NIOSH publication An 
Identification System for Occupationally Hazardous Materials [292] describes 
the types of information on physical, chemical, and toxicologic properties of 
materials that should be kept in written form. This information should be 
readily available to persons who handle cobalt-containing substances, and each 
cobalt compound used should have a corresponding material safety data sheet.
(b) Workplace Monitoring
Manufacturers of all cobalt compounds and users (unless trivial amounts 
are involved) should conduct an industrial hygiene survey at each location 
where cobalt is used to determine where workers are likely to be exposed to 
cobalt. Surveys should be repeated at least once every 3 years, preferrably 
annually, and as soon as possible after any process change that is likely to 
increase the concentration of airborne cobalt.
For workers in areas where the concentration of airborne cobalt is likely 
to exceed 0.05 mg cobalt/cu m (one-half the Federal limit), the employer 
should establish the following program.
1. Personal monitoring should be conducted to identify and measure, or 
permit calculation of, the exposure of each worker. Appropriate methods for 
sampling and analysis are listed in the Appendix.
2. Samples should be representative of the breathing zone air of workers, 
but source and area monitoring can be a useful supplement for identifying 
leaks or other sources of emissions.
3. While all workers do not have to be monitored, sufficient samples 
should be collected to characterize the exposure of all workers. Variations 
in exposure during different shifts, because of location or job function and 
of changes in production schedule, should be considered in deciding the number 
of samples to be collected.
4. If a worker is exposed to cobalt at concentrations exceeding the 
Federal standard, improved measures to control exposure should be taken 
immediately. Once the control measures are in effect, exposure monitoring 
should be repeated. If two consecutive measurements, taken at least 1 week
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apart, are below the Federal standard, the worker's exposure may be considered 
no longer excessive.
Personal monitoring records should be kept for 30 years to ensure 
compliance with new OSHA regulations concerning worker rights to information 
about their exposure (29 CFR 1910.20).
(c) Medical Surveillance
N10SH encourages the provision of medical surveillance programs for 
workers. Some companies already maintain high-quality programs that allow 
absorption of hazardous chemicals to be detected at the earliest possible 
time. This allows early intervention by surveying the workplace and
initiating work practice and engineering changes necessary to protect workers.
Medical surveillance programs should ideally include preplacement 
examinations and periodic réévaluations that will, based on the
characteristics of the individual substance or agent, allow detection of 
absorption before onset of perceptible damage. In most programs, periodic 
examinations should be carried out on an annual basis. Since cobalt has been 
implicated to lesser or greater degrees with many effects on the body, these
examinations should include not only the points discussed below but also be
thorough enough to give reasonable assurance that effects have not occurred 
elsewhere in the body. The circumstances of each workplace and the types of 
cobalt compounds present will of course influence the program chosen by the 
responsible physician.
The most dramatic effect of cobalt is on the lungs, Involving development 
of pulmonary fibrosis. As a result, a medical history is important to 
determine the presence of factors that would argue against placement in a job 
requiring exposure to cobalt. The physical examination should give special 
attention to the chest and lungs. Because pulmonary function studies are 
sensitive indicators of early changes in lung tissues, NIOSH recommends that 
they be conducted yearly. The forced expiratory volume in 1 second (FEV 1) 
and forced vital capacity (FVC) tests are sensitive and easy to administer. 
Chest x-rays can be useful but are somewhat less able to detect early changes 
as compared to pulmonary function tests, so 3 years is probably a suitable 
time between radiologic examinations.
The skin should receive attention because cobalt compounds can cause 
allergic responses and sensitization. Once sensitized, a worker can probably 
not tolerate any additional exposure. As a result, any worker with a previous 
history of allergic skin disease should be carefully counselled and schooled 
in techniques that will minimize contact with cobalt. In addition, skin 
protection should be stressed in the workplace to keep the number of new cases 
of skin sensitization at a minimum.
Cobalt affects the thyroid gland, and results in production of goiter. 
While the strength of this association is not clear, it seems that palpation 
of the thyroid for enlargement would be a prudent and simple step to include.
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Thyroid function studies do not seem necessary unless enlargement or some 
other sign or symptom of thyroid dysfunction la present.
Present information suggests the possibility of polycythemia in the blood 
and electrocardiographic changes in the heart being produced by exposure to 
cobalt. The information is very unclear and appears to show effects only at a 
very high dosage. Therefore, no specific tests are suggested for these organ 
systems unless there is a potential for exposute to high levels of cobalt in 
the workplace.
The medical surveillance program should be reevaluated frequently and 
changed to reflect current working conditions and knowledge of health effects.
Medical records should be kept for 30 years after the worker's last 
exposure to cobalt. This will ensure compliance with OSHA's (29 CFR 1910.20) 
standard concerning worker's rights to his or her own medical records.
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V. BASIS FOR STANDARDS CONCERNING OCCUPATIONAL EXPOSURE TO COBALT
A TLV for workplace exposure to cobalt of 0.5 mg/cu m was proposed by the 
ACGIH in 1962 [293] and adopted in 1963 [294]. ACGIH1s 1966 Documentation of 
Threshold Limit Values [295] supported the TLV by citing the development of 
pulmonary changes in workers in the tungsten carbide industry. Reports by 
Miller et al [23] and Lundgren and Swenssen [296] were mentioned as evidence 
that cobalt was the etiologic agent involved. Work by Fairhall and colleagues 
[37,297] was cited as showing the potential for serious and occasionally fatal 
responses to cobalt at exposure concentrations of 1-2 mg/cu m or less in the 
tungsten carbide industry. These reports indicated that lung impairment often 
diminished when workers were removed from the workplace environment and that a 
hypersensitivity reaction appeared to be involved. A study by Stokinger and 
Wagner [138] was cited as evidence for the involvement of hypersensitivity in 
cobalt-exposed animals. A description by Schwartz et al [298] of an allergic 
dermatitis observed after exposure to cobalt was also noted. Irritation and
itching had also been cited by ACGIH in its 1966 documentation [295].
A change in the TLV for cobalt from 0.5 to 0.1 mg/cu m as cobalt metal 
dust and fume was recommended by the ACGIH in 1966 [299] and adopted in 1968 
[7]. The 1971 documentation (1976 addendum) [300] supported this lower TLV 
and cited additional information including a 1955 report by Schepers [55], 
which showed that intratracheal administration of cobalt metal led to chronic 
pneumonitis in guinea pigs. The results of surveys in Michigan and 
Pennsylvania were also cited. These showed that workplace concentrations of 
cobalt could be reduced to 0.1 mg/cu m or less. A concomitant reduction in 
cases of pneumonitis or dermatitis was observed in the Michigan survey over 18 
years when cobalt levels were reduced from 14.42 mg/cu m to below 0.1 mg/cu m.
A reduction of the TLV from 0.1 to 0.01 mg/cu m was tentatively 
recommended in 1975 by the ACGIH Committee on Threshold Limits [8]. This 
recommendation was subsequently revised, and a limit of 0.05 mg/cu m was
proposed by the TLV committee in 1976 [9]. The supporting documentation for
both recommendations was the same and can be found in the 1974-75 and 1976 
supplements to the Documentation of Threshold Limit Values for Substances in 
Workroom Air [300] or in the Transactions of the 38th Annual ACGIH Meeting 
[301]. Information cited to support the change included reports by Siegesmund 
et al [22] and Kerfoot et al [44]. The reason for lowering the TLV from 0.1
mg/cu m was not clear from the documentation, but it probably was based on the
finding of Kerfoot et al [44] that swine exposed at 0.1 mg/cu m developed 
pulmonary changes.
Standards for occupational exposure to cobalt in other countries are
listed in Table V-l. Since 1971, a commission of the German Research
Association of the Federal Republic of Germany has included cobalt in the form 
of respirable dusts of metallic cobalt and sparingly soluble cobalt salts on 
its list of animal carcinogens (D Henschler, written communication, November 
1978). Documents considered in this decision included papers on
carcinogenicity [169,170,174,177,178,302-304] and other studies [305,306].
44
The present US limit (29 CFR 1910.1000) for workplace exposure to cobalt 
metal, fume, and dust measured as cobalt is an 8-hour TWA concentration limit 
of 0.1 mg/cu m. This standard is based on the TLV adopted by the AC6IH in 
1968.
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TABLE V -l
OCCUPATIONAL ENVIRONMENTAL LIMITS FOR COBALT IN FOREIGN COUNTRIES
Country Compound Concentration 
(mg/cu m)
Reference
No.
Australia Cobalt and 
cobaltous oxide
0.1 307
Belgium If 0.01 307
Bulgaria H 0.5 307
Czechoslovakia Cobalt metal» 
fume, and dust
0.1 308
Finland Cobalt and 
cobaltous oxide
0.1 307
Germany
(Federal Republic)
Cobalt metal, 
fume, and dust
0.5 308,
309
Germany " 
(Democratic Republic)
0.1 308
Italy Cobalt and 
cobaltous oxide
0.1 307
Netherlands II 0.1 307
Poland Cobalt 0.5 310
Romania Cobalt and 
cobaltous oxide
0.2 (av.) 
0.5 (max)
310
Sweden Cobalt metal, 
fume, and dust
0.1 308
Switzerland Cobalt and 
cobaltous oxide
0.1 307
USSR Cobalt metal, 
dust, and fume
0.5 308
Yugoslavia Cobalt 0.1 310
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V I. RESEARCH NEEDS
Much research conducted on cobalt compounds has served a very specific 
purpose, and the investigations have not examined overall toxicity. Very few 
reports except for those concerning pulmonary fibrosis in the hard metal 
industry have examined the effects of cobalt exposure in the workplace. 
Considerably more research needs to be done on cobalt, but the following is 
particularly needed.
The possibility that cobalt compounds in general are fibrogenic should be 
considered. Inhalation studies in animals should include as a minimum a 
cobalt salt. Workers in industries other than those manufacturing or using 
cemented carbide should be examined for adverse lung effects. For both 
animals and humans, an attempt should be made to obtain dose-response data if 
fibrosis or prefibrotic changes are found.
The possibility that certain specialty steels cannot release cobalt in the 
lung following inhalation should be examined. Some of these substances are 
used because of their extreme heat and corrosion resistance. It is possible 
that their toxic effects are unrelated to their cobalt content.
An effort should be made to determine the prevalence of dermatitis caused 
by sensitization to cobalt in various US industries. Information should be 
collected for different types of cobalt and should Include cobalt metal, 
cemented carbide, and cobalt salts. Work practices and types of protective 
clothing should be considered in order to determine the protection needed by 
workers to minimize their chances of becoming sensitized.
The issue of the possible carcinogenicity of cobalt is very much 
unresolved. Inhalation studies need to be conducted in animals, and such 
studies could be performed in conjunction with examination of possible 
fibrotic effects. In humans, epidemiologic studies should be conducted. The 
cemented carbide Industry, In particular, should be examined since the process 
is sufficiently old that an appropriate cohort should be available. Any 
epidemiologic study should also collect information on heart disease. The 
possibility that cobalt exposure at fairly low levels over a considerable 
period of time could lead to heart disease cannot be ruled out from 
information now available.
Finally, many cobalt compounds in commercial use have not been examined 
for toxicity, or very little information of limited use is reported. For 
example, some cobalt pigments and cobalt driers for oil-based paints have 
widespread use. Compounds such as these should be subjected to thorough 
testing for toxicity.
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O c c u p a t i o n a l  S a f e t y  and  H e a l t h  S e r i e s  No.  3 7 .  G e n e v a ,  I n t e r n a t i o n a l  
L a b o u r  O f f i c e ,  1 9 7 7 ,  pp 3 3 , 7 6 - 7 9
3 0 8 .  W i n e l l  MA: An i n t e r n a t i o n a l  c o m p a r i s o n  o f  h y g i e n i c  s t a n d a r d s  f o r
c h e m i c a l s  i n  t h e  w o rk  e n v i r o n m e n t .  Ambio 4 : 3 4 - 3 6 ,  1975
3 0 9 .  [Maximum Work P l a c e  C o n c e n t r a t i o n s  197 6— C o m m iss io n  f o r  t h e  S t u d y  o f  
H a r m f u l  Work S u b s t a n c e s  C o m m u n i c a t io n  X I I . ]  B onn ,  D e u t s c h e  
F o r s c h u n g s g e m e i n s c h a f t ,  1 9 7 6 ,  pp 5 - 1 0 , 2 5 , 3 7 - 4 0 , 4 8 - 5 0  (G e r )
3 1 0 .  P e r m i s s i b l e  L e v e l s  o f  T o x i c  S u b s t a n c e s  i n  t h e  W ork in g  
E n v i r o n m e n t — S i x t h  S e s s i o n  o f  t h e  J o i n t  ILO/WHO C o m m i t t e e  on 
O c c u p a t i o n a l  H e a l t h ,  G e n e v a ,  J u n e  4 - 1 0 ,  1 9 6 8 .  G e n e v a ,  I n t e r n a t i o n a l  
L a b o u r  O f f i c e ,  1 9 7 0 ,  pp 1 9 7 , 2 1 0 , 2 2 3 , 2 3 1 , 2 7 8 , 2 8 7 , 3 0 3 , 3 4 3 , 3 4 7
3 1 1 .  B a r b o r i k  M, D u s ek  J :  C a r d i o m y o p a t h y  a c c o m p a n y i n g  i n d u s t r i a l  c o b a l t .
Br  H e a r t  J  3 4 : 1 1 3 - 1 1 6 ,  1972
31 2 .  W i n d h o l z  M: The M er ck  I n d e x — An E n c y c l o p e d i a  o f  C h e m i c a l s  and D r u g s ,
ed  9 .  Rahway,  N J ,  M er ck  and  Co I n c ,  1 9 7 6 ,  pp 3 1 1 - 1 4
3 1 3 .  S u r v e y  A n a l y s i s  and  S u p p l e m e n t a l  T a b l e s ,  i n  N a t i o n a l  O c c u p a t i o n a l  
H a z a r d  S u r v e y ,  DHEW (NIOSH) P u b l i c a t i o n  No. 7 8 - 1 1 4 .  C i n c i n n a t i ,  US 
D e p t  o f  H e a l t h ,  E d u c a t i o n ,  and W e l f a r e ,  P u b l i c  H e a l t h  S e r v i c e ,  C e n t e r  
f o r  D i s e a s e  C o n t r o l ,  N a t i o n a l  I n s t i t u t e  f o r  O c c u p a t i o n a l  S a f e t y  and  
H e a l t h ,  v o l  I I I ,  792 pp
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V I I I .  APPENDIX
SAMPLING AND ANALYSIS
Th e s a m p l i n g  an d  a n a l y t i c a l  p r o c e d u r e s  a r e  b a s e d  on  M ethod  No.  P&CAM 173 
o f  t h e  NIOSH M a n u a l  o f  A n a l y t i c a l  M e t h o d s  [ 2 6 8 ] ,  t h e  NIOSH M an u a l  o f  S a m p l i n g  
D a t a  S h e e t s  [ 2 6 9 ] ,  t h e  C o m p l e t e  T e s t i n g  o f  NIOSH M ethod  f o r  t h e  D e t e r m i n a t i o n  
o f  T r a c e  M e t a l s  b y  A t o m i c  A b s o r p t i o n  S p e c t r o p h o t o m e t r y  [ 2 6 6 ] ,  an d  u p d a t e s  b y  
NIOSH, I n o r g a n i c  M e th o d s  D e v e l o p m e n t  S e c t i o n .
S am ple  a n a l y s i s  b y  a t o m i c  a b s o r p t i o n  s p e c t r o p h o t o m e t r y  (AAS) i s  p r o b a b l y  
t h e  m o s t  e c o n o m i c a l  m e t h o d  f o r  t h e  m e a s u r e m e n t  o f  c o b a l t .  NIOSH re com mends 
t h i s  m e t h o d  f o r  d e t e r m i n i n g  c o m p l i a n c e  w i t h  t h e  F e d e r a l  s t a n d a r d  f o r  c o b a l t .
G e n e r a l  S a m p l i n g  R e q u i r e m e n t s
C o l l e c t  p e r s o n a l  s a m p l e s  i n  t h e  b r e a t h i n g  z o n e  o f  i n d i v i d u a l  w o r k e r s  
w i t h o u t  i n t e r f e r i n g  w i t h  t h e  w o r k e r s '  f r e e d o m  o f  m o v em e n t .  E no ug h s a m p l e s  
s h o u l d  b e  o b t a i n e d  t o  p e r m i t  c a l c u l a t i o n  o f  a  TWA c o n c e n t r a t i o n  an d  t o  
e v a l u a t e  t h e  e x p o s u r e  o f  e a c h  w o r k e r  a t  e v e r y  o p e r a t i o n  o r  l o c a t i o n  i n  w h i c h  
t h e r e  i s  w o r k p l a c e  e x p o s u r e  t o  c o b a l t .  R e c o r d  t h e  s a m p l i n g  l o c a t i o n s  and 
c o n d i t i o n s ,  I n c l u d i n g  a m b i e n t  t e m p e r a t u r e  an d  p r e s s u r e  a s  n e e d e d ,  e q u i p m e n t  
u s e d ,  t i m e  an d  r a t e  o f  s a m p l i n g ,  an d  an y  o t h e r  p e r t i n e n t  i n f o r m a t i o n .
E q u i p m e n t  f o r  A i r  S a m p l i n g
( a )  F i l t e r :  37-mm c e l l u l o s e  e s t e r  mem brane f i l t e r  w i t h  a  p o r e  s i z e  o f  
0 . 8  im  s h o u l d  b e  m o u n te d  w i t h  b a c k u p  p a d  i n  a  t w o -  o r  t h r e e - p i e c e  c l o s e d - f a c e  
c a s s e t t e .
( b )  B a t t e r y - o p e r a t e d  p e r s o n a l  s a m p l i n g  pump: Th e pump s h o u l d  h a v e  a  
d e v i c e ,  s u c h  a s  a  c l i p ,  f o r  a t t a c h m e n t  t o  t h e  w o r k e r ' s  c l o t h i n g .  A l l  pumps 
a n d  f l o w m e t e r s  m u s t  b e  c a l i b r a t e d  u s i n g  a  c a l i b r a t e d  t e s t  m e t e r  o r  o t h e r  
r e f e r e n c e ,  a s  d e s c r i b e d  i n  C a l i b r a t i o n  o f  E q u i p m e n t . B a t t e r y - o p e r a t e d  pumps 
s h o u l d  b e  c a p a b l e  o f  o p e r a t i n g  a t  f l o w r a t e s  o f  1-2  l i t e r s / m i n  t o  m a i n t a i n  a  
f a c e  v e l o c i t y  o f  2 . 6  cm /s  a n d  m u s t  b e  c a p a b l e  o f  up  t o  8 h o u r s  o f  c o n t i n u o u s  
o p e r a t i o n  w i t h o u t  r e c h a r g i n g .
( c )  T h e r m o m e t e r .
(d )  M a n o m e t e r .
( e )  S t o p w a t c h .
( f )  V a r i o u s  c l i p s ,  t u b i n g ,  s p r i n g  c o n n e c t o r s ,  o r  b e l t  s u f f i c i e n t  t o  
c o n n e c t  s a m p l i n g  a p p a r a t u s  t o  w o r k e r  b e i n g  s a m p l e d .
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C a lib r a t io n  o f Equipment
S i n c e  t h e  a c c u r a c y  o f  a n  a n a l y s i s  c a n  b e  n o  g r e a t e r  t h a n  t h e  a c c u r a c y  w i t h
w h i c h  t h e  v o lu m e  o f  a i r  i s  m e a s u r e d ,  a c c u r a t e  c a l i b r a t i o n  o f  t h e  s a m p l i n g  pump
i s  e s s e n t i a l .  Th e f r e q u e n c y  o f  c a l i b r a t i o n  r e q u i r e d  d e p e n d s  on t h e  u s e ,  c a r e ,  
and  h a n d l i n g  t h a t  t h e  pump r e c e i v e s .  Pumps s h o u l d  b e  r e c a l i b r a t e d  i f  t h e y
h a v e  b e e n  a b u s e d  o r  i f  t h e y  h a v e  j u s t  b e e n  r e p a i r e d  o r  r e c e i v e d  f r o m  t h e
m a n u f a c t u r e r .  M a i n t e n a n c e  an d  c a l i b r a t i o n  s h o u l d  b e  p e r f o r m e d  on  a  r o u t i n e  
s c h e d u l e ,  and r e c o r d s  o f  t h e s e  s h o u l d  b e  m a i n t a i n e d .
O r d i n a r i l y ,  t o  c o l l e c t  a  l a r g e  n um ber  o f  f i e l d  s a m p l e s ,  pumps s h o u l d  b e  
c a l i b r a t e d  i n  t h e  l a b o r a t o r y  b o t h  b e f o r e  an d  a f t e r  t h e y  h a v e  b e e n  u s e d .  I f  
e x t e n s i v e  f i e l d  s a m p l i n g  i s  p e r f o r m e d ,  t h e  pumps s h o u l d  b e  c a l i b r a t e d  
p e r i o d i c a l l y  d u r i n g  s a m p l i n g  t o  e n s u r e  c o n t i n u o u s  s a t i s f a c t o r y  o p e r a t i o n  o f  
t h e  pump a n d  s a m p l e r .  Th e a c c u r a c y  o f  c a l i b r a t i o n  d e p e n d s  on  t h e  t y p e  o f  
i n s t r u m e n t  u s e d  a s  a  r e f e r e n c e .  Th e c h o i c e  o f  c a l i b r a t i o n  i n s t r u m e n t  w i l l  
d e p e n d  l a r g e l y  on w h e r e  t h e  c a l i b r a t i o n  i s  t o  b e  p e r f o r m e d .  F o r  l a b o r a t o r y  
t e s t i n g ,  a  s p i r o m e t e r  o r  s o a p b u b b l e  m e t e r  i s  re co m m en d e d ,  a l t h o u g h  o t h e r  
c a l i b r a t i o n  i n s t r u m e n t s  s u c h  a s  a  w e t - t e s t  m e t e r ,  d r y  g a s  m e t e r ,  o r  c a l i b r a t e d  
r o t a m e t e r  c a n  b e  u s e d .  Th e c a l i b r a t i o n  i n s t r u m e n t  s h o u l d  b e  c a l i b r a t e d  t o
+5%. The  a c t u a l  s e t u p s  w i l l  b e  s i m i l a r  f o r  a l l  i n s t r u m e n t s .
The c a l i b r a t i o n  s e t u p  f o r  a  p e r s o n a l  s a m p l i n g  pump w i t h  a  membrane f i l t e r
i s  shown i n  F i g u r e  X - 5 .  S i n c e  t h e  f l o w r a t e  g i v e n  b y  a  pump d e p e n d s  on t h e
p r e s s u r e  d r o p  a c r o s s  t h e  s a m p l i n g  d e v i c e ,  t h e  pump m u s t  b e  c a l i b r a t e d  w h i l e  
o p e r a t i n g  w i t h  a  r e p r e s e n t a t i v e  f i l t e r  i n  l i n e .  I n s t r u c t i o n s  f o r  c a l i b r a t i o n  
w i t h  t h e  s o a p b u b b l e  m e t e r  f o l l o w .  I f  a n o t h e r  c a l i b r a t i o n  d e v i c e  i s  s e l e c t e d ,  
e q u i v a l e n t  p r o c e d u r e s  s h o u l d  b e  u s e d .
( a )  Check  t h e  v o l t a g e  o f  t h e  pump b a t t e r y  w i t h  a  v o l t m e t e r  t o  e n s u r e  
a d e q u a t e  v o l t a g e  f o r  c a l i b r a t i o n .  C h a r g e  t h e  b a t t e r y  i f  n e c e s s a r y .
(b )  P l a c e  a  membrane f i l t e r  i n  t h e  h o l d e r .
( c )  A s s e m b l e  t h e  s a m p l i n g  t r a i n .
( d )  T u r n  o n  t h e  pump an d  m o i s t e n  t h e  i n s i d e  o f  t h e  s o a p b u b b l e  m e t e r  b y  
i m m e r s i n g  t h e  b u r e t  i n  t h e  s o a p  s o l u t i o n  an d  d r a w i n g  b u b b l e s  up  t h e  i n s i d e  
u n t i l  t h e y  a r e  a b l e  t o  t r a v e l  t h e  e n t i r e  l e n g t h  o f  t h e  b u r e t  w i t h o u t  b u r s t i n g .
( e )  A d j u s t  t h e  pump f l o w  c o n t r o l l e r  t o  p r o v i d e  t h e  d e s i r e d  f l o w r a t e .
( f )  Check  t h e  w a t e r  m a n o m e t e r  t o  e n s u r e  t h a t  t h e  p r e s s u r e  d r o p  a c r o s s  t h e  
s a m p l i n g  t r a i n  d o e s  n o t  e x c e e d  33 cm o f  w a t e r  ( a p p r o x i m a t e l y  2 . 5 4  cm o f  
m e r c u r y ) .
( g )  S t a r t  a  s o a p b u b b l e  up t h e  b u r e t  an d  m e a s u r e  w i t h  a  s t o p w a t c h  t h e  t i m e  
t h e  b u b b l e  t a k e s  t o  move f r o m  o n e  c a l i b r a t i o n  m a rk  t o  a n o t h e r .
( h )  R e p e a t  t h e  p r o c e d u r e  i n  (g )  a t  l e a s t  t h r e e  t i m e s ,  a v e r a g e  t h e  
r e s u l t s ,  a n d  c a l c u l a t e  t h e  f l o w r a t e  b y  d i v i d i n g  t h e  v o l u m e  b e t w e e n  t h e
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p r e s e l e c t e d  m a r k s  b y  t h e  t i m e  r e q u i r e d  f o r  t h e  s o a p b u b b l e  t o  t r a v e r s e  t h e  
d i s t a n c e .
( i )  R e c o r d  t h e  d a t a  f o r  t h e  c a l i b r a t i o n  i n c l u d i n g  v o l u m e  m e a s u r e d ,  
e l a p s e d  t i m e ,  p r e s s u r e  d r o p ,  a i r  t e m p e r a t u r e ,  a t m o s p h e r i c  p r e s s u r e ,  s e r i a l  
num ber  o f  t h e  pump, d a t a ,  an d  t h e  name o f  t h e  p e r s o n  p e r f o r m i n g  t h e  
c a l i b r a t i o n .
C o l l e c t i o n  Sam p le s
( a )  A s s e m b l e  a  s a m p l i n g  t r a i n  c o n s i s t i n g  o f  t h e  recommended  s i z e  
c e l l u l o s e  e s t e r  membrane f i l t e r  w i t h  a  p o r t a b l e ,  b a t t e r y - o p e r a t e d  p e r s o n a l  
s a m p l i n g  pump.
( b )  E s t a b l i s h  t h e  c a l i b r a t e d  f l o w r a t e  a s  a c c u r a t e l y  a s  p o s s i b l e ,  u s i n g  
t h e  m a n u f a c t u r e r ' s  d i r e c t i o n s .  T he  recommended s a m p l i n g  f l o w r a t e  i s  1 . 5  
l i t e r / m i n ,  c o r r e s p o n d i n g  t o  a  s a m p l i n g  v o l u m e  o f  0 . 7 2  cu  m f o r  a n  8- h o u r  
s a m p l e  o r  a b o u t  0 . 0 2  c u  m f o r  a  1 5 - m i n u t e  s a m p l e .
( c )  M e a s u r e  an d  r e c o r d  t h e  t e m p e r a t u r e  and  p r e s s u r e  o f  t h e  a t m o s p h e r e  
b e i n g  s a m p l e d ,  a s  n e e d e d .
( d )  R e c o r d  t h e  e l a p s e d  t i m e .  Th e s a m p l e  v o l u m e  i s  o b t a i n e d  by 
m u l t i p l y i n g  t h e  f l o w r a t e  b y  t h e  e l a p s e d  t i m e .
( e )  I m m e d i a t e l y  a f t e r  s a m p l i n g ,  r e p l a c e  t h e  p l u g s  i n  t h e  c a s s e t t e .
( f )  T r e a t  a t  l e a s t  o n e  f i l t e r  i n  t h e  same m a n n e r  a s  t h e  s a m p l e  ( o p e n  and 
r e c l o s e  c a s s e t t e ,  s e a l ,  an d  s h i p ) ,  b u t  do  n o t  d r a w  a i r  t h r o u g h  i t .  T h i s  
f i l t e r  w i l l  s e r v e  a s  a  b l a n k .
P r i n c i p l e  o f  t h e  A n a l y t i c a l  Method
The s a m p l e ,  c o l l e c t e d  o n  a  c e l l u l o s e  mem brane f i l t e r ,  i s  a s h e d  u s i n g  a  
m i x t u r e  o f  n i t r i c  a c i d  an d  p e r c h l o r i c  a c i d  [2 6 6 ]  t o  d e s t r o y  t h e  o r g a n i c  m a t t e r  
and  t o  b r i n g  c o b a l t  i n t o  s o l u t i o n .  S a m p l e s ,  b l a n k s ,  an d  s t a n d a r d s  a r e
a s p i r a t e d  i n t o  t h e  a i r - a c e t y l e n e  f l a m e  o f  t h e  AAS. A h o l l o w  c a t h o d e  l am p  f o r  
c o b a l t  p r o v i d e s  a  c h a r a c t e r i s t i c  l i n e  a t  2 4 0 . 7  nm [ 2 6 8 ] .  T he  a b s o r p t i o n  o f  
t h i s  l i n e  b y  t h e  g r o u n d - s t a t e  a t o m s ’ i n  t h e  f l a m e  i s  p r o p o r t i o n a l  t o  t h e  c o b a l t  
c o n c e n t r a t i o n  i n  t h e  a s p i r a t e d  s a m p l e .
Range and S e n s i t i v i t y
F o r  c o b a l t ,  t h e  a b s o l u t e  d e t e c t i o n  l i m i t  i s  a p p r o x i m a t e l y  0 . 0 1  jug 
c o b a l t / m l ,  b u t  t h e  l o w e r  l i m i t  f o r  q u a n t i t a t i v e  d e t e r m i n a t i o n  i s  0 . 2  u g  
c o b a l t / m l .  The  u p p e r  l i m i t  f o r  q u a n t i t a t i v e  d e t e r m i n a t i o n  i s  5 . 0  jug 
c o b a l t / m l ,  b u t  t h e  m e th o d  c a n  b e  e x t e n d e d  t o  a  h i g h e r  c o n c e n t r a t i o n  by 
d i l u t i o n  o f  t h e  s a m p l e .  F o r  a  10 -m l  s o l u t i o n  a n d  0 . 7 2  cu  m o f  s a m p l e d  a i r ,
73
t h i s  c o r r e s p o n d s  t o  a  r a n g e  o f  2 . 8 - 7 0  jug/cu m. F o r  a  0 . 0 2 - c u  m s a m p l e ,  t h e  
l o w e r  l i m i t  c o r r e s p o n d s  t o  100  jug/cu  m.
I n t e r f e r e n c e s
P h y s i c a l  i n t e r f e r e n c e s  may r e s u l t  i f  t h e  p h y s i c a l  p r o p e r t i e s  o f  t h e  
s a m p l e s  v a r y  s i g n i f i c a n t l y .  C h an g es  i n  v i s c o s i t y  an d  s u r f a c e  t e n s i o n  c a n  
a f f e c t  t h e  s a m p l e  a s p i r a t i o n  r a t e  and t h u s  c a u s e  e r r o n e o u s  r e s u l t s .  Sample  
d i l u t i o n  o r  t h e  m e th o d  o f  s t a n d a r d  a d d i t i o n s  a r e  u s e d  t o  c o r r e c t  s u c h  
i n t e r f e r e n c e s .  H i g h  c o n c e n t r a t i o n s  o f  s i l i c a t e s  i n  t h e  s a m p l e  c a n  c a u s e  a n
i n t e r f e r e n c e  and may c a u s e  a s p i r a t i o n  p r o b l e m s .  I f  l a r g e  a m o u n t s  o f  s i l i c a t e s  
a r e  e x t r a c t e d  f r o m  t h e  s a m p l e s ,  t h e  s a m p l e s  s h o u l d  b e  a l l o w e d  t o  s t a n d  f o r  
s e v e r a l  h o u r s  and b e  c e n t r i f u g e d  o r  f i l t e r e d  t o  r e m o v e  t h e  s i l i c a t e s .
B a c k g r o u n d  o r  n o n s p e c i f i c  a b s o r p t i o n  c a n  o c c u r  f r o m  p a r t i c l e s  p r o d u c e d  i n  
t h e  f l a m e ,  w h i c h  c a n  s c a t t e r  t h e  i n c i d e n t  r a d i a t i o n ,  c a u s i n g  a n  a p p a r e n t  
a b s o r p t i o n  s i g n a l .  L i g h t - s c a t t e r i n g  p r o b l e m s  may b e  e n c o u n t e r e d  when 
s o l u t i o n s  o f  h i g h  s a l t  c o n t e n t  a r e  b e i n g  a n a l y z e d .  L i g h t - s c a t t e r i n g  p r o b l e m s  
a r e  m o s t  s e v e r e  when m e a s u r e m e n t s  a r e  made a t  t h e  l o w e r  w a v e l e n g t h s ,  i e ,  b e l o w  
a b o u t  250 nm. B a c k g r o u n d  a b s o r p t i o n  may a l s o  o c c u r  a s  t h e  r e s u l t  o f  t h e  
f o r m a t i o n  o f  v a r i o u s  m o l e c u l a r  s p e c i e s  t h a t  c a n  a b s o r b  l i g h t .  The  b a c k g r o u n d  
a b s o r p t i o n  s h o u l d  b e  a c c o u n t e d  f o r  b y  t h e  u s e  o f  b a c k g r o u n d  c o r r e c t i o n  
t e c h n i q u e s ,  p r e f e r a b l y  b y  t h e  u s e  o f  a  n o n a b s o r b i n g  w a v e l e n g t h ,  a n d ,  i f  
n e c e s s a r y ,  b y  t h e  u s e  o f  D2 o r  H2 c o n t i n u u m .
P r e c i s i o n  an d  A c c u r a c y
F o r  a n a l y s i s  o n l y ,  t h e  r e l a t i v e  s t a n d a r d  d e v i a t i o n  (RSD) i s  54% a t  0 . 0 5  jug 
c o b a l t / m l ,  co m pared  w i t h  a  RSD o f  9% a t  0 . 2  jug c o b a l t / m l .  From 0 . 5  t o  5 jug 
c o b a l t / m l ,  t h e  RSD o f  t h e  a n a l y t i c a l  m e a s u r e m e n t  i s  a p p r o x i m a t e l y  3% [ 2 6 8 ] .
A d v a n t a g e s  a n d  D i s a d v a n t a g e s
Th e m e th o d  i s  r a p i d  b e c a u s e  t h e r e  i s  l i t t l e  s a m p l e  p r e p a r a t i o n  i n v o l v e d .  
I t  c a n  b e  p e r f o r m e d  w i t h  g e n e r a l l y  a v a i l a b l e  l a b o r a t o r y  e q u i p m e n t  an d  by 
g e n e r a l  l a b o r a t o r y  p e r s o n n e l ,  an d  i t  i s  s u f f i c i e n t l y  s e n s i t i v e .  H o w e v e r ,  t h e  
m e th o d  m e a s u r e s  t o t a l  c o b a l t  an d  i s  n o t  c a p a b l e  o f  d i s t i n g u i s h i n g  i n d i v i d u a l  
c o b a l t  compo un ds .
A p p a r a t u s  an d  E q u ip m en t
( a )  H o l l o w  c a t h o d e  l am p  f o r  c o b a l t .
(b )  A tom ic  a b s o r p t i o n  s p e c t r o p h o t o m e t e r  e q u i p p e d  w i t h  a  b u r n e r  h e a d  f o r  
a i r - a c e t y l e n e  f l a m e .
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( c )  O x i d a n t :  A i r  s u p p l y ,  w i t h  a  minimum p r e s s u r e  o f  40  p o u n d s  p e r  s q u a r e  
i n c h ,  f i l t e r e d  t o  r e m o v e  o i l  and  w a t e r .
( d )  F u e l :  A c e t y l e n e ,  c o m m e r c i a l l y  a v a i l a b l e  f o r  a t o m i c  a b s o r p t i o n  u s e .
( e )  P r e s s u r e - r e d u c i n g  v a l v e s :  A t w o - g a u g e ,  t w o - s t a g e  p r e s s u r e - r e d u c i n g
v a l v e  an d  a p p r o p r i a t e  h o s e  c o n n e c t i o n s  f o r  e a c h  c o m p r e s s e d  g a s  t a n k  u s e d .
( f )  G l a s s w a r e ,  b o r o s i l i c a t e :
( 1) 125-m l  P h i l l i p s  o r  G r i f f i n  b e a k e r s  w i t h  w a t c h g l a s s  c o v e r s .
( 2) 15 -m l  g r a d u a t e d  c e n t r i f u g e  t u b e s .
(3 ) 10- m l  v o l u m e t r i c  f l a s k s .
(4 ) 100- m l  v o l u m e t r i c  f l a s k s .
( 5 ) 1- l i t e r  v o l u m e t r i c  f l a s k s .
( 6) 1 2 5 -m l  p o l y e t h y l e n e  b o t t l e s .
A d d i t i o n a l  a u x i l i a r y  g l a s s w a r e  s u c h  a s  p l p e t s  an d  d i f f e r e n t  s i z e  v o l u m e t r i c  
g l a s s w a r e  w i l l  b e  r e q u i r e d  d e p e n d i n g  o n  t h e  e l e m e n t s  b e i n g  d e t e r m i n e d  an d  t h e  
d i l u t i o n s  r e q u i r e d  t o  h a v e  s a m p l e  c o n c e n t r a t i o n s  a b o v e  t h e  d e t e c t i o n  l i m i t  and  
i n  t h e  l i n e a r  r e s p o n s e  r a n g e .  A l l  p i p e t s  an d  v o l u m e t r i c  f l a s k s  r e q u i r e d  i n  
t h i s  p r o c e d u r e  s h o u l d  b e  c a l i b r a t e d  c l a s s  A v o l u m e t r i c  g l a s s w a r e .
( g )  H o t p l a t e  ( s u i t a b l e  f o r  o p e r a t i o n  a t  1 4 0 ° C ) .
R e a g e n t s
( a )  P u r i t y :  ACS a n a l y t i c a l  r e a g e n t  g r a d e  c h e m i c a l s  o r  e q u i v a l e n t  s h o u l d
b e  u s e d  i n  a l l  t e s t s .  R e f e r e n c e s  t o  w a t e r  s h a l l  b e  u n d e r s t o o d  t o  mean  d o u b l e  
d i s t i l l e d  w a t e r  o r  e q u i v a l e n t .  C a r e  i n  s e l e c t i o n  o f  r e a g e n t s  and i n  f o l l o w i n g  
t h e  l i s t e d  p r e c a u t i o n s  i s  e s s e n t i a l  i f  l o w  b l a n k  v a l u e s  a r e  t o  b e  o b t a i n e d .
( b )  C o n c e n t r a t e d  n i t r i c  a c i d  ( 6 8 - 7 1 % ) ,  r e d i s t i l l e d ,  s p e c i f i c  g r a v i t y  
1 . 4 2 .
( c )  S t a n d a r d  s t o c k  s o l u t i o n s  ( 1 , 0 0 0  jug/ml f o r  c o b a l t ) ,  c o m m e r c i a l l y
p r e p a r e d  o r  p r e p a r e d  p e r  i n s t r u m e n t  m a n u f a c t u r e r ' s  r e c o m m e n d a t i o n s .(
( d )  P e r c h l o r i c  a c i d ,  r e a g e n t  g r a d e .
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P r o c e d u r e
( a )  C l e a n i n g  o f  E q u ip m en t
B e f o r e  i n i t i a l  u s e ,  c l e a n  g l a s s w a r e  w i t h  s a t u r a t e d  s o l u t i o n  o f  s o d iu m  
d i c h r o m a t e  i n  c o n c e n t r a t e d  s u l f u r i c  a c i d  a n d  t h e n  r i n s e  t h o r o u g h l y  w i t h  warm 
t a p w a t e r ,  c o n c e n t r a t e d  n i t r i c  a c i d ,  t a p w a t e r ,  an d  d e i o n i z e d  w a t e r ,  i n  t h a t  
o r d e r ,  and  t h e n  d r y .  S o a k  a l l  g l a s s w a r e  i n  a  m i l d  d e t e r g e n t  s o l u t i o n  
i m m e d i a t e l y  a f t e r  u s e  t o  r e m o v e  a n y  r e s i d u a l  g r e a s e  o r  c h e m i c a l s .  F o r  
g l a s s w a r e  t h a t  h a s  p r e v i o u s l y  b e e n  s u b j e c t e d  t o  t h e  e n t i r e  c l e a n i n g  p r o c e d u r e ,  
i t  i s  n o t  n e c e s s a r y  t o  u s e  t h e  c h r o m i c  a c i d  c l e a n i n g  s o l u t i o n .  T h i s  g l a s s w a r e  
s h o u l d  b e  c l e a n e d  i n  1:1  d i l u t e d  n i t r i c  a c i d  and r i n s e d  s e v e r a l  t i m e s  w i t h  
d i s t i l l e d  w a t e r .
(b )  P r e p a r a t i o n  o f  S a m p le s
T r a n s f e r  s a m p l e s  an d  b l a n k s  ( a  minimum o f  1 f i l t e r  b l a n k  f o r  e v e r y  10 
f i l t e r  s a m p l e s )  t o  c l e a n  12 5 -m l  b e a k e r s ,  an d  ad d  1 ml  o f  c o n c e n t r a t e d  HC104 
a n d  6 ml  o f  c o n c e n t r a t e d  HN03 t o  e a c h .  C o v e r  e a c h  b e a k e r  w i t h  a  w a t c h g l a s s ,  
and  h e a t  on  a  h o t  p l a t e  ( 1 4 0 °C) i n  a  fum e h o o d .  C o m p l e t i o n  o f  d i g e s t i o n  i s  
i n d i c a t e d  b y  a  c o l o r l e s s  s o l u t i o n  o r  a  w h i t e  r e s i d u e  i n  t h e  b e a k e r .  Once t h e  
a s h i n g  i s  c o m p l e t e ,  r e m o v e  t h e  w a t c h g l a s s ,  and  a l l o w  t h e  s a m p l e  t o  e v a p o r a t e  
t o  n e a r  d r y n e s s  ( a p p r o x i m a t e l y  0 . 5  m l ) .  I f  c h a r r i n g  o c c u r s ,  ad d  HN03 (1 m l )  
a n d  e v a p o r a t e  t o  n e a r  d r y n e s s  ( 0 . 5  m l )  a g a i n .  R e p e a t ,  i f  n e c e s s a r y .
Remove t h e  b e a k e r  f r o m  t h e  h o t p l a t e ,  c o o l ,  a n d  a d d  1 ml  HN03 and 2 - 3  ml  o f  
d i s t i l l e d  w a t e r .  T r a n s f e r  t h e  s o l u t i o n  q u a n t i t a t i v e l y  w i t h  d i s t i l l e d  w a t e r  t o  
a  10- m l  v o l u m e t r i c  f l a s k ,  an d  t h e n  d i l u t e  t h e  s a m p l e s  t o  v o l u m e  (10  m l )  w i t h  
w a t e r .
Th e 10 -m l  s o l u t i o n  may b e  a n a l y z e d  d i r e c t l y  f o r  a n y  e l e m e n t  o f  v e r y  l o w  
c o n c e n t r a t i o n  i n  t h e  s a m p l e  t h a t  was  d i s s o l v e d  b y  t h i s  a s h i n g  p r o c e d u r e .  
A l i q u o t s  o f  t h i s  s o l u t i o n  may t h e n  b e  d i l u t e d  t o  a n  a p p r o p r i a t e  v o l u m e  f o r  
c o b a l t  p r e s e n t  a t  h i g h e r  c o n c e n t r a t i o n s .
( c )  A n a l y s i s  o f  Sam p le s
S e t  t h e  i n s t r u m e n t  o p e r a t i n g  c o n d i t i o n s  a s  recommended  b y  t h e  
m a n u f a c t u r e r .  Th e i n s t r u m e n t  s h o u l d  b e  s e t  a t  2 4 0 . 7  nm f o r  c o b a l t .
M atch  s t a n d a r d  s o l u t i o n s  w i t h  t h e  s a m p l e  m a t r i x  a s  c l o s e l y  a s  p o s s i b l e ,  
a n d  r u n  i n  d u p l i c a t e .  A s p i r a t e  w o r k i n g  s t a n d a r d  s o l u t i o n s ,  f r e s h l y  p r e p a r e d  
e a c h  d a y ,  i n t o  t h e  f l a m e ,  an d  r e c o r d  t h e  a b s o r b a n c e .  P r e p a r e  a  c a l i b r a t i o n  
g r a p h  a s  d e s c r i b e d  i n  a  l a t e r  s e c t i o n .  ( N o t e :  A l l  c o m b u s t i o n  p r o d u c t s  f r o m
t h e  a t o m i c  a b s o r p t i o n  f l a m e  m u s t  b e  re m o v ed  b y  d i r e c t  e x h a u s t i o n  t h r o u g h  t h e  
u s e  o f  a  good s e p a r a t e  f l a m e  v e n t i l a t i o n  s y s t e m . )  B l a n k  f i l t e r s  m u s t  b e  
c a r r i e d  t h r o u g h  t h e  e n t i r e  p r o c e d u r e  e a c h  t i m e  s a m p l e s  a r e  a n a l y z e d .
A s p i r a t e  t h e  a p p r o p r i a t e l y  d i l u t e d  s a m p l e s  d i r e c t l y  i n t o  t h e  i n s t r u m e n t ,  
an d  r e c o r d  t h e  a b s o r b a n c e  f o r  c o m p a r i s o n  w i t h  s t a n d a r d s .  S h o u l d  t h e  
a b s o r b a n c e  b e  a b o v e  t h e  c a l i b r a t i o n  r a n g e ,  d i l u t e  a n  a p p r o p r i a t e  a l i q u o t  t o  10
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m l .  A s p i r a t e  w a t e r  a f t e r  e a c h  s a m p l e .  As a  minimum, a  m i d r a n g e  s t a n d a r d  m u s t  
b e  a s p i r a t e d  w i t h  s u f f i c i e n t  f r e q u e n c y ,  i e ,  o n c e  e v e r y  f i v e  s a m p l e s ,  t o  e n s u r e  
t h e  a c c u r a c y  o f  t h e  s a m p l e  d e t e r m i n a t i o n s .  I t  i s  b e s t  t o  r u n  a  s t a n d a r d  w i t h  
a  c o n c e n t r a t i o n  c l o s e  t o  t h a t  o f  a  s a m p l e  a f t e r  e a c h  s a m p l e  i s  r u n .  To t h e  
e x t e n t  p o s s i b l e ,  b a s e  a l l  d e t e r m i n a t i o n s  on  r e p l i c a t e  a n a l y s e s .
C a l i b r a t i o n  an d  S t a n d a r d s
( a )  D i l u t e  s t a n d a r d s  ( 1 0 0  ¡ig m e t a l / m l ) . P i p e t  10 ml  o f  t h e  s t o c k  ( 1 , 0 0 0  
Hg c o b a l t / m l )  i n t o  a  10 0 -m l  v o l u m e t r i c  f l a s k ,  ad d  10 ml  HN03, an d  d i l u t e  t o  
v o l u m e  w i t h  d i s t i l l e d  w a t e r .  P r e p a r e  f r e s h  s t a n d a r d s  a t  l e a s t  w e e k l y ,  
p r e f e r a b l y  w i t h  e a c h  u s e ,  a n d  s t o r e  i n  p o l y e t h y l e n e  b o t t l e s .  P o l y e t h y l e n e  
c o n t a i n e r s  a r e  s u i t a b l e  f o r  s t o r a g e  b e c a u s e  o f  t h e i r  l o w  m e t a l l i c  c o n t e n t  and 
n o n p o l a r  s u r f a c e s .
(b )  W or k in g  s t a n d a r d s .  P r e p a r e  w o r k i n g  s t a n d a r d s  b y  d i l u t i o n  o f  t h e  
d i l u t e  s t a n d a r d s  o r  t h e  s t o c k  s t a n d a r d s  s o  t h a t  t h e  f i n a l  a c i d  c o n c e n t r a t i o n  
i s  t h e  same f o r  t h e  s a m p l e s  an d  s t a n d a r d s ,  i e ,  10% V/V HN03, 5% V/V HC104.  
C o n c e n t r a t i o n s  o f  t h e  w o r k i n g  s t a n d a r d s  s h o u l d  c o v e r  t h e  r a n g e  0 . 5 - 5 . 0  ¡ ig / m l .  
P r e p a r e  f r e s h  s o l u t i o n s  d a i l y .
( c )  S t a n d a r d  s o l u t i o n s .  A s p i r a t e  s t a n d a r d  s o l u t i o n s  i n t o  t h e  f l a m e ,  an d  
r e c o r d  t h e  a b s o r b a n c e  ( o r  c o n c e n t r a t i o n ) . I f  t h e  i n s t r u m e n t  u s e d  d i s p l a y s  
t r a n s m i t t a n c e ,  c o n v e r t  t h e s e  v a l u e s  t o  a b s o r b a n c e .  P r e p a r e  a  c a l i b r a t i o n  
c u r v e  b y  p l o t t i n g  a b s o r b a n c e  ( u n i t s )  v s  m e t a l  c o n c e n t r a t i o n .  Th e b e s t  f i t  
c u r v e  ( c a l c u l a t e d  b y  l i n e a r  l e a s t  s q u a r e  r e g r e s s i o n  a n a l y s i s )  i s  f i t t e d  t o  t h e  
d a t a  p o i n t s .  T h i s  l i n e ,  o r  t h e  e q u a t i o n  d e s c r i b i n g  t h e  l i n e ,  i s  u s e d  t o  
o b t a i n  t h e  c o b a l t  c o n c e n t r a t i o n  i n  t h e  s a m p l e s  b e i n g  a n a l y z e d .
(d )  P r e p a r a t i o n  p r o c e d u r e .  To e n s u r e  t h a t  t h e  p r e p a r a t i o n  p r o c e d u r e  i s  
b e i n g  p r o p e r l y  f o l l o w e d ,  s p i k e  c l e a n  membrane f i l t e r s  w i t h  known a m o u n t s  o f  
c o b a l t  by  a d d i n g  a p p r o p r i a t e  a m o u n t s  o f  t h e  p r e v i o u s l y  d e s c r i b e d  s t a n d a r d s ,  
a n d  c a r r y  them  t h r o u g h  t h e  e n t i r e  p r o c e d u r e .  D e t e r m i n e  t h e  am oun t  o f  c o b a l t ,  
and  c a l c u l a t e  t h e  p e r c e n t  r e c o v e r y .  T h e s e  t e s t s  w i l l  p r o v i d e  r e c o v e r y  an d  
p r e c i s i o n  d a t a  f o r  t h e  p r o c e d u r e  a s  i t  i s  c a r r i e d  o u t  i n  t h e  l a b o r a t o r y  f o r  
t h e  s o l u b l e  c o b a l t  compounds  b e i n g  d e t e r m i n e d .
( e )  A n a l y s i s  by  t h e  m e th o d  o f  s t a n d a r d  a d d i t i o n s .  I n  o r d e r  t o  c h e c k  f o r  
i n t e r f e r e n c e s ,  a n a l y z e  s a m p l e s  i n i t i a l l y  an d  p e r i o d i c a l l y  by  t h e  m e th o d  o f  
s t a n d a r d  a d d i t i o n s ,  a n d  c o m p a r e  " t h e  r e s u l t s  w i t h  t h o s e  o b t a i n e d  by  t h e  
c o n v e n t i o n a l  a n a l y t i c a l  d e t e r m i n a t i o n .  F o r  t h i s  m e t h o d ,  d i v i d e  t h e  s a m p l e  
i n t o  t h r e e  2 -m l  a l i q u o t s .  To o n e  o f  t h e  a l i q u o t s ,  ad d  a n  am ou nt  o f  c o b a l t  
a p p r o x i m a t e l y  e q u a l  t o  t h a t  i n  t h e  s a m p l e .  To a n o t h e r  a l i q u o t  ad d  t w i c e  t h i s  
a m o u n t .  (N o t e : A d d i t i o n s  s h o u l d  b e  made  b y  m i c r o p i p e t t i n g  t e c h n i q u e s  s o  t h a t
t h e  v o l u m e  d o e s  n o t  e x c e e d  1% o f  t h e  o r i g i n a l  a l i q u o t  v o l u m e ,  i e ,  10- ju l  an d  
2 0 - / i l  a d d i t i o n s  t o  a  2 -m l  a l i q u o t .  T h i s  m e th o d  s h o u l d  b e  a p p l i e d  o n l y  i f  t h e  
c o n c e n t r a t i o n  o f  c o b a l t  i n  t h e  s o l u t i o n s  i s  s u f f i c i e n t l y  low t h a t  a b s o r b a n c e  
i s  l i n e a r l y  r e l a t e d  t o  c o n c e n t r a t i o n . )  T h en  a n a l y z e  t h e  s o l u t i o n s ,  an d  p l o t  
t h e  a b s o r b a n c e  r e a d i n g s  a g a i n s t  m e t a l  ad d e d  t o  t h e  o r i g i n a l  s a m p l e .  The l i n e  
o b t a i n e d  f r o m  s u c h  a  p l o t  i s  e x t r a p o l a t e d  t o  z e r o  a b s o r b a n c e ,  a n d  t h e
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I n t e r c e p t  o n  t h e  c o n c e n t r a t i o n  a x i s  i s  t a k e n  a s  t h e  am oun t  o f  m e t a l  i n  t h e  
o r i g i n a l  s a m p l e .  I f  t h e  r e s u l t  o f  t h i s  d e t e r m i n a t i o n  d o e s  n o t  a g r e e  t o  w i t h i n  
10* o f  t h e  v a l u e s  o b t a i n e d  w i t h  t h e  p r o c e d u r e  d e s c r i b e d  i n  ( c ) , a n  
i n t e r f e r e n c e  i s  i n d i c a t e d  a n d  s t a n d a r d  a d d i t i o n  t e c h n i q u e s  s h o u l d  b e  u t i l i z e d  
f o r  s a m p l e  a n a l y s i s .
C a l c u l a t i o n s
( a )  T he  e s t i m a t e d  a i r  v o l u m e  may n e e d  t o  b e  c o r r e c t e d  f o r  e l e v a t i o n  an d  
t e m p e r a t u r e .  F o r  p e r s o n a l  s a m p l i n g  pumps w i t h  r o t a m e t e r s  o n l y ,  t h e  f o l l o w i n g  
c o r r e c t i o n  f o r  a i r  v o l u m e  s h o u l d  b e  m ade:
v  “  f  x  t  L i n  x  T2 ]
1 , 0 0 0  y l  P2  T l J
w h e r e :
V ”  s a m p l e  v o l u m e  ( c u  m)
f  «  s a m p l e  f l o w r a t e  ( l l t e r s / m i n )
t  = s a m p l i n g  t i m e  ( m i n u t e s )
P I  ™ p r e s s u r e  d u r i n g  c a l i b r a t i o n  o f  s a m p l i n g  pump ( i n  mmHg)
P2 «  p r e s s u r e  a i r  s a m p l e s  ( i n  mmHg)
T l  -  t e m p e r a t u r e  d u r i n g  c a l i b r a t i o n  o f  s a m p l i n g  pump (K)
T2 -  t e m p e r a t u r e  o f  a i r  s a m p l e d  (K)
(b )  T h e  u n c o r r e c t e d  v o l u m e  c o l l e c t e d  b y  t h e  f i l t e r  i s  c a l c u l a t e d  by  
a v e r a g i n g  t h e  b e g i n n i n g  an d  e n d i n g  s a m p l e  f l o w r a t e s ,  c o n v e r t i n g  t o  c u b i c  
m e t e r s ,  an d  m u l t i p l y i n g  b y  t h e  s a m p l e  c o l l e c t i o n  t i m e .  T he  f o r m u l a  f o r  t h i s  
c a l c u l a t i o n  i s :
V -  ( f b  +  f e ) t  
2 ,0 0 0
w h e r e :
V ■ s a m p l e  v o l u m e  ( c u  m)
f b  *  s a m p l e  f l o w r a t e  a t  b e g i n n i n g  o f  s a m p l e  c o l l e c t i o n  
( l i t e r / m i n )
f e  »  s a m p l e  f l o w r a t e  a t  en d  o f  s a m p l e  c o l l e c t i o n  ( l i t e r / m i n )  
t  = s a m p l e  c o l l e c t i o n  t i m e  ( m i n u t e s )
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( c )  C o b a l t  c o n c e n t r a t i o n s  a r e  c a l c u l a t e d  b y  m u l t i p l y i n g  t h e  m i c r o g r a m s  o f  
c o b a l t / m l  i n  t h e  s a m p l e  a l i q u o t  b y  t h e  a l i q u o t  v o l u m e  an d  d i v i d i n g  b y  t h e  
v o l u m e  o f  a i r  s a m p l e d  b y  t h e  f i l t e r :
jug c o b a l t / c u  m = (C x  Va) -  B
V
w h e r e :
C = c o n c e n t r a t i o n  (¿tg c o b a l t / m l )  i n  t h e  a l i q u o t  
Va = v o l u m e  o f  a l i q u o t  (ml)
B = t o t a l  jug o f  c o b a l t  i n  t h e  b l a n k  
V = v o l u m e  o f  a i r  s a m p l e d  ( c u  m)
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IX .  TABLES
TABLE IX-1  
ESTIMATED WORKER EXPOSURE TO COBALT
S u b s t a n c e No.  o f  W o r k e r s  E x p o s e d *
C o b a l t  m e t a l 2 3 5 , 0 0 0
C o b a l t  o x i d e s 8 6 7 , 0 0 0
C o b a l t  d r i e r * * 3 0 1 , 0 0 0
C o b a l t  p a s t e  d r i e r * * 8 , 3 0 0
C o b a l t  n a p h t h e n a t e 7 9 , 0 0 0
C o b a l t  n e o d e c a n o a t e 1 , 3 0 0
C o b a l t  o c t a n o a t e 8 ,1 0 0
C o b a l t  t a l l a t e 1 9 , 0 0 0
C o b a l t  t i t a n a t e 900
C o b a l t o u s  a c e t a t e 21 ,0 00
C o b a l t o u s  c a r b o n a t e 5 , 1 0 0
C o b a l t o u s  c h l o r i d e 10 ,0 00
C o b a l t o u s  n i t r a t e 8 , 6 0 0
C o b a l t o u s  o x a l a t e 1 , 7 0 0
C o b a l t o u s  s u l f a t e 8 , 3 0 0
C o b a l t  c y a n i d e 7 , 2 0 0
C o b a l t  h y d r o x i d e 2 , 5 0 0
C o b a l t  2 - e t h y l h e x o a t e 3 , 9 0 0
*Many o f  t h e s e  w o r k e r s  w o u ld  b e  p o t e n t i a l l y  e x p o s e d  t o  o n l y  s m a l l  am o u n t s  
o f  c o b a l t  t h r o u g h  i n h a l a t i o n ,  i n g e s t i o n ,  o r  d e r m a l  c o n t a c t .  Th e e x p o s u r e  
e s t i m a t e s  a r e  n o t  a d d i t i v e ,  s i n c e  some w o r k e r s  w o u l d  b e  e x p o s e d  t o  m o re  
t h a n  o n e  compound.
* * S u b s t a n c e ( s )  c o m p r i s i n g  t h e  d r i e r  w e r e  n o t  i d e n t i f i e d .
From t h e  NIOSH N a t i o n a l  O c c u p a t i o n a l  H a z a r d  S u r v e y ,  1 9 7 2 - 7 4  [313]
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TABLE IX-2
EFFECTS OF WORKPLACE EXPOSURE TO COBALT-CONTAINING SUBSTANCES
Substance(s)
and Composition Concentration Duration, No. of Reference
(If known) (ng cobalt/cu m) Years Workers Effect No.
Cobalt metal 2-5
Cobalt oxide
Cobaltous oxide
Tungsten carbide, 
cobalt
Tungsten carbide 
95.9-97.6/1, 
cobalt 2.4-4.1Z
*
*
1-303 
(av. 106)
0.8-12
0.05-0.14
12.5
(av.)
15-20
4.4
(av.)
7 Respiratory irritation; no 51
evidence of fibrosis
1 Marked pulmonary fibrosis 50
resulting in death; elevated 
cobalt levels in lungs
120 1 case of increased pulmonary 52
reticulations
1 Death from cardiac insufficiency; 311
elevated cardiac levels of cobalt
6 No evidence of pulmonary damage 34
* Chronic bronchitis and respiratory 52
insufficiency
247 Pulmonary changes in 8 (3.2Z) 35
1,802 Abnormal lung radiographic 37
findings in 13 (0.8Z)
Tungsten carbide 
75-96Z, 
cobalt 4-25Z
Tungsten carbide, 
cobalt 6-11Z
Tungsten carbide, 
titanium carbide, 
cobalt 4.3-8.4Z
0.6-25
0.043-0.57 
(av. 0.21)
1-13
(av. 6)
61.3Z for 1-5, 
37.1Z for 5
3-26
193 Lung radiographic changes in 31 33
(16Z); spirometrlc abnormalities 
in 25 of 116 (22Z)
62 Chronic bronchitis in 5 (8.1Z); 29
decreased vital capacity in 9 
(14.5Z)
305 Lung radiographic changes in 56 34
(18.4Z)
EFFECTS OF WORKPLACE EXPOSURE TO COBALT-CONTAINING SUBSTANCES
TABLE IX-2 (CONTINUED)
Substance(s)
and Composition Concentration Duration, No. of Reference
(If known) (mg cobalt/cu m) Years Workers Effect No.
Tungsten carbide, 
titanium carbide, 
cobalt 10Z
0.5-4 27 Bronchitis in 11 (41Z), pneumo­
coniosis in 9 (33Z), radiographic 
lung changes in 8 (30Z)
11
Tungsten carbide, 
cobalt
0.007-0.19 5-16 29 Well-established fibrosis In 3, 24
labored breathing in 11 25
0.1-0.2 
*
(av. 6) 200-300 Pneumoconiosis in 3 23
14 1 Pulmonary fibrosis; tungsten, 17
nickel, and titanium found in lungs
17 Well-established pulmonary 
fibrosis
21
00S3
0.045-0.47 
(av. 0.22)
1-30 22 No radiographic evidence of
(av. 11) pulmonary fibrosis; possible
reduction of vital capacity
40
0.03-0.56 
(av. 0.24)
1 Well-established pulmonary 
fibrosis
20
*
0.6-3.2 (up to 3) 
5
1
178
1
Pulmonary irritation in 50Z
Well-established pulmonary 
fibrosis; titanium found in lungs
15
46
19
0.4-3.3
2-8
0.08-28 
(av. 12.6)
117 Chronic bronchitis in 35 (30Z);
mild fibrosis in 33 (28.2Z)
3 Pulmonary fibrosis in
one lung biopsy specimen
1,500 Pulmonary fibrosis in 9 (0.6Z)
35
12
26
27
0.03-0.3 1-14 
(av. 5.8)
10 Mild fibrosis 13
TABLE IX-2 (CONTINUED)
EFFECTS OF WORKPLACE EXPOSURE TO COBALT-CONTAINING SUBSTANCES
Substance(s) 
and Composition 
(if known)
Concentration 
(mg cobalt/cu ■)
Duration,
Tears
No. of 
Workers Effect
Reference
No.
tl 0.006-1.3 30Z for <10, 
44Z for 10-20, 
26Z for >20
61 Pulmonary changes in 30 30
ff * * 1 Asthma-like labored breathing 47
It * 9 1 Harked.fibrosis and emphysema; 
cobalt and other metals found In 
lung
15
M * 8 1 It 16
•• * * 5 Asthma-like labored breathing 26
27
II * 1.5 1 tt 14
Tungsten carbide/oxide, 
titanium, cobalt
0.4-2.9 * 178 Respiratory irritation in 73 
(41Z); bronchitis with labored 
breathing In 2
36
Tungsten carbide, 
titanium carbide, 
niobium, cobalt
* 0.08-9 100 Pulmonary irritation in 15 
subjects; progressing to fibrosis 
in 5
28
Tungsten carbide, 
titanium, cobalt
* 6 1 Well-established pulmonary 
fibrosis
18
Tungsten carbide, 
titanium carbide, 
cobalt
* * 200-250 6-10Z with labored breathing; 
radiographic changes in 4Z
38
Hard-metal tool 
manufacturing
*
*
16-50 
(av. 36)
12 Well-established pulmonary 
fibrosis
14
Welding fumes * 15 
(2 h/d)
1 Well-established pulmonary 
fibrosis; cobalt, chromium, 
nickel, and iron found in lung 
tissue
22
*Data not reported
TABLE IX-3
CHEMICAL AND PHYSICAL PROPERTIES OF COBALT AND SELECTED COBALT COMPOUNDS
Melting Solubility
Molecular Formula Point  (a/100 cc)_______________
Compound Formula Height (C) Density H20 Other Solvents
Cobalt Co
00-P-
Cobaltous acetate Co(C2H302)2.4H20
tetrahydrate
Cobaltic acetyl- 
acetonate
Co(HC(COCH3)2)3
Cobaltous carbonate CoC03 
(spherocobaltite)
Cobaltous chromate CoCr04
Cobaltous citrate Co3(C6HS07)2.2H20
Cobaltous cyanide Co(CN)2.2H20 
dihydrate
Cobaltous formate Co(CH02)2.2H20
Cobalt halides:
Cobaltous
bromide
Cobaltous
chloride
CoBr2
CoC12
58.933
249.08 
(-4H20,177.03)
356.26
118.94
Basic cobaltous 2CoC03.3Co(0H)2.H20 534.74
carbonate
174.93
591.04
147.00
185.00
218.75
129.84
1,495
-4H20, 140 
241
Decomposes
-2H20, 150
-2H20, 280 
(decomposes 
at 300)
-2H20, 140 
(decomposes 
at 175)
678 (under HBr 
and N2)
735
8.9
1.705 
(19 C)
1.43 
(15 C)
4.13
Anhydrous 
1.872 
(25 C)
2.129 
(22 C)
4.909
3.356 
(25 C)
0.8 in 
cold
0.00418 
in cold
5.03 in 
cold
66.7 
(59 C), 
68.1 
(97 C)
45 (7 C), 
105 (96 C)
Acid
Dilute acids, alcohol 
pentyl acetate
Acid
Decomposes Acid, (NH4)2C03 
in hot
Decomposes Mineral acids, NH40H 
in hot
Dilute acids 
KCN, HC1, NH40H
77.1 alcohol, 58.6 
methanol; acetone, 
ether, methyl acetate
54.4 alcohol, 8.6 
acetone, 38.5 meth­
anol, slightly 
soluble, ether, 
glycerol, pyridine
TABLE IX-3 (CONTINUED)
CHEMICAL AND PHYSICAL PROPERTIES OF COBALT AND SELECTED COBALT COMPOUNDS
Compound
Molecular
Formula
Formula
Height
Melting
Point
(C) Density H20
Solubility 
(g/100 cc)
Other Solvents
00Ui
Cobaltous
fluoride
Cobaltlc
fluoride
Cobaltous
iodide
Cobaltous
hydroxide
Cobaltlc
hydroxide
Cobaltous
linoleate
Cobaltous
naphthenate
CoF2
CoF3
Col 2
Co(OH)2
Co(OH)3 
(Co203.3H20)
Co(C18H3102)2
A  mixture of many 
cobalt naphthenates 
that have varying 
chain lengths
Cobaltous nitrate Co(N03)2
Cobaltous oleate Co(C18H3302)2
Cobaltous oxalate CoC204
Cobalt oxides:
Cobaltous oxide CoO
Cobaltlc oxide Co203
96.93
115.93
312.74
92.95
109.96
(219.91)
617.83
ca 1,200
182.96
621.86
146.95
74.93
165.86
515 (In a 
vacuum)
Decomposes
Decomposes
Decomposes
100-105
235
Decomposes
250
1,935
Decomposes
895
4.43 (25 C) 1.5 (25 C) Harm mineral acids 
(decomposes 
in hot)
3.88
5.68
3.597 
(15 C)
4.46
2.49
3.02 (25 C) 
6.45
4.81-5.60
Decomposes 
to Co (OH) 3
159 (0 C) Alcohol, acetone 
420 (100 C)
Acids, NH4 salts
Acids
Alcohol, ether, 
acetone
Alcohol, ether, oil
Most organic solvents
Alcohol, ether, oils, 
benzene
Acid, NH40H
Acid, alkali 
Acid
TABLE IX-3 (CONTINUED)
CHEMICAL AND PHYSICAL PROPERTIES OF COBALT AND SELECTED COBALT COMPOUNDS
Compound
Molecular
Formula
Formula
Height
Melting
Point
(C) Density H20
Solubility 
(g/100 cc)
Other Solvents
00
Cobaltous 
cobaltic oxide
Cobaltous
phosphate
Cobalt
aonosllicide
Cobalt dlsllicide
Dicobalt
monosilicide
Cobalt disulfide 
Cobaltic sulfide
Cobalt tallate
Cobalt
thlocyanate
Cobaltous
tungstate
Co 304
Co3(P04)2
CoSi
CoS12
Co2Si
Cobaltous sulfate CoS04
Cobaltous sulfide CoS
CoS 2 
Co2S3
Cobalt derivative of 
refined tall oil - of 
varying composition
Co(SCN)2
CoH04
240.80
366.74
87.03
115.11
145.95
155.00
91.00
123.06
214.06
175.10
306.78
Transition 
point to 
CoO 900-950
1,395
1,277
1,327
735
1,116
-3H20, 105
6.07
2.587 
(25 C)
5.3
7.28 (0 C) 
3.472
Alkalis, acids
H3P04, NH40H
HC1
Decomposes in acid
36.2 (20 C) 1.04 (18 C) methanol 
83 (100 C)
5.45 (18 C) 0.00038
(18 C)
4.269 —
4.8
8.42
Slightly soluble 
acids
HN03, aqua regia
Decomposes in a d d ,  
aqua regia
Alcohols, ether, 
acetone, CHC13
Hot concentrated 
slightly soluble 
dilute acid
Adapted from references 2,247,312
SIMPLE COBALT SALTS, ORGANIC AND INORGANIC
TABLE IX-4
CAS NO. NAME CAS NO. NAME CAS NO. NAME
71-48-7 cobaltous acetate 11114-55-9 alloy;Al, Co 14640-56-3 cobalt pyrophosphate
136-52-7 cobalt 2-ethylhexanoate 12006-78-9 cobalt boride 14666-94-5 cobalt oleate
513-79-1 cobaltoua carbonate 12013-10-4 cobalt sulfide (CoS2) 14666-96-7 cobalt llnoleate
542-84-7 cobaltous cyanide 12016-80-7 cobalt hydroxide oxide 14965-99-2 cobaltlc cyanide
544-18-3 cobaltoua formate 12017-01-5 Co, Ti oxide (CoT103) 15238-00-3 cobaltous iodide
814-89-1 cobaltous oxalate 12017-12-8 cobalt s u i c i d e 18718-10-0 cobaltous 
phosphate (2:1)
866-81-9 cobaltous citrate 12017-13-9 cobalt telluride 21041-93-0 cobaltous hydroxide
932-69-4 cobalt benzoate 12017-38-8 Co, Ti oxide (Co2T104) 26490-63-1 cobalt tetrafluoro- 
borate
1307-96-6 cobaltous oxide 12017-68-7 Co; cmpd. with Sm (5:1) 27016-73-1 cobalt arsenide
1307-99-9 cobalt selenide 12044-42-7 cobaltous arsenide 27253-31-2 cobalt neodecanoate *
1308-04-9 cobaltlc oxide 12045-01-1 cobaltous boride 34262-88-9 cobalt terephthalate
1308-06-1 cobaltous cobaltlc oxide 12052-28-7 Co, Fe oxide 37261-99-7 alloy; HC 88, Co 12
1317-42-6 cobalt sulfide (CoS) 12052-42-5 cobalt antlmonide 38582-17-1 cobalt cyclohexanebutanoate
1333-88-6 Al, Co oxide 12134-02-0 cobalt phosphide 42978-77-8 cobalt methylbenzoate
1345-19-3 cobalt tin oxide 12214-13-0 Ce, cmpd. with Co (1:5) 49676-83-7 cobalt; 3,5,5-trimethyl- 
hexanoate
3017-60-5 cobalt thlocyanate 12256-04-7 cobaltlc arsenide 53219-02-6 alloy; Co 9.9-90, Al 9.8-90
6700-85-2 cobalt octanoate 12263-08-0 cobalt molybdophosphate 58197-53-8 cobalt, 2-propionate
7440-48-4 cobalt 12774-15-1 alloy; WC 94, Co 6 58591-45-0 co, N1 oxide
7646-79-9 cobaltous chloride 13455-25-9 cobaltous chromate 67801-57-4 cobalt; 1 ,2,4-benzenetricarboxy- 
late
7789-43-7 cobaltous bronlde 13455-31-7 cobaltous perchlorate 67952-53-8
68016-03-5
cobalt; 2-methyl 2-propionate 
molybdic acid; Co, Ni salt 
(2:1:1)
10026-17-2 cobaltous fluoride 13455-36-2 cobaltous phosphate 68123-03-5 cobalt, 4-aminobenzoate
10026-18-3 cobaltlc fluoride 13596-21-9 cobaltous phosphate 68647-47-2 cobalt molybdate (1:3)
10101-58-3 cobaltous tungstate 13762-14-6 cobalt molybdate (1:1) 69011-09-2 Co, Zr oxide
10124-43-3 cobaltous sulfate 14017-41-5 cobalt sulfanate 12190-79-3 Co, LI oxide
10141-05-6 cobaltous nitrate 14590-13-7 cobaltous ammonium phosphate 13586-84-6 cobalt octadecanoate
*Alternate CAS No. of 52270-44-7
TABLE I X - 5
ORGANOCOBALT COMPLEXES AND COMPLEX COBALT SALTS
CAS No. M o l e c u l a r  F o r m u l a CAS No. M o l e c u l a r  F o r m u l a
3 2 5 2 - 9 9 - 1
3 3 1 7 - 6 7 - 7
10210- 68-1
1 0 5 3 4 - 8 9 - 1
1 2 6 0 2 - 2 3 - 2
C8-H14-CO-N4-04
C32-H16-Co-N8
C 8 -C o2-0 8
C l . 1 /2C0-H18-N6
C 2-H6-C o-012
4 9 6 5 1 - 1 0 - 7
5 1 0 8 4 - 3 2 - 3
5 1 8 3 9 - 2 4 - 8
5 2 7 2 9 - 6 7 - 6
6 2 2 0 7 - 7 6 - 5
C 4 2 -B r2 - C o -P 2  
C 9 - H 8 - 0 4 . l / 2 C o  
C 2 -H 6 -C o 5 -0 1 2 .H 2 0  
C 3 2 - H 1 5 - C o - N 8 - 0 3 - S . Na 
C16-H12 -C O-F2-N 2-02
1 2 7 1 5 - 6 1 - 6
1 3 4 0 8 - 7 3 - 6
1 3 5 8 6 - 8 2 - 8
1 3 8 5 9 - 5 1 - 3
1 3 8 6 9 - 3 0 - 2
C 3 2 - H 3 0 -C o -N 8 -0 10 - S  2
C 6 -H 2 4 -C o -N 6 .3 C l
C 8 - H l 6 - 0 2 . x C o
C1-CO-H15-N5.2C1
C4-H 5-Co-N -0 4
6 7 8 7 5 - 3 8 - 1
6 7 9 0 6 - 1 8 - 7
6 8 1 3 3 - 8 5 - 7
6 8 1 8 9 - 4 0 - 2
6 8 2 3 9 - 5 6 - 5
C 3 2 - H 1 5 - C l - C o - N 8 - 0 2 - S
C6-H20-CO-N4. 2C2-Au-N2
C4- H 5-C o-N -0 4
C 32 -H 14 -C 1 2 - C o - N 8 - 0 4 - S e
( C 1 0 - H 1 8 - C o - N 2 - 0 4 ) x
1 4 0 2 4 - 4 8 - 7
1 4 1 2 3 - 0 8 - 1
1 4 1 2 6 - 3 2 - 0
1 4 9 3 1 - 8 3 - 0
2 1 6 7 9 - 4 6 - 9
C 10- H 14-C o-0 4  
C6- C 0- N 6 . 3 / 2Co 
C36 -H 30-B r  2 -C o -P  2 
C10-H12-CO-N2-08 
C15-H21-CO-06
6 8 2 3 9 - 5 8 - 7
6 8 4 7 5 - 4 5 - 6
6 8 9 5 8 - 9 0 - 7
6 9 1 4 0 - 5 9 - 6
6 9 1 4 0 - 6 0 - 9
(C 6-H 1 2 - C 1 2 - C o -N 2 )x  
C 14-H 2 6 -C o -0 1 6  
C 4 -H 16-C o-N 4 . 2C2-Au-N2 
C 2 - H 8 - 0 7 - P 2 . C o .2 K  
C 2 - H 8 - 0 7 - P 2 . C o . 2Na
2 5 9 7 1 - 1 5 - 7
2 9 3 8 3 - 2 9 - 7
3 0 6 3 8 - 0 8 - 5
4 0 6 2 1 - 1 0 - 1
C 2 6 - H 3 8 - C o 2 - N l0 - 0 8  
C 3 2 -H 1 4 -C O - N 8 -0 6 -S 2 . 2H 
C32 -H15-C O -N 8-0 3-S .H  
C12 - H 2 3 - P - S  2 . 1 / 2Co
6 9 1 7 8 - 3 4 - 3
6 9 1 7 8 - 4 2 - 3
6 9 1 9 8 - 4 3 - 2
C 2 - H 8 - 0 7 - P 2 . Co . 2H3-N 
C34-H32-C0 -N8- O 10 -S 2  
C 4 8-H5 4 - B r  2 -C o -P  2
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TABLE IX- 6  
SUBSTANCES OF UNIDENTIFIED STRUCTURE
CAS No. D e s c r ip t io n
1 3 4 5 - 1 6 - 0
5 9 3 1 - 8 9 - 5
8 0 1 1 - 8 7 - 8
1 1 1 0 4 - 6 1 - 3
1 2 6 5 3 - 5 6 - 4
1 2 6 7 2 - 2 7 - 4
1 2 7 3 7 - 3 0 - 3
3 7 3 6 7 - 9 0 - 1
3 7 3 8 2 - 2 4 - 4
2 9 2 6 1 - 7 5 - 6
6 1 7 8 9 - 5 1 - 3
6 1 7 8 9 - 5 2 - 4
6 3 4 9 7 - 0 9 - 6
6 8 1 3 0 - 3 7 - 0
6 8 1 5 2 - 9 1 - 0
6 8 1 8 6 - 8 5 - 6
6 8 1 8 6 - 8 6 - 7
6 8 1 8 6 - 8 7 - 8
6 8 1 8 6 - 8 9 - 0
6 8 1 8 6 - 9 7 - 0
6 8 1 8 7 - 0 5 - 3  
6 8 1 8 7 - 1 1 - 1  
6 8 1 8 7 - 4 0 - 6  
6 8 1 8 7 - 4 9 - 7  
6 8 1 8 7 - 5 0 - 8  
6 8 4 0 9 - 8 1 - 4
6 8 4 1 1 - 0 8 - 5
6 8 4 1 2 - 7 4 - 8  
6 8 4 4 2 - 9 6 - 6
6 8 4 5 7 - 1 3 - 6
6 8 4 5 7 - 9 0 - 9
6 8 4 7 8 - 5 7 - 9
6 8 4 7 8 - 5 8 - 0
6 8 5 1 2 - 3 1 - 2
6 8 5 5 3 - 1 5 - 1
6 8 5 8 4 - 9 6 - 3
C l  p i g m e n t  b l u e  28
c o b a l t  a c e t a t e
C l  p i g m e n t  g r e e n  19
c o b a l t  o x i d e
c o b a l t  s u l f i d e
al u m in u m  c o b a l t  o x i d e
c o b a l t  n i c k e l  o x i d e
c o b a l t  b o r a t e
ch ro mium  c o b a l t  o x i d e
c o b a l t  z i r c o n i u m  o x i d e
c o b a l t  n a p h t h e n a t e
f a t t y  a c i d s ,  t a l l - o i l ,  Co s a l t s
ch ro mium c o b a l t  i r o n  o x i d e
Co,  m o ly -d en u m  h y d r o x i d e  o x i d e  p h o s p h a t e
t a l l  o i l s ,  c o b a l t  s a l t
s p i n e l s ;  Co,  T i  g r e e n
s p i n e l s ;  A l ,  Co b l u e
s p i n e l s ;  A l ,  Co,  Zn b l u e
p e r i c l a s e ;  Co,  N i  g r a y
s p i n e l s ;  C r ,  Co,  Fe  b l a c k
s p i n e l s ;  Co,  Sn g r a y
s p i n e l s ;  A l ,  C r ,  Co b l u e  g r e e n
o l i v i n e , c o b a l t  b l u e
s p i n e l s ;  C r ,  Co g r e e n
s p i n e l s ;  Co,  F e  b l a c k
f a t t y  a c i d s ,  C 6 - 1 9 - b r a n c h e d ,  Co s a l t s
Co,  d e x t r i n  c o m p l e x e s
p h e n a k i t e ;  Co,  Zn b l u e
h y d r o f l u o r i c  a c i d ,  r e a c t i o n  p r o d u c t s  w i t h  
a l u m i n a  and c o b a l t  c h l o r i d e  
Co,  b o r a t e  n e o d e c a n o a t e  c o m p l e x e s  
z i r c o n i u m ,  ' c a r b o n a t e  d i p r o p y l e n e  g l y c o l
2- e t h y l h e x a n o a t e  i s o b u t y l  a l c o h o l  o x o p r o p i o n a t e  
c o b a l t  c o m p l e x e s  
Co,  2 - e t h y l h e x a n o a t e  i s o n o n a t e  c o m p l e x e s  
Co,  2 - e t h y l h e x a n o a t e  3 , 5 , 5 - t r i m e t h y l h e x a n o a t e  
c o m p l e x e s  
p e r i c l a s e ,  Co b l u e  g r a y  
l i n s e e d  o i l ;  Co,  Mn, s a l t
2 - n a p h t h a l e n e  s u l f o n i c  a c i d ,  6 - h y d r o x y - 5 - n i t r o s o ;  
Co,  Na s a l t ;  co m p lex  w i t h  v i n y l p y r r o l i d o n e  
p o l y m e r
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TABLE IX -6  (CONTINUED)
SUBSTANCES OF UNIDENTIFIED STRUCTURE
CAS No. D e s c r i p t i o n
6 8 6 0 8 - 0 9 - 3 s p i n e l s ;  A l ,  Co,  Sn
6 8 6 0 8 - 9 3 - 5 b o r i c  a c i d ;  Co,  Mg s a l t ;  r e d - b l u e
6 8 6 0 9 - 0 2 - 9 Co,  b o r a t e  i s o n o n o a t e  n e o d e c a n o a t e  c o m p l e x e s
6 8 6 1 0 - 1 3 - 9 p h o s p h o r i c  a c i d ;  Co,  L i  s a l t ;  v i o l e t
6 8 7 8 4 - 1 0 - 1 CdS;  s o l i d  s o l n .  w i t h  ZnS ,  A l ,  Cu ,  an d  Co;
A g -d o p e d
6 8 8 5 5 - 8 6 - 7 f a t t y  a c i d s ,  t a l l o w ,  h y d r o g e n a t e d ,  Co s a l t s
6 8 9 5 5 - 8 3 - 9 f a t t y  a c i d s ,  C 9 - 1 3 - n e o - ,  Co s a l t s
6 8 9 5 6 - 8 2 - 1 r e s i n  a c i d s  an d  r o s i n  a c i d s ,  Co s a l t s
6 8 9 8 8 - 1 0 - 3 z i r c o n i u m ,  d i p r o p y l e n e  g l y c o l ,  i s o b u t y l  a l c o h o l ,
n e o d e c a n o a t e ,  p r o p i o n a t e  Co c o m p l e x e s
6 9 0 1 2 - 3 7 - 9 s l i m e s  and s l u d g e s ,  Co t e r e p h t h a l a t e
6 9 0 1 2 - 7 1 - 1 l e a c h  r e s i d u e s ,  Zn o r e - c a l c i n e ,  Co r e p u l p
6 9 0 1 2 - 7 2 - 2 l e a c h  r e s i d u e s ;  Zn o r e - c a l c i n e ;  Z n ,  Co
7 0 1 3 1 - 6 1 - 2 c o b a l t  s a l t  o f  m i x e d  p o l y m e r
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FIGURE X - l .  EXHAUST BOOTH FOR PORTABLE GRINDIMG
91
DUCT TO FAN
FIGURE X -2 . ENCLOSURE FOR FILTER PRESSES
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SLOT 
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HANDLE FOR 
TILTING TRAYS
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FIGURE X -3 . ENCLOSURE FOR EMPTYING TRAYS OF CAKED POWDERS
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FIGURE X -A . TYPICAL ARRANGEMENTS FOR FILLING CONTAINERS
Beaker So<tp
Solution
FIGURE X-5. CALIBRATION SETUP FOR PERSONAL SAMPLING PUMP WITH FILTER CASSETTE
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